MDL | - |
---|---|
Molecular Weight | 261.09 |
Molecular Formula | C7H15Cl2N2O2P |
SMILES | ClCCN(CCCl)P1(OCCCN1)=O |
Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.
DNA Alkylator [1]
Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide [1] . Cyclophosphamide inhibits the AChE reversibly with an IC 50 of 511 μM [2] . Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cyclophosphamide (injected i.p.;2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Six to eight-week old female C3H/HeN mice bearing SW1 tumors [4] |
Dosage: | 2 mg/mouse |
Administration: | Injected i.p.; 2mg/mouse in 0.1 mL PBS; 4 days |
Result: | Increased the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03107988 | New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids´ Cancer US+EU|Children´s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade´s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids´ Cancer |
Neuroblastoma
|
September 5, 2017 | Phase 1 |
NCT02999854 | Kiadis Pharma |
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome
|
November 29, 2017 | Phase 3 |
NCT01962636 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelofibrosis|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Lymphoblastic Lymphoma|Burkitt´s Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma
|
December 2016 | Not Applicable |
NCT04230265 | AvenCell Europe GmbH|PHARMALOG Institut für klinische Forschung GmbH |
Acute Myeloid Leukemia (AML)
|
January 28, 2020 | Phase 1 |
NCT00089453 | University of Arkansas |
Multiple Myeloma
|
September 2003 | Phase 1 |
NCT00162656 | Gustave Roussy, Cancer Campus, Grand Paris |
B-Cell Lymphoma
|
May 1996 | Phase 3 |
NCT00602459 | National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group |
Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
January 15, 2008 | Phase 2 |
NCT02234921 | UbiVac|Providence Health & Services|Providence Cancer Center|Providence Cancer Center, Earle A. Chiles Research Institute |
Adenocarcinoma of the Prostate
|
October 24, 2014 | Phase 1 |
NCT01090128 | University of Utah|Celgene Corporation |
Stages II-III Breast Cancer
|
September 2008 | Phase 1 |
NCT02529839 | Hadassah Medical Organization |
Multiple Sclerosis
|
October 2015 | Not Applicable |
NCT03609047 | European Organisation for Research and Treatment of Cancer - EORTC|Pfizer|Swedish Association of Breast Oncologists|ETOP IBCSG Partners Foundation|German Adjuvant Breast Cancer Group|SOLTI Breast Cancer Research Group|UNICANCER|Gruppo Oncologico Italiano di Ricerca Clinica|Breast International Group |
Breast Cancer Stage II|Breast Cancer Stage III
|
June 14, 2019 | Phase 2 |
NCT01759732 | Asan Medical Center |
Acquired Aplastic Anemia
|
September 2012 | Phase 2 |
NCT00115414 | Amgen |
Breast Cancer|Fever|Neutropenia
|
Phase 2 | |
NCT00711828 | Mayo Clinic|National Cancer Institute (NCI) |
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
August 2008 | Phase 2 |
NCT00211185 | Eisai Inc. |
Lymphoma, T-Cell, Peripheral
|
March 14, 2004 | Phase 2 |
NCT02960646 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Aplastic Anemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Recurrent Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Therapy-Related Myelodysplastic Syndrome
|
January 18, 2017 | Phase 1 |
NCT03342638 | Northwestern University |
Multiple Sclerosis, Relapsing-Remitting
|
November 8, 2017 | Phase 3 |
NCT02807103 | Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group |
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
|
December 5, 2016 | Phase 3 |
NCT00001384 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasms
|
May 1994 | Phase 2 |
NCT03959085 | Children´s Oncology Group|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia
|
October 28, 2019 | Phase 3 |
NCT05031897 | Thomas Jefferson University |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aplastic Anemia|Chronic Lymphocytic Leukemia|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Hematopoietic and Lymphoid Cell Neoplasm|Hodgkin Lymphoma|Myelodysplastic Syndromes|Myelofibrosis|Myeloid Leukemia|Myeloid Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|Polycythemia Vera|Small Lymphocytic Lymphoma
|
October 25, 2021 | Phase 2 |
NCT02229084 | University of Arkansas |
Breast Cancer|Breast Neoplasms
|
January 14, 2015 | Phase 1|Phase 2 |
NCT00800839 | M.D. Anderson Cancer Center |
Hematologic Diseases|Leukemia|Lymphoma|Myeloma
|
September 2008 | Phase 2 |
NCT00424203 | UNICANCER |
Breast Cancer|Cognitive+Functional Effects|Depression|Malnutrition|Psychosocial Effects of Cancer and Its Treatment
|
January 2006 | Phase 2 |
NCT00918723 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
June 2009 | Phase 1|Phase 2 |
NCT00436566 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Cancer|Cardiac Toxicity
|
March 16, 2007 | Phase 2 |
NCT01064375 | Maria Liljefors|Karolinska Institutet|Swedish Institute for Infectious Disease Control|Cyto Pulse Sciences, Inc.|Karolinska University Hospital |
Colorectal Cancer
|
December 2009 | Phase 1|Phase 2 |
NCT02337985 | City of Hope Medical Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|HIV Infection|AIDS Related Non-Hodgkin Lymphoma
|
November 20, 2015 | Phase 1 |
NCT00002755 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
November 1995 | Phase 3 |
NCT04735471 | Adicet Bio, Inc |
Lymphoma, Follicular|Lymphoma, Mantle-Cell|Marginal Zone Lymphoma|Primary Mediastinal B-cell Lymphoma|Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin
|
March 4, 2021 | Phase 1 |
NCT02013336 | South Plains Oncology Consortium |
Recurrent or Refractory Solid Tumors|Ewing Sarcoma|Rhabdomyosarcoma|Neuroblastoma|Osteosarcoma
|
December 2013 | Phase 1 |
NCT02685657 | Russian Academy of Medical Sciences|Russian Society of Clinical Oncology |
Triple Negative Breast Cancer
|
September 2016 | Phase 2 |
NCT05035407 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Kita-kyushu Lung Cancer Antigen 1, Human
|
March 8, 2022 | Phase 1 |
NCT03136146 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Burkitt Leukemia|Recurrent Burkitt Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Acute Lymphoblastic Leukemia|Refractory Burkitt Leukemia|Refractory Burkitt Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Lymphoblastic Lymphoma
|
August 9, 2017 | Phase 2 |
NCT01547741 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
April 2012 | Phase 3 |
NCT00290433 | M.D. Anderson Cancer Center|Ortho Biotech, Inc. |
Lymphoma
|
September 2003 | Phase 2 |
NCT00931918 | Millennium Pharmaceuticals, Inc.|Takeda |
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
|
October 2009 | Phase 2 |
NCT02652455 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Iovance Biotherapeutics, Inc. |
Melanoma (Skin)|Skin Cancer
|
March 8, 2016 | Early Phase 1 |
NCT04031703 | Fudan University |
Breast Cancer
|
January 1, 2011 | Phase 3 |
NCT03943472 | Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital |
Multiple Myeloma
|
July 8, 2019 | Early Phase 1 |
NCT00047138 | University of Leicester|Societe Francaise Oncologie Pediatrique|Children´s Cancer and Leukaemia Group|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Kidney Cancer
|
January 2001 | Phase 3 |
NCT03912831 | Kite, A Gilead Company|Gilead Sciences |
Human Papillomavirus (HPV) 16&addition; Relapsed+Refractory Cancer
|
April 30, 2019 | Phase 1 |
NCT02779283 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
January 13, 2016 | Phase 1 |
NCT03992326 | Centre Hospitalier Universitaire Vaudois |
Solid Tumor, Adult
|
September 1, 2019 | Phase 1 |
NCT00007904 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2000 | Phase 2 |
NCT00003943 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Carcinoma of Unknown Primary|Lung Cancer
|
September 1998 | Phase 2 |
NCT00307645 | Assistance Publique - Hôpitaux de Paris |
ANCA Associated Systemic Vasculitis Including Wegener´s|Granulomatosis and Microscopic Polyangiitis and|Renal Limited Vasculitis
|
May 2003 | Phase 3 |
NCT03774654 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Refractory B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Small Lymphocytic Lymphoma|Relapsed Adult ALL|Relapsed CLL|Relapsed Non Hodgkin Lymphoma
|
June 22, 2020 | Phase 1 |
NCT00017368 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
April 2001 | Phase 2 |
NCT05420454 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
NCT01593020 | M.D. Anderson Cancer Center|Eisai Inc. |
Breast Cancer
|
August 3, 2012 | Phase 2 |
NCT00516425 | Charing Cross Hospital|National Cancer Institute (NCI) |
Breast Cancer
|
January 2007 | Phase 3 |
NCT00538031 | City of Hope Medical Center |
Fallopian Tube Cancer|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer
|
December 22, 2003 | Phase 2 |
NCT00003577 | University Hospital Birmingham|National Cancer Institute (NCI) |
Breast Cancer
|
March 1996 | Phase 3 |
NCT03387085 | ImmunityBio, Inc. |
Triple Negative Breast Cancer
|
March 16, 2018 | Phase 1|Phase 2 |
NCT00010413 | Johns Hopkins University|Office of Rare Diseases (ORD) |
Pemphigus
|
April 1999 | Phase 2 |
NCT00003113 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
July 1997 | Phase 2 |
NCT02660762 | Sun Yat-sen University |
Leukaemia,Lymphoblastic
|
January 2016 | Phase 2 |
NCT00278421 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
NCT00287950 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
September 1992 | Not Applicable |
NCT03012100 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Bilateral Breast Carcinoma|Breast Inflammatory Carcinoma|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma|Unilateral Breast Carcinoma
|
March 31, 2017 | Phase 2 |
NCT03357159 | Sheba Medical Center |
Graft Versus Host Disease
|
September 6, 2018 | Phase 2 |
NCT00217425 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
July 2006 | Phase 2 |
NCT00397800 | Technical University of Munich |
Lymphoma
|
June 2005 | Phase 1|Phase 2 |
NCT03892330 | Shengjing Hospital |
0.5-14 Year Old Children With Nephroblastoma
|
June 1, 2019 | Phase 4 |
NCT04941885 | Sun Yat-sen University |
Breast Cancer
|
June 25, 2021 | Phase 2 |
NCT00002576 | Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) |
Lymphoma
|
November 1992 | Phase 3 |
NCT00574496 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
November 13, 2007 | Phase 2 |
NCT00022516 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
November 2000 | Phase 3 |
NCT00002565 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
May 25, 1994 | Phase 3 |
NCT03202446 | Eske Corporation S.A.C |
Breast Cancer Stage IIIA|Breast Cancer, Stage IIIB|Breast Cancer Stage IV
|
June 13, 2016 | Phase 3 |
NCT00054665 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
B-Cell Lymphoma
|
February 2003 | Phase 2 |
NCT01659658 | Millennium Pharmaceuticals, Inc.|Takeda |
Relapsed or Refractory Systemic Light Chain Amyloidosis
|
December 12, 2012 | Phase 3 |
NCT01716689 | National Cancer Centre, Singapore |
Sarcoma
|
June 2012 | Phase 2 |
NCT01530607 | King Faisal Specialist Hospital & Research Center |
Breast Cancer
|
November 2009 | Phase 3 |
NCT02844062 | Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd. |
Glioblastoma Multiforme
|
July 2016 | Phase 1 |
NCT05327023 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hematologic Neoplasms
|
May 23, 2022 | Phase 1|Phase 2 |
NCT05296564 | Hadassah Medical Organization |
Sarcoma, Synovial|Sarcoma,Soft Tissue|Melanoma Stage IV|Triple Negative Breast Cancer|Metastatic Cancer|Non Small Cell Lung Cancer|Bladder Urothelial Carcinoma|Neuroblastoma, Metastatic|Ovary Cancer
|
April 1, 2022 | Phase 1|Phase 2 |
NCT02876978 | CARsgen Therapeutics Co., Ltd. |
Lung Squamous Cell Carcinoma
|
March 2016 | Phase 1 |
NCT01156883 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
April 2010 | Not Applicable |
NCT00076752 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lupus Erythematosus, Systemic
|
January 30, 2004 | Phase 2 |
NCT03013504 | Prestige Biopharma Limited |
HER2 Positive Breast Cancer
|
January 1, 2018 | Phase 3 |
NCT00005959 | Amgen|National Cancer Institute (NCI) |
Lymphoma
|
December 1999 | Phase 2 |
NCT00005977 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 2000 | Phase 3 |
NCT02482090 | Inge Marie Svane|Herlev Hospital |
Metastatic Ovarian Cancer
|
July 2015 | Phase 1 |
NCT01219907 | University of Washington|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Stage IV Breast Cancer
|
June 2012 | Phase 1 |
NCT04637763 | Caribou Biosciences, Inc. |
Lymphoma, Non-Hodgkin|Relapsed Non Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B Cell Non-Hodgkin´s Lymphoma
|
May 26, 2021 | Phase 1 |
NCT00455312 | Masonic Cancer Center, University of Minnesota |
Dyskeratosis Congenita|Aplastic Anemia
|
August 2007 | Phase 2|Phase 3 |
NCT02133196 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Advanced Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinoma
|
October 23, 2014 | Phase 2 |
NCT01689987 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
September 2012 | Phase 1 |
NCT00295932 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University |
Leukemia|Lymphoma
|
December 13, 2005 | Phase 1|Phase 2 |
NCT03036488 | Merck Sharp & Dohme LLC |
Triple Negative Breast Neoplasms
|
March 7, 2017 | Phase 3 |
NCT00430105 | Cambridge University Hospitals NHS Foundation Trust |
ANCA Associated Systemic Vasculitis|Wegener´s Granulomatosis|Microscopic Polyangiitis
|
February 1998 | Phase 2|Phase 3 |
NCT00789581 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Breast Cancer
|
December 2008 | Phase 3 |
NCT00334867 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
December 2005 | Phase 3 |
NCT02548468 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Stage IIB Mycosis Fungoides and Sezary Syndrome|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome
|
November 20, 2015 | Phase 1 |
NCT00450801 | University of Miami |
Lymphoma
|
April 2004 | Phase 2 |
NCT01936064 | Lagos State University |
Haematological Abnormality
|
October 2016 | Phase 1|Phase 2 |
NCT00492921 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Graft Versus Host Disease
|
May 2007 | Phase 2 |
NCT00946023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Lymphoma|B-cell Lymphoma|Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
July 2009 | Phase 2 |
NCT05322733 | The First Affiliated Hospital with Nanjing Medical University |
Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma
|
April 15, 2022 | Phase 2 |
NCT00032149 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
October 2001 | Phase 1|Phase 2 |
NCT02541565 | University of Washington|National Cancer Institute (NCI) |
Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma
|
November 24, 2015 | Phase 1 |
NCT00003782 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
March 1999 | Phase 3 |
NCT00912444 | Shanghai Jiao Tong University School of Medicine |
Breast Cancer
|
July 2009 | Phase 3 |
NCT01964391 | Hoffmann-La Roche |
Breast Cancer
|
February 21, 2014 | Phase 3 |
NCT02444091 | Haukeland University Hospital|The Kavli Foundation|Oslo University Hospital |
Chronic Fatigue Syndrome (CFS)|Myalgic Encephalomyelitis (ME)
|
March 2015 | Phase 2 |
NCT02512926 | Stanford University|Pediatric Oncology Experimental Therapeutics Investigators´ Consortium|Amgen |
Relapsed Solid Tumors|Refractory Solid Tumors|Relapsed Leukemia|Refractory Leukemia
|
February 16, 2016 | Phase 1 |
NCT00085202 | St. Jude Children´s Research Hospital |
Brain and Central Nervous System Tumors
|
August 2003 | Phase 3 |
NCT05106296 | Theodore S. Johnson|Augusta University |
Ependymoma|Medulloblastoma|Glioblastoma|Primitive Neuroectodermal Tumor (PNET)
|
February 8, 2022 | Phase 1 |
NCT00352976 | Masonic Cancer Center, University of Minnesota |
Fanconi Anemia
|
May 18, 2006 | Phase 2|Phase 3 |
NCT00625898 | NSABP Foundation Inc|Cancer International Research Group (CIRG)|Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
April 2008 | Phase 3 |
NCT00433537 | National Cancer Institute (NCI) |
Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma
|
May 2007 | Phase 2 |
NCT01222715 | National Cancer Institute (NCI) |
Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Pleomorphic Rhabdomyosarcoma|Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma
|
October 2010 | Phase 2 |
NCT00941330 | Emory University|Pfizer |
Breast Cancer
|
July 2009 | Phase 2 |
NCT05020860 | Baylor Breast Care Center |
Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer
|
June 15, 2022 | Phase 2 |
NCT01509300 | Asan Medical Center |
Acute Leukemia|Myelodysplastic Syndrome|Solid Tumors
|
January 2012 | Phase 1|Phase 2 |
NCT05447702 | West China Hospital|Jiangsu HengRui Medicine Co., Ltd. |
Triple Negative Breast Cancer
|
July 10, 2022 | Phase 2 |
NCT00005987 | Masonic Cancer Center, University of Minnesota |
Multiple Myeloma and Plasma Cell Neoplasm
|
August 2000 | Phase 2 |
NCT00262886 | University of Rochester |
Kidney Cancer
|
August 2001 | Phase 2 |
NCT01445535 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma
|
January 13, 2009 | Phase 1 |
NCT04093596 | Allogene Therapeutics |
Relapsed+Refractory Multiple Myeloma
|
September 23, 2019 | Phase 1 |
NCT03728179 | Centre Hospitalier Universitaire Vaudois |
Solid Tumor, Adult
|
January 16, 2019 | Phase 1 |
NCT02926833 | Kite, A Gilead Company|Genentech, Inc.|Gilead Sciences |
Refractory Diffuse Large B Cell Lymphoma
|
September 29, 2016 | Phase 1|Phase 2 |
NCT04897321 | St. Jude Children´s Research Hospital |
Pediatric Solid Tumor|Osteosarcoma|Rhabdomyosarcoma|Neuroblastoma|Ewing Sarcoma|Wilms Tumor|Adrenocortical Cancer|Desmoplastic Small Round Cell Tumor|Germ Cell Cancer|Rhabdoid Tumor|Clear Cell Sarcoma|Hepatoblastoma|Melanoma|Carcinoma|Malignant Peripheral Nerve Sheath Tumors|Soft Tissue Sarcoma
|
June 29, 2022 | Phase 1 |
NCT02059850 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Synovial Sarcoma|Myxoid+Round Cell Liposarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma
|
July 2014 | Phase 1 |
NCT00058422 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 10, 2003 | Phase 2 |
NCT00070447 | National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 2 |
NCT02621021 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma
|
December 4, 2015 | Phase 2 |
NCT00877006 | Teva Branded Pharmaceutical Products R&D, Inc. |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
April 30, 2009 | Phase 3 |
NCT03049449 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, Large-Cell, Anaplastic|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Extranodal NK-T-Cell|Lymphoma, T-Cell, Peripheral
|
March 17, 2017 | Phase 1 |
NCT02937662 | Institute of Hematology & Blood Diseases Hospital |
Acute Myeloid Leukemia
|
October 2016 | Phase 2 |
NCT05040568 | M.D. Anderson Cancer Center |
Colon Cancer|Resected Stage
|
February 28, 2022 | Phase 1 |
NCT00670358 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
August 25, 2008 | Phase 1|Phase 2 |
NCT05032183 | M.D. Anderson Cancer Center |
Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia
|
February 17, 2022 | Phase 1|Phase 2 |
NCT00542191 | Leo W. Jenkins Cancer Center |
Breast Cancer
|
July 2007 | Phase 2 |
NCT00075725 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
December 29, 2003 | Phase 3 |
NCT00003603 | Riverside Haematology Group|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
March 1998 | Phase 3 |
NCT02112916 | National Cancer Institute (NCI) |
Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia
|
September 30, 2014 | Phase 3 |
NCT00408408 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
November 2006 | Phase 3 |
NCT00025623 | European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1999 | Phase 2 |
NCT01319565 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
March 24, 2011 | Phase 2 |
NCT04545762 | C. Babis Andreadis|University of California, Davis|University of California, San Francisco |
Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma
|
September 11, 2020 | Phase 1 |
NCT00103792 | University Medical Center Groningen |
Wegener´s Granulomatosis|Vasculitis
|
December 2004 | Phase 3 |
NCT00764907 | University Hospital, Motol|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 3 |
NCT02867345 | Peking University |
Hormone Refractory Prostate Cancer
|
November 2016 | |
NCT00081055 | Mesoblast International Sàrl|National Cancer Institute (NCI)|Mesoblast, Ltd. |
Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes
|
Phase 2 | |
NCT00003816 | Roswell Park Cancer Institute |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific
|
October 19, 1998 | Phase 2|Phase 3 |
NCT00413959 | Oncology Specialists, S.C.|Millennium Pharmaceuticals, Inc. |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell
|
August 2006 | Phase 2 |
NCT03600649 | Salarius Pharmaceuticals, LLC|National Pediatric Cancer Foundation |
Ewing Sarcoma|Myxoid Liposarcoma|Sarcoma,Soft Tissue|Desmoplastic Small Round Cell Tumor|Extraskeletal Myxoid Chondrosarcoma|Angiomatoid Fibrous Histiocytoma|Clear Cell Sarcoma|Primary Pulmonary Myxoid Sarcoma|Myoepithelial Tumor|Sclerosing Epithelioid Fibrosarcoma|Fibromyxoid Tumor
|
June 4, 2018 | Phase 1 |
NCT00004112 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
September 1999 | Phase 3 |
NCT01850108 | Vanderbilt-Ingram Cancer Center |
Sickle Cell Disease|Hemoglobinopathies
|
May 2013 | Not Applicable |
NCT05008224 | Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma
|
October 7, 2021 | Phase 2 |
NCT00049634 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
January 2002 | Phase 1|Phase 2 |
NCT00303836 | National Cancer Institute (NCI) |
Recurrent Melanoma|Stage IV Melanoma
|
November 2005 | Phase 2 |
NCT00574587 | Albert Einstein College of Medicine|Merck Sharp & Dohme LLC |
Breast Cancer
|
December 2007 | Phase 1|Phase 2 |
NCT00003490 | The Cleveland Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
October 1998 | Phase 2 |
NCT01659099 | The Lymphoma Academic Research Organisation|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma CD20 Positive
|
September 2012 | Phase 3 |
NCT01093586 | Case Comprehensive Cancer Center |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia
|
September 2007 | Phase 2 |
NCT04314843 | Kite, A Gilead Company|Humanigen, Inc.|Gilead Sciences |
Relapsed+Refractory Large B-cell Lymphoma
|
May 26, 2020 | Phase 1 |
NCT00138229 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Melanoma (Skin)
|
July 2005 | Phase 2 |
NCT00074165 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Drug+Agent Toxicity by Tissue+Organ|Lymphoma|Thrombocytopenia
|
January 2003 | Phase 2 |
NCT00513695 | University of Washington|National Cancer Institute (NCI) |
Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
June 2007 | Phase 2 |
NCT02583828 | Capital Medical University |
Breast Neoplasms|Neoplasm Metastasis
|
June 2015 | Not Applicable |
NCT04426669 | Intima Bioscience, Inc.|Masonic Cancer Center, University of Minnesota |
Gastrointestinal Epithelial Cancer|Gastrointestinal Neoplasms|Cancer of Gastrointestinal Tract|Cancer, Gastrointestinal|Gastrointestinal Cancer|Colo-rectal Cancer|Pancreatic Cancer|Gall Bladder Cancer|Colon Cancer|Esophageal Cancer|Stomach Cancer
|
May 15, 2020 | Phase 1|Phase 2 |
NCT01369875 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
June 17, 2011 | Phase 2 |
NCT03158935 | University Health Network, Toronto|Merck Sharp & Dohme LLC |
Advanced Ovarian Cancer|Malignant Melanoma
|
July 7, 2017 | Phase 1 |
NCT00001155 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Vasculitis|Wegener´s Granulomatosis
|
February 1976 | Phase 2 |
NCT03081910 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia
|
November 1, 2017 | Phase 1 |
NCT00414128 | Cambridge University Hospitals NHS Foundation Trust|Aspreva Pharmaceuticals|Vifor Pharma |
Vasculitis
|
March 2007 | Phase 2|Phase 3 |
NCT04626752 | Hebei Senlang Biotechnology Inc., Ltd. |
Relapsed or Refractory Multiple Myeloma
|
April 1, 2020 | Early Phase 1 |
NCT00774852 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis|Lupus Erythematosus, Systemic
|
November 2008 | Phase 2 |
NCT00393029 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Anti-p53 TCR-Gene
|
October 2006 | Phase 2 |
NCT00072319 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pharmacia|Amgen |
Breast Cancer
|
August 2003 | Phase 2 |
NCT00060346 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2004 | Phase 2 |
NCT00389506 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Lymphoma
|
September 2006 | Not Applicable |
NCT04043494 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Lymphoblastic Lymphoma, Childhood
|
August 23, 2019 | Phase 3 |
NCT01024010 | Mayo Clinic|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
March 2010 | Phase 2 |
NCT02588612 | GlaxoSmithKline |
Neoplasms
|
February 1, 2016 | Phase 1 |
NCT04933617 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Burkitt Lymphoma|High-grade B-cell Lymphoma|T-cell+Histocyte-rich Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Germinal Center B-cell Type (GCB)
|
March 24, 2022 | Phase 1 |
NCT00866307 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
February 23, 2009 | Phase 1 |
NCT00017108 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia
|
March 2001 | Phase 3 |
NCT00176930 | Masonic Cancer Center, University of Minnesota |
Leukemia, Myeloid, Chronic|AML|Leukemia, Lymphocytic, Acute|MDS|Leukemia, Lymphocytic, Chronic|JMML|Hodgkin´s Disease|Non-hodgkin´s Lymphoma|Multiple Myeloma
|
October 2001 | Not Applicable |
NCT03743246 | Celgene |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin
|
October 17, 2018 | Phase 1|Phase 2 |
NCT00002627 | St. Louis University|National Cancer Institute (NCI) |
Breast Cancer
|
November 1994 | Phase 1|Phase 2 |
NCT00004221 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Malignant Ovarian Mixed Epithelial Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Undifferentiated Ovarian Carcinoma
|
November 1999 | Phase 2 |
NCT00265031 | University of Cologne |
Hodgkin´s Lymphoma
|
January 1999 | Phase 3 |
NCT03269669 | National Cancer Institute (NCI) |
Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Refractory Follicular Lymphoma
|
August 10, 2017 | Phase 2 |
NCT03579888 | M.D. Anderson Cancer Center|Ziopharm Oncology |
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Ph-Like Acute Lymphoblastic Leukemia|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma
|
June 26, 2020 | Phase 1 |
NCT00004031 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group |
Lymphoma
|
July 1997 | Phase 3 |
NCT00505921 | M.D. Anderson Cancer Center|Bayer |
Lymphoma
|
March 2003 | Phase 2 |
NCT02781467 | Celularity Incorporated |
Leukemia, Myeloid, Acute
|
July 11, 2016 | Phase 1 |
NCT03791827 | Xiqiang Dang|The Children´s Hospital Affiliated to Suzhou University|Shandong Provincial Hospital|Guizhou Provincial People´s Hospital|LanZhou University|The First Affiliated Hospital of Inner Mongolia Medical College|People´s Hospital of Zhangjiajie|Puyang Oilfield General Hospital|The First Affiliated Hospital of Anhui Medical University|Guizhou Maternal and Child Health Care Hospital|The Second Affiliated Hospital & Yuying Children´s Hospital of Wenzhou Medical University|Shenzhen Children´s Hospital|The Second Affiliated Hospital of Harbin Medical University|Yichang Central People´s Hospital|Xian Children´s Hospital|Wuhan Children´s Hospital, Tongji Medical College, Huazhong University of Science & Technology|The First People´s Hospital of Yunnan|The First Affiliated Hospital of Xiamen University|The First Affiliated Hospital of Xinxiang Medical College|Shanxi Provincial Maternity and Children´s Hospital|Liaocheng People´s Hospital|Fujian Provincial Hospital|First Affiliated Hospital of Guangxi Medical University|Second Hospital of Lanzhou University|Guangzhou First People´s Hospital|The Second Hospital of Shandong University|Children´s Hospital of Hebei Province|Beijing Children´s Hospital|Zhengzhou Children´s Hospital|The Children´s Hospital of Chongqing Medical University|Wuxi Children´s Hospital|The Children´s Hospital of Fudan University|Shanghai Children´s Medical Center|Qilu Children´s Hospital of Shandong University|Second Xiangya Hospital of Central South University |
Lupus Nephritis|Children|Steroid|Immunosuppressive Treatment
|
December 1, 2018 | |
NCT01004497 | The Catholic University of Korea |
Acute Lymphoblastic Leukemia
|
March 2010 | Phase 2 |
NCT00478218 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
July 2006 | Phase 2 |
NCT00572169 | University of Arkansas |
Multiple Myeloma
|
November 2006 | Phase 3 |
NCT00924001 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Malignant Melanoma|Melanoma, Experimental
|
August 2007 | Phase 1|Phase 2 |
NCT02004262 | Aduro Biotech, Inc.|Johns Hopkins University |
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
|
February 5, 2014 | Phase 2 |
NCT00054340 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
October 2002 | Phase 1|Phase 2 |
NCT01374620 | Centre Oscar Lambret |
Cancer
|
June 2011 | Phase 1 |
NCT02450058 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
Breast Cancer|Chemotherapy, Adjuvant
|
November 1996 | Phase 3 |
NCT00040690 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
November 2008 | Phase 2 |
NCT00002596 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B |
Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor
|
September 1994 | Phase 3 |
NCT01339663 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent Melanoma|Stage IV Melanoma
|
March 2012 | Phase 1 |
NCT04625907 | University of Birmingham |
Rhabdomyosarcoma
|
September 17, 2020 | Phase 1|Phase 2 |
NCT01980589 | Amgen |
Multiple Myeloma
|
August 2013 | Phase 1 |
NCT00844506 | University Medical Center Groningen|ISA Pharmaceuticals B.V.|Dutch Cancer Society |
Ovarian Cancer
|
October 2008 | Phase 2 |
NCT02443077 | National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
|
July 6, 2016 | Phase 3 |
NCT00436709 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2006 | Not Applicable |
NCT05422066 | Li Zhiming|Antengene Corporation|Sun Yat-sen University |
DLBCL Germinal Center B-Cell Type
|
July 26, 2022 | Phase 2 |
NCT00003696 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lung Cancer
|
October 1998 | Phase 3 |
NCT01190930 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive
|
August 9, 2010 | Phase 3 |
NCT00301821 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
NCT02838225 | Peking Union Medical College Hospital |
Breast Cancer
|
January 2009 | Phase 2 |
NCT01283776 | University of Cologne |
Multiple Myeloma|Non-Hodgkin-Lymphoma|Hodgkin´s Disease
|
March 2011 | Phase 2 |
NCT00004171 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
NCT01096368 | Children´s Oncology Group|National Cancer Institute (NCI) |
Anaplastic Ependymoma|Brain Ependymoma|Cellular Ependymoma|Clear Cell Ependymoma|Ependymoma|Papillary Ependymoma
|
March 29, 2010 | Phase 3 |
NCT02586038 | Mario Boccadoro|University of Turin, Italy |
Multiple Myeloma
|
October 2015 | Phase 2 |
NCT00003425 | University of Kentucky |
Breast Cancer|Leukemia|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific
|
December 1997 | Phase 1|Phase 2 |
NCT00871013 | University of Arkansas |
Myeloma
|
March 2009 | Phase 2 |
NCT00636155 | David Rizzieri|Eleos, Inc.|Duke University |
Lymphoma, Small Lymphocytic|Leukemia, Lymphocytic, Chronic
|
February 2008 | Phase 2 |
NCT05075993 | M.D. Anderson Cancer Center|Lyvgen Biopharma Holdings Limited |
Metastatic Esophageal|Gastric Cancer|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic HPV Related Solid Tumors|Metastatic Ovarian Carcinoma|Metastatic Soft Tissue Sarcoma|Metastatic Uveal Melanoma
|
November 12, 2021 | Phase 1 |
NCT01704716 | St. Anna Kinderkrebsforschung |
Neuroblastoma
|
February 2002 | Phase 3 |
NCT00968253 | M.D. Anderson Cancer Center|Novartis |
Leukemia|Acute Lymphocytic Leukemia
|
November 2009 | Phase 1|Phase 2 |
NCT05077527 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Non-Hodgkin Lymphoma|HIV Infection|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma
|
April 1, 2022 | Phase 1 |
NCT02013817 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
October 11, 2005 | Phase 2 |
NCT03018626 | Nanfang Hospital of Southern Medical University |
Lymphoma, Large B-Cell, Diffuse
|
July 27, 2017 | Phase 3 |
NCT00416910 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
July 1999 | Phase 3 |
NCT05113251 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer
|
October 25, 2021 | Phase 3 |
NCT02055820 | Hoffmann-La Roche|AbbVie |
Lymphoma, Non-Hodgkin
|
November 17, 2013 | Phase 1|Phase 2 |
NCT05147493 | Hellenic Society of Hematology|Sanofi |
Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases
|
April 2022 | Phase 2 |
NCT00002553 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
August 1990 | Phase 2 |
NCT05270057 | Medical College of Wisconsin |
B-cell Lymphoma|Burkitt Lymphoma
|
December 2022 | Phase 1 |
NCT00003638 | Oncothyreon Canada Inc.|National Cancer Institute (NCI) |
Breast Cancer
|
January 1999 | Phase 3 |
NCT01910844 | Centre Jean Perrin |
Metastatic Breast Cancer
|
July 2013 | Phase 2 |
NCT03794167 | Soonchunhyang University Hospital |
Non-hodgkin Lymphoma
|
June 1, 2012 | Phase 2 |
NCT00525603 | M.D. Anderson Cancer Center|Bayer |
Leukemia|Chronic Lymphocytic Leukemia
|
June 2005 | Phase 2 |
NCT01256398 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
December 14, 2010 | Phase 2 |
NCT00002522 | Temple University |
Lymphoma
|
February 1993 | Phase 2 |
NCT01468818 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
September 2011 | Phase 2 |
NCT00719888 | Fred Hutchinson Cancer Center |
Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Burkitt Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Follicular Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|Prolymphocytic Leukemia|Refractory Anemia|Small Lymphocytic Lymphoma
|
November 18, 2005 | Phase 2 |
NCT05287984 | Institute of Hematology & Blood Diseases Hospital |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Newly Diagnosed
|
March 22, 2022 | Phase 2 |
NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
NCT03586869 | ImmunityBio, Inc. |
Pancreatic Cancer
|
July 28, 2018 | Phase 1|Phase 2 |
NCT00002680 | Yale University |
Breast Cancer
|
February 1994 | Phase 2 |
NCT05170828 | Ossium Health, Inc.|Center for International Blood and Marrow Transplant Research |
Acute Leukemia|Myelodysplastic Syndromes|T-lymphoblastic Lymphoma|Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Acute Biphenotypic Leukemia|Acute Undifferentiated Leukemia
|
March 2022 | Phase 1 |
NCT00636909 | Beth Israel Deaconess Medical Center|Amgen |
AML|ALL|CML Chronic Phase, Accelerated Phase, or Blast Crisis|CLL|MDS|RELAPSED NON-HODGKIN´S OR HODGKIN´S LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
|
July 1999 | Phase 2 |
NCT01047072 | Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Systemic Scleroderma
|
Phase 2 | |
NCT00134082 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
November 2005 | Phase 1|Phase 2 |
NCT04713371 | Rampart Health, L.L.C. |
Metastatic Cancer
|
May 19, 2021 | Phase 2 |
NCT02954055 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
September 13, 2017 | Phase 2 |
NCT02645565 | Jawaharlal Institute of Postgraduate Medical Education & Research |
Lupus Nephritis
|
December 2015 | Phase 4 |
NCT00002744 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
May 1996 | Phase 3 |
NCT00199017 | Johann Wolfgang Goethe University Hospital |
Lymphoma, Lymphoblastic
|
April 2004 | Phase 4 |
NCT00690560 | Centre Antoine Lacassagne |
Lymphoma
|
May 2007 | Phase 2 |
NCT02937844 | Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd. |
Glioblastoma Multiforme
|
July 2016 | Phase 1 |
NCT03208556 | Peking University|Marino Biotechnology Co., Ltd. |
Relapsed or Refractory B-cell Lymphoma
|
June 21, 2017 | Phase 1 |
NCT00431080 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
August 2004 | Phase 3 |
NCT04660799 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
February 24, 2021 | Phase 2 |
NCT00002474 | Loyola University|National Cancer Institute (NCI) |
Ovarian Cancer
|
February 1991 | Phase 2 |
NCT03779854 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Biphenotypic Leukemia|Acute Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blasts Under 25 Percent of Bone Marrow Nucleated Cells|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2
|
August 29, 2019 | Phase 2 |
NCT01009970 | Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
May 2010 | Phase 2 |
NCT00343863 | University of Washington|National Cancer Institute (NCI) |
Male Breast Cancer|Nausea and Vomiting|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
January 2006 | Not Applicable |
NCT00950846 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Congenital Pediatric Disorders
|
September 2009 | Not Applicable |
NCT00024128 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
Lymphoma
|
August 2001 | Phase 2 |
NCT02617485 | Mabion SA |
Diffuse Large B-Cell Lymphoma
|
December 2015 | Phase 3 |
NCT02596971 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
|
December 22, 2015 | Phase 1|Phase 2 |
NCT03907852 | TCR2 Therapeutics|Bristol-Myers Squibb |
Mesothelioma|Mesothelioma, Malignant|Mesothelioma; Pleura|Mesotheliomas Pleural|Mesothelioma Peritoneum|Cholangiocarcinoma|Cholangiocarcinoma Recurrent|Ovarian Cancer|Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|High Grade Ovarian Serous Adenocarcinoma
|
April 15, 2019 | Phase 1|Phase 2 |
NCT00328861 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Metastatic Kidney Cancer
|
May 2006 | Phase 2 |
NCT05535166 | St. Jude Children´s Research Hospital |
Medulloblastoma
|
November 2022 | Phase 2 |
NCT00201708 | Ohio State University Comprehensive Cancer Center |
Breast Cancer
|
October 2004 | Phase 2 |
NCT00005988 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myeloma
|
February 2000 | Phase 1 |
NCT00493649 | US Oncology Research|Sanofi |
Breast Cancer
|
June 2007 | Phase 2 |
NCT02911142 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Effusion Lymphoma|B-Cell Neoplasm
|
July 3, 2017 | Phase 1|Phase 2 |
NCT04980222 | Hoffmann-La Roche |
Lymphoma
|
March 22, 2022 | Phase 2 |
NCT01088750 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
November 1, 2009 | Phase 4 |
NCT01925131 | Southwest Oncology Group|National Cancer Institute (NCI) |
Acute Leukemias of Ambiguous Lineage|B-cell Adult Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma
|
April 2014 | Phase 1 |
NCT00002858 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) |
Lung Cancer
|
March 1993 | Phase 3 |
NCT02994927 | ChemoCentryx |
ANCA-Associated Vasculitis
|
March 15, 2017 | Phase 3 |
NCT00006184 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
February 8, 2001 | Phase 2 |
NCT02025881 | Gustave Roussy, Cancer Campus, Grand Paris |
High-risk Medulloblastoma
|
September 14, 2013 | Phase 1|Phase 2 |
NCT04220008 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
|
June 1, 2023 | Phase 2 |
NCT02122081 | Ohio State University Comprehensive Cancer Center |
Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia
|
July 27, 2015 | Not Applicable |
NCT05532111 | RenJi Hospital |
Efficacy and Safety
|
September 1, 2022 | Not Applicable |
NCT01498588 | Emory University|Eisai Inc. |
Breast Neoplasms|Breast Cancer|Breast Tumors|Cancer of the Breast|Neoplasms, Breast|Tumors, Breast
|
November 2011 | Phase 2 |
NCT03118492 | City of Hope Medical Center|National Cancer Institute (NCI) |
Secondary Myelofibrosis
|
May 24, 2017 | Phase 1 |
NCT00310089 | National Cancer Institute (NCI) |
Breast Cancer
|
January 2006 | Not Applicable |
NCT02513186 | Sanofi |
Plasma Cell Myeloma
|
September 30, 2015 | Phase 1 |
NCT00428142 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
December 2006 | Phase 2 |
NCT04643574 | Centre Hospitalier Universitaire Vaudois |
Solid Tumor, Adult
|
March 9, 2021 | Phase 1 |
NCT00290498 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
August 1, 2005 | Phase 2 |
NCT00007475 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
Focal Segmental Glomerulosclerosis
|
December 2000 | Phase 1|Phase 2 |
NCT01049425 | West German Study Group|Sanofi|Amgen |
Primary Breast Cancer|Her2 Non-overexpressing
|
February 5, 2009 | Phase 3 |
NCT00130195 | Japan Adult Leukemia Study Group |
Acute Lymphoblastic Leukemia
|
September 2002 | Phase 2 |
NCT03302403 | Kang YU|CARsgen Therapeutics Co., Ltd.|First Affiliated Hospital of Wenzhou Medical University |
B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction
|
December 29, 2017 | Not Applicable |
NCT01677949 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia
|
December 2013 | Phase 2 |
NCT04872985 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|Hormone-receptor Positive Breast Cancer
|
April 20, 2021 | Phase 2 |
NCT02918747 | Hunan Cancer Hospital |
Lymphoma
|
September 2016 | Phase 2 |
NCT03700450 | Universitätsklinikum Hamburg-Eppendorf|Riemser|Clinical Trial Center North (CTC North GmbH & Co. KG) |
Multiple Myeloma
|
March 16, 2018 | Phase 2 |
NCT02449252 | Wuhan University |
Follicular Lymphoma
|
October 2015 | Phase 3 |
NCT01554371 | University of California, San Francisco|Eisai Inc. |
Malignant Solid Tumour|Breast Cancer Nos Metastatic Recurrent|Neuropathy
|
March 27, 2012 | Phase 1|Phase 2 |
NCT00005866 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
February 2000 | Phase 3 |
NCT02671708 | Nanfang Hospital of Southern Medical University|Third Affiliated Hospital, Sun Yat-Sen University|Peking University People´s Hospital|Zhujiang Hospital|Guangzhou First People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Autologous Hematopoietic Stem Cell Transplantation|Acute Myeloid Leukemia|Conditioning
|
January 2016 | Phase 2|Phase 3 |
NCT03191981 | University of Leeds|Myeloma UK|Karyopharm Therapeutics Inc |
Myeloma Multiple
|
August 1, 2017 | Phase 1|Phase 2 |
NCT02879669 | Targovax Oy|Theradex|Targovax ASA |
To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
|
June 2016 | Phase 1|Phase 2 |
NCT04673617 | Artiva Biotherapeutics, Inc. |
Non Hodgkin Lymphoma
|
March 29, 2021 | Phase 1|Phase 2 |
NCT00721747 | Grupo Oncológico Gallego|Pivotal S.L. |
Breast Cancer
|
January 2008 | Phase 2 |
NCT02992743 | GlaxoSmithKline |
Neoplasms
|
December 6, 2016 | Phase 2 |
NCT00005962 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 2000 | Phase 2 |
NCT03658785 | Tongji Hospital |
Recurrence Tumor|Metastatic Cancer|Solid Tumor
|
December 10, 2018 | Phase 1|Phase 2 |
NCT01871766 | St. Jude Children´s Research Hospital |
Rhabdomyosarcoma
|
December 4, 2013 | Phase 2 |
NCT00025103 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Kidney Cancer
|
May 2001 | Phase 2 |
NCT05207514 | Samyang Biopharmaceuticals Corporation |
Breast Cancer
|
February 1, 2022 | Phase 3 |
NCT00389818 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
January 2007 | Phase 2 |
NCT01706666 | Mayo Clinic |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
December 7, 2012 | Phase 2 |
NCT02461121 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Acute Myeloid Leukemia
|
May 2004 | Phase 3 |
NCT00002718 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
November 1995 | Phase 2 |
NCT00024440 | Genta Incorporated|National Cancer Institute (NCI) |
Leukemia
|
July 2001 | Phase 3 |
NCT00544570 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
April 1998 | Not Applicable |
NCT01985724 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
October 2007 | Phase 3 |
NCT00296205 | Stony Brook University |
Multiple Sclerosis
|
October 2003 | Phase 2 |
NCT00014755 | Fred Hutchinson Cancer Center|Office of Rare Diseases (ORD) |
Multiple Sclerosis
|
December 1997 | Phase 1 |
NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia
|
July 15, 2015 | Phase 2 |
NCT00174707 | Sanofi |
Breast Neoplasms
|
December 1997 | Phase 3 |
NCT00002803 | Children´s Hospital Medical Center, Cincinnati|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1995 | Phase 2 |
NCT02670109 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Triple-Negative Invasive Breast Carcinoma|Residual Tumor
|
February 1, 2018 | Phase 2 |
NCT00586560 | Baylor College of Medicine|Pediatric Brain Tumor Consortium |
Solid Tumors
|
February 2007 | Phase 1 |
NCT00787722 | Northwestern University |
Devic´s Disease
|
October 10, 2009 | Phase 1|Phase 2 |
NCT04942730 | St. Petersburg State Pavlov Medical University |
Leukemia, Acute Lymphoblastic|Myeloid Leukemia, Acute|Biphenotypic Acute Leukemia|Lymphoblastic Lymphoma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm
|
January 21, 2021 | Phase 2 |
NCT02793544 | Center for International Blood and Marrow Transplant Research|National Marrow Donor Program |
Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)+T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL)
|
December 2016 | Phase 2 |
NCT00038142 | M.D. Anderson Cancer Center |
Ewing´s Sarcoma
|
November 1997 | Phase 2 |
NCT00036985 | Imunon|National Cancer Institute (NCI) |
Breast Cancer
|
August 2001 | Phase 2 |
NCT03274492 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
November 16, 2017 | Phase 3 |
NCT04679012 | Weill Medical College of Cornell University|Genentech, Inc. |
Richter Syndrome|Chronic Lymphocytic Leukemia
|
September 24, 2021 | Phase 2 |
NCT00017654 | Northwestern Memorial Hospital|Office of Rare Diseases (ORD) |
Graft Versus Host Disease|Aplastic Anemia
|
April 2001 | Not Applicable |
NCT00464646 | NSABP Foundation Inc|Genentech, Inc.|International Drug Development Institute |
Breast Cancer
|
May 2007 | Phase 2 |
NCT00002773 | St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI) |
Pancreatic Cancer
|
May 1996 | Phase 2 |
NCT01374841 | European Institute of Oncology |
Hematologic Neoplasms
|
August 2010 | Phase 2 |
NCT03016377 | UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals |
Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders
|
March 22, 2012 | Phase 1|Phase 2 |
NCT00602836 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2008 | Phase 2 |
NCT00282412 | Northwestern University |
Rheumatoid Arthritis
|
September 2002 | Phase 1 |
NCT00641095 | University College, London|Cancer Research UK |
Lymphoma
|
December 7, 2006 | Phase 2|Phase 3 |
NCT00083538 | University of Arkansas |
Multiple Myeloma
|
February 2001 | Phase 2 |
NCT03475134 | Centre Hospitalier Universitaire Vaudois |
Metastatic Melanoma
|
February 21, 2018 | Phase 1 |
NCT00038844 | M.D. Anderson Cancer Center |
Lymphoma|Leukemia
|
June 2001 | Not Applicable |
NCT04120519 | Peking Union Medical College Hospital |
Langerhans Cell Histiocytosis
|
October 10, 2019 | Phase 2 |
NCT01218867 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer|Metastatic Melanoma|Renal Cancer
|
November 10, 2010 | Phase 1|Phase 2 |
NCT01082939 | M.D. Anderson Cancer Center|Bayer |
Chronic Lymphocytic Leukemia
|
December 2002 | Phase 2 |
NCT02702960 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Fibrolamellar Cancer Foundation |
Fibrolamellar Hepatocellular Carcinoma|Hepatocellular Carcinoma (Fibrolamellar Variant)|Hepatocellular Carcinoma
|
March 2016 | Phase 2 |
NCT01228331 | Universitätsklinikum Hamburg-Eppendorf |
Leukemia
|
October 2010 | Phase 2|Phase 3 |
NCT02431988 | University College, London |
Diffuse Large B-Cell Lymphoma
|
June 2016 | Phase 1 |
NCT03066947 | BriaCell Therapeutics Corporation|Cancer Insight, LLC |
Breastcancer|Breast Neoplasm
|
May 5, 2017 | Phase 1|Phase 2 |
NCT04088864 | Stanford University |
B Cell Lymphoma|Acute Lymphoblastic Leukemia, Pediatric|Lymphoma
|
January 10, 2020 | Phase 1 |
NCT00856492 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
April 2010 | Phase 2 |
NCT00121992 | Spanish Breast Cancer Research Group|Sanofi |
Breast Neoplasms
|
July 1999 | Phase 3 |
NCT02030964 | New Approaches to Neuroblastoma Therapy Consortium|National Cancer Institute (NCI) |
Neuroblastoma
|
December 2013 | Phase 1 |
NCT02203643 | Mario Boccadoro|University of Turin, Italy |
MULTIPLE MYELOMA (MM)
|
February 2015 | Phase 2 |
NCT01868269 | Institut Curie |
Opsoclonus Myoclonus Syndrome|Neuroblastoma
|
April 18, 2013 | Phase 3 |
NCT01971658 | Nantes University Hospital |
Multiple Myeloma
|
October 2013 | Phase 3 |
NCT00006258 | Children´s Hospital Los Angeles|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
November 1997 | Phase 2 |
NCT00089726 | Cell Genesys |
Lung Cancer|Carcinoma, Non-Small-Cell Lung
|
March 2003 | Phase 2 |
NCT04717531 | The First Affiliated Hospital with Nanjing Medical University |
Breast Cancer
|
June 3, 2021 | Phase 2 |
NCT01420965 | Augusta University |
Prostatic Neoplasms
|
September 2012 | Phase 2 |
NCT02659943 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, B-Cell|Lymphoma, Non-hodgkins
|
January 21, 2016 | Phase 1 |
NCT00136565 | Lymphoma Study Association|Janssen-Cilag International NV |
Peripheral T-cell Lymphoma
|
January 8, 2006 | Phase 2 |
NCT00983944 | Ohio State University Comprehensive Cancer Center |
Lymphoma
|
September 2009 | Phase 2 |
NCT03277729 | Fred Hutchinson Cancer Center|Mustang Bio |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
|
December 5, 2017 | Phase 1|Phase 2 |
NCT00683319 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Cognitive+Functional Effects|Long-term Effects Secondary to Cancer Therapy in Children|Ototoxicity
|
April 2008 | |
NCT00005581 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|National Cancer Institute (NCI) |
Breast Cancer
|
June 2000 | Phase 3 |
NCT02153580 | City of Hope Medical Center|National Cancer Institute (NCI) |
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma
|
September 24, 2014 | Phase 1 |
NCT04181489 | The First Affiliated Hospital with Nanjing Medical University |
EBV-Positive DLBCL, Nos
|
January 1, 2019 | Phase 2 |
NCT01807611 | St. Jude Children´s Research Hospital|Assisi Foundation |
Leukemia|Lymphoma
|
May 16, 2013 | Phase 2 |
NCT00001498 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasms
|
February 1996 | Phase 2 |
NCT04392648 | Takeda |
Relapsed and+or Refractory Multiple Myeloma
|
June 24, 2020 | Phase 1 |
NCT03493854 | Hoffmann-La Roche |
Early Breast Cancer
|
June 14, 2018 | Phase 3 |
NCT00526292 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
August 2007 | Phase 2 |
NCT03573700 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory
|
July 24, 2018 | Phase 1|Phase 2 |
NCT01303705 | Providence Health & Services|MedImmune LLC |
Metastatic Prostate Cancer|Cancer of the Prostate|Prostate Cancer
|
October 14, 2010 | Phase 1 |
NCT00055640 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
NCT00005585 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
NCT01247688 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant
|
November 2010 | Not Applicable |
NCT02978495 | Barretos Cancer Hospital |
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
|
May 17, 2017 | Phase 2 |
NCT00429299 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2006 | Phase 2 |
NCT04418154 | Fudan University |
Triple Negative Breast Cancer
|
June 9, 2020 | Phase 2 |
NCT01413100 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Systemic Scleroderma
|
September 15, 2011 | Phase 2 |
NCT02389309 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Recurrent Brain Neoplasm|Recurrent Malignant Solid Neoplasm|Refractory Brain Neoplasm
|
October 5, 2015 | Phase 1 |
NCT03333486 | Roswell Park Cancer Institute |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3+ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome
|
December 7, 2017 | Phase 2 |
NCT02625480 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory B-precursor Acute Lymphoblastic Leukemia|Relapsed+Refractory B-Cell Non-Hodgkin Lymphoma
|
February 1, 2016 | Phase 1|Phase 2 |
NCT02755844 | Hospices Civils de Lyon |
Recurrent Endometrial Cancer
|
September 23, 2016 | Phase 1|Phase 2 |
NCT03467373 | Hoffmann-La Roche |
B-Cell Lymphoma|Non-Hodgkin Lymphoma
|
March 13, 2018 | Phase 1 |
NCT00538395 | King Faisal Specialist Hospital & Research Center |
Breast Cancer
|
September 2007 | Not Applicable |
NCT04002115 | Milton S. Hershey Medical Center |
Acute Myeloid Leukemia
|
June 3, 2020 | Phase 2 |
NCT00723658 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2008 | Phase 2 |
NCT00066482 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor
|
July 2004 | Not Applicable |
NCT01085617 | University College, London |
Leukemia|Mucositis|Oral Complications
|
December 2010 | Phase 3 |
NCT00365274 | National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma
|
August 2006 | Phase 2 |
NCT00004067 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
February 2000 | Phase 3 |
NCT00759798 | M.D. Anderson Cancer Center |
Chronic Lymphocytic Leukemia|Leukemia
|
August 13, 2008 | Phase 2 |
NCT00974792 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
NCT00096135 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2004 | Not Applicable |
NCT01117441 | University Hospital Schleswig-Holstein|Deutsche Krebshilfe e.V., Bonn (Germany) |
Leukemia
|
June 2010 | Phase 3 |
NCT00199186 | Johann Wolfgang Goethe University Hospital |
Philadelphia Positive Acute Lymphoblastic Leukemia|Lymphoid Blastic Phase of Chronic Myeloid Leukemia
|
March 2002 | Phase 2 |
NCT00003423 | United Kingdom Children´s Cancer Study Group|National Cancer Institute (NCI) |
Lymphoma
|
May 1995 | Phase 3 |
NCT00275106 | Children´s Cancer and Leukaemia Group|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI) |
Lymphoma
|
September 2004 | Phase 3 |
NCT05406401 | Merck Sharp & Dohme LLC |
Lymphoma, Large B-Cell, Diffuse (DLBCL)
|
July 14, 2022 | Phase 2 |
NCT00016406 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
May 2001 | Phase 3 |
NCT00458250 | Tehran University of Medical Sciences |
Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute
|
September 2006 | Phase 1 |
NCT02650635 | Mayo Clinic|National Cancer Institute (NCI) |
Colorectal Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Melanoma of the Skin|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Renal Cell Carcinoma|Solid Neoplasm|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer
|
February 5, 2016 | Phase 1 |
NCT02601313 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Mantle Cell Lymphoma
|
November 9, 2015 | Phase 2 |
NCT00832338 | Emory University|Sanofi |
Breast Neoplasms|Breast Cancer|Cancer of the Breast
|
April 2009 | Phase 2 |
NCT00499603 | M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI) |
Breast Cancer
|
July 2007 | Phase 2 |
NCT00022230 | Roger Williams Medical Center |
Breast Cancer
|
January 2000 | Phase 1|Phase 2 |
NCT00002835 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 30, 1995 | Phase 3 |
NCT01946529 | St. Jude Children´s Research Hospital|University of Tennessee Health Science Center|University of Florida|Nemours Children´s Clinic |
Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor
|
December 27, 2013 | Phase 2 |
NCT05477589 | Vastra Gotaland Region |
Acute Myeloid Leukemia (AML) in Remission|Stem Cell Transplantation
|
June 7, 2022 | Phase 3 |
NCT00002967 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
May 1997 | Phase 3 |
NCT00124111 | Amgen |
Breast Cancer
|
Phase 2 | |
NCT00003243 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
January 1998 | Phase 1 |
NCT04024462 | Hoffmann-La Roche |
HER2-positive Early Breast Cancer
|
February 5, 2020 | Phase 3 |
NCT01427881 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Myeloid Leukemia in Remission|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
September 2011 | Phase 2 |
NCT00133991 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 2 |
NCT02950259 | Providence Health & Services|Brooklyn ImmunoTherapeutics, LLC |
Breast Neoplasm|Breast Neoplasm, Male|Triple Negative Breast Cancer
|
February 9, 2017 | Phase 1 |
NCT04350021 | Vastra Gotaland Region |
Breast Cancer Metastatic|Chemotherapy Effect
|
March 1, 2019 | |
NCT00589563 | City of Hope Medical Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms|Precancerous Condition|Secondary Myelofibrosis|Small Intestine Cancer
|
May 2007 | Phase 2 |
NCT00368355 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Acute Lymphoblastic Leukemia|Non Hodgkins Lymphoma|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Hemophagocytic Lymphohistiocytosis (HLH)|Familial Hemophagocytic Lymphohistiocytosis (FLH)|Viral-associated Hemophagocytic Syndrome (VAHS)|X-linked Lymphoproliferative Disease (XLP)
|
April 2000 | Phase 2 |
NCT04914741 | Peter MacCallum Cancer Centre, Australia|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma
|
June 29, 2021 | Phase 1|Phase 2 |
NCT00819806 | Hassane M. Zarour, MD|National Cancer Institute (NCI)|University of Pittsburgh |
NY-ESO-1-expressing Tumors
|
January 2009 | Phase 1 |
NCT04780464 | European Organisation for Research and Treatment of Cancer - EORTC |
Advanced Soft-tissue Sarcoma
|
April 11, 2022 | Phase 3 |
NCT01652092 | Masonic Cancer Center, University of Minnesota |
SCID|Omenn´s Syndrome|Reticular Dysgenesis|Wiskott-Aldrich Syndrome|Bare Lymphocyte Syndrome|Common Variable Immunodeficiency|Chronic Granulomatous Disease|CD40 Ligand Deficiency|Hyper IgM Syndrome|X-linked Lymphoproliferative Disease|Hemophagocytic Lymphohistiocytosis|Griscelli Syndrome|Chediak-Higashi Syndrome|Langerhan´s Cell Histiocytosis
|
September 4, 2012 | Not Applicable |
NCT00176462 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Lymphocytic Leukemia
|
February 2001 | Phase 2 |
NCT05049473 | PETHEMA Foundation|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Mature B-Cell Leukemia Burkitt Type|Burkitt Lymphoma (BL)|Unclassifiable Lymphoma Between DCBL and BL
|
January 2014 | Phase 2 |
NCT03089203 | University of Pennsylvania |
Prostate Cancer
|
March 8, 2017 | Phase 1 |
NCT03876886 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Triple Negative Breast Cancer
|
February 22, 2019 | Phase 3 |
NCT05451849 | TCR2 Therapeutics |
Mesothelioma|Mesotheliomas Pleural|Mesothelioma, Malignant|Mesothelioma Peritoneum|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Pancreatic Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer|Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Ovarian Adenocarcinoma|Pancreatic Neoplasms|Colorectal Neoplasms|Ovarian Neoplasms
|
June 21, 2022 | Phase 1|Phase 2 |
NCT00070018 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
NCT03984448 | National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Double-Expressor Lymphoma|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
|
August 7, 2019 | Phase 2|Phase 3 |
NCT03553238 | Nanfang Hospital of Southern Medical University |
Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic
|
February 14, 2016 | Phase 2|Phase 3 |
NCT04633148 | AvenCell Europe GmbH|PHARMALOG Institut für klinische Forschung GmbH |
Prostate Cancer
|
November 23, 2020 | Phase 1 |
NCT00393107 | Gruppo Italiano Studio Linfomi |
Follicular Lymphoma
|
March 2000 | Phase 2 |
NCT00550992 | Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children´s Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom |
Leukemia
|
January 2006 | Not Applicable |
NCT01740401 | Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb |
Melanoma
|
October 2012 | Phase 2 |
NCT01055314 | National Cancer Institute (NCI) |
Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Metastatic Childhood Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma
|
January 2010 | Phase 2 |
NCT03926091 | Fudan University |
Breast Cancer
|
July 3, 2018 | Phase 3 |
NCT00489281 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Sickle Cell Disease
|
June 23, 2008 | Phase 2 |
NCT01026116 | Fudan University |
Breast Neoplasms
|
December 2009 | Phase 3 |
NCT01570764 | Assistance Publique - Hôpitaux de Paris|Hôpital Claude-Huriez |
Systemic Sclerosis|Scleroderma|Interstitial Lung Disease|Lung Fibrosis
|
January 14, 2013 | Phase 3 |
NCT00322101 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Myeloid Leukemia+Transient Myeloproliferative Disorder|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes
|
January 2006 | Phase 3 |
NCT00092222 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoproliferative Disorder|HHV-8|Malignancy|HIV
|
October 28, 2004 | Phase 2 |
NCT03139851 | Centre Leon Berard|Merck Sharp & Dohme LLC |
Metastatic Breast Cancer
|
June 27, 2017 | Phase 2 |
NCT00169130 | Lymphoma Study Association|Fondation ARC |
Lymphoma, Large-Cell, Diffuse
|
October 1999 | Phase 2|Phase 3 |
NCT00002772 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B |
Breast Cancer
|
July 1996 | Phase 3 |
NCT00809276 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|M.D. Anderson Cancer Center|Fred Hutchinson Cancer Center|Otsuka Pharmaceutical Co., Ltd. |
Lymphoma|Multiple Myeloma|Leukemia|Myelodysplastic Syndrome
|
May 2009 | Phase 1|Phase 2 |
NCT00026208 | Stanford University |
Lymphoma, Hodgkin Disease|Lymphoma|Hodgkin Disease|Lymphoma: Hodgkin
|
June 2001 | Phase 2 |
NCT00270894 | Accelerated Community Oncology Research Network|Aventis Pharmaceuticals |
Breast Neoplasm
|
November 2005 | Phase 2 |
NCT00901069 | Shams Shakil|Celgene|University of Kentucky |
Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin
|
May 2009 | Phase 1 |
NCT00003662 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Thymic Carcinoma
|
August 1998 | Phase 2 |
NCT00006390 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
February 2001 | Phase 2 |
NCT00055679 | UNICANCER |
Breast Cancer
|
August 2002 | Phase 3 |
NCT03709680 | Pfizer|Children´s Oncology Group (COG) |
Ewing Sarcoma|Solid Tumors|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma
|
May 24, 2019 | Phase 2 |
NCT05114837 | Masonic Cancer Center, University of Minnesota |
Lymphoma Leukemia
|
November 2022 | Phase 1|Phase 2 |
NCT04530565 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
October 14, 2020 | Phase 3 |
NCT01336933 | University of Nebraska|National Cancer Institute (NCI)|Spectrum Pharmaceuticals, Inc |
Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma
|
July 2011 | Phase 2 |
NCT02446964 | City of Hope Medical Center|National Cancer Institute (NCI) |
Adult Acute Lymphoblastic Leukemia in Complete Remission|Acute Myeloid Leukemia in Remission|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Childhood Acute Lymphoblastic Leukemia in Complete Remission
|
June 25, 2015 | Phase 1 |
NCT02224599 | Kiromic, Inc. |
Progressive Solid Malignancies|Refractory Solid Malignancies|Cancer
|
July 28, 2017 | Phase 1|Phase 2 |
NCT03349177 | Zhiyong Yu|Shandong Cancer Hospital and Institute |
Breast Cancer|Pathological Complete Response|Neoadjuvant Chemotherapy
|
November 27, 2017 | Phase 2|Phase 3 |
NCT02784015 | Samsung Medical Center |
Unresectable Localized Soft Tissue Sarcoma
|
May 2016 | Phase 2 |
NCT03594162 | UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals |
Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders
|
||
NCT00004175 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer
|
November 1998 | Phase 2 |
NCT05005299 | Melbourne Health |
Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute, L1|Leukemia, Lymphoblastic, Acute, L2|Myelodysplastic Syndromes|Non-hodgkin Lymphoma|Plasma Cell Myeloma
|
June 8, 2022 | Phase 1 |
NCT04608487 | Dana-Farber Cancer Institute|Kite, A Gilead Company |
Lymphoma|Lymphoma Cns
|
December 4, 2020 | Phase 1 |
NCT00005797 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
March 1993 | Phase 2 |
NCT04569032 | Seagen Inc. |
Peripheral T-cell Lymphoma
|
November 12, 2020 | Phase 2 |
NCT00004255 | Chimeric Therapies|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes
|
March 2000 | Phase 2|Phase 3 |
NCT00029380 | National Heart, Lung, and Blood Institute (NHLBI) |
Hematologic Diseases|Anemia, Sickle Cell|Beta-Thalassemia|Hematopoietic Stem Cell Transplantation
|
January 1999 | Phase 2 |
NCT00772668 | University of Miami |
Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma
|
September 25, 2009 | Not Applicable |
NCT01516307 | OBI Pharma, Inc |
Metastatic Breast Cancer
|
December 2011 | Phase 2 |
NCT00002649 | National Cancer Institute (NCI) |
Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma
|
May 1995 | Phase 3 |
NCT02757391 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Colorectal Adenocarcinoma|Metastatic Cholangiocarcinoma|Metastatic Colorectal Carcinoma|Metastatic Digestive System Carcinoma|Metastatic Esophageal Carcinoma|Metastatic Gastric Carcinoma|Metastatic Pancreatic Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7
|
August 9, 2019 | Phase 1 |
NCT00004230 | Northwestern University|National Cancer Institute (NCI) |
Cancer
|
October 1999 | Phase 3 |
NCT04757337 | UNICANCER |
Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma
|
June 18, 2021 | Phase 3 |
NCT01124526 | Asociacion Espanola de Hematologia y Hemoterapia |
Non Hodgkin Lymphoma
|
September 2004 | Phase 4 |
NCT03778619 | GC Cell Corporation |
Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma
|
November 28, 2018 | Phase 1|Phase 2 |
NCT00486668 | NSABP Foundation Inc|GlaxoSmithKline |
Invasive Breast Cancer
|
July 2007 | Phase 3 |
NCT04881240 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory|Pediatric ALL
|
November 2022 | Phase 1 |
NCT00074139 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 2003 | Phase 1 |
NCT04098653 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital |
Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning|Myeloid Tumors
|
September 2019 | Phase 2|Phase 3 |
NCT01421017 | NYU Langone Health|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer
|
August 19, 2011 | Phase 1|Phase 2 |
NCT01287741 | Hoffmann-La Roche|Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
July 26, 2011 | Phase 3 |
NCT01897441 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
June 2013 | Not Applicable |
NCT01967823 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Meningioma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer
|
October 24, 2013 | Phase 2 |
NCT01856192 | National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
August 27, 2013 | Phase 2 |
NCT00378534 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome
|
September 2006 | Phase 2 |
NCT00866905 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Breast Cancer
|
April 2009 | Phase 2 |
NCT00312208 | Sanofi|Cancer International Research Group (CIRG) |
Breast Cancer
|
November 2001 | Phase 3 |
NCT05517213 | Affiliated Hospital to Academy of Military Medical Sciences |
Multiple Myeloma
|
February 1, 2022 | Not Applicable |
NCT01493453 | Professor Robert Hawkins|The Christie NHS Foundation Trust |
CD19 Positive Non-Hodgkin Lymphoma
|
March 2008 | Phase 1 |
NCT00553306 | Fred Hutchinson Cancer Center |
Recurrent Melanoma|Stage IV Melanoma
|
September 2007 | Phase 1|Phase 2 |
NCT03579875 | Masonic Cancer Center, University of Minnesota |
Fanconi Anemia|Severe Aplastic Anemia|Myelodysplastic Syndromes
|
November 13, 2018 | Phase 2 |
NCT05514015 | First Affiliated Hospital, Sun Yat-Sen University |
Idiopathic Membranous Nephropathy
|
August 25, 2022 | Phase 4 |
NCT04074746 | M.D. Anderson Cancer Center |
Recurrent Anaplastic Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Classic Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
|
July 18, 2020 | Phase 1|Phase 2 |
NCT04093648 | Baylor College of Medicine|The Methodist Hospital Research Institute |
Hepatocellular Carcinoma|Hepatoblastoma
|
January 2020 | Phase 1 |
NCT03301350 | University of Wisconsin, Madison |
Breast Cancer|Triple Negative Breast Cancer
|
November 7, 2017 | Phase 2 |
NCT00079261 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma|Small Intestine Cancer
|
January 2004 | Phase 2 |
NCT04678401 | Dana-Farber Cancer Institute |
Stem Cell Transplant Complications|Graft Vs Host Disease|Myeloid Leukemia, Acute|Myeloid Leukemia in Relapse (Disorder)|Myelodysplastic Syndromes
|
January 12, 2021 | Phase 1 |
NCT00678327 | University College, London|Cancer Research UK|Cancer Research UK & UCL Cancer Trials Centre |
Lymphoma
|
August 29, 2008 | Phase 3 |
NCT00254410 | M.D. Anderson Cancer Center|OSI Pharmaceuticals|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
March 14, 2005 | Phase 2 |
NCT02447055 | Washington University School of Medicine |
Multiple Myeloma|Myeloma-Multiple
|
December 2015 | Early Phase 1 |
NCT00747877 | Leeds Cancer Centre at St. James´s University Hospital|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
April 2008 | Phase 3 |
NCT03563157 | ImmunityBio, Inc. |
Colorectal Cancer Metastatic|mCRC
|
May 25, 2018 | Phase 1|Phase 2 |
NCT03339700 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Acute Lymphoblastic Leukemia, Adult
|
September 15, 2018 | Phase 2 |
NCT00857389 | M.D. Anderson Cancer Center |
Stem Cell Transplantation|Leukemia|Lymphoma
|
March 2, 2009 | Phase 2 |
NCT03147612 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia With BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
February 8, 2018 | Phase 2 |
NCT00425516 | Centre Jean Perrin |
Individualized Chemotherapy
|
January 2007 | Phase 2 |
NCT00933517 | Centre Jean Perrin |
Pathological Response Rate
|
September 2009 | Phase 2 |
NCT01356290 | Medical University of Vienna |
Medulloblastoma Recurrent|Ependymoma Recurrent|ATRT Recurrent
|
April 2014 | Phase 2 |
NCT00305760 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
December 2005 | Phase 2 |
NCT01581970 | Masonic Cancer Center, University of Minnesota |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma
|
June 2012 | Phase 2 |
NCT00334646 | GlaxoSmithKline |
Nausea and Vomiting, Chemotherapy-Induced
|
August 10, 2005 | Phase 1 |
NCT01321008 | M.D. Anderson Cancer Center |
Lymphoma
|
May 2011 | Phase 1|Phase 2 |
NCT02073097 | Case Comprehensive Cancer Center |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
January 28, 2015 | Phase 1|Phase 2 |
NCT05192889 | St. Jude Children´s Research Hospital|AbbVie |
Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia
|
August 25, 2022 | Phase 1|Phase 2 |
NCT00536601 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor (PNET)|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Neuroblastoma|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Regional Neuroblastoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia
|
June 29, 2006 | Not Applicable |
NCT00003215 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
April 1997 | Phase 3 |
NCT00003214 | Swiss Group for Clinical Cancer Research |
Ovarian Cancer
|
July 1996 | Phase 3 |
NCT00753103 | University Hospital Birmingham NHS Foundation Trust |
Wegener´s Granulomatosis|Renal Limited Vasculitis|Microscopic Polyangiitis
|
January 2003 | Phase 2 |
NCT03003676 | Targovax Oy|Targovax ASA |
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
|
December 2016 | Phase 1 |
NCT00923364 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
MDS|Immunodeficiency|GATA2
|
May 7, 2009 | Phase 2 |
NCT00024050 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
February 2001 | Phase 2 |
NCT01044745 | University of Nebraska|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia+Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides+Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult T-cell Leukemia+Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides+Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenström Macroglobulinemia
|
December 2009 | Phase 2 |
NCT03994705 | Cartesian Therapeutics |
Multiple Myeloma
|
August 6, 2019 | Phase 1|Phase 2 |
NCT01004991 | Weill Medical College of Cornell University|Celgene |
Diffuse Large B Cell Lymphoma
|
January 2010 | Phase 1|Phase 2 |
NCT00003086 | Louisiana State University Health Sciences Center Shreveport |
Breast Cancer
|
March 1997 | Phase 1|Phase 2 |
NCT04823091 | Wuhan Union Hospital, China|Beijing GoBroad Hospital Management Co.,Ltd|Shanghai YaKe Biotechnology Ltd. |
T-Cell Lymphocytic Leukemia|T-Cell Chronic Lymphocytic Leukemia|T Cell Non-Hodgkin Lymphoma
|
April 15, 2021 | Phase 1 |
NCT04088890 | Stanford University |
B-ALL|B-cell Non Hodgkin Lymphoma|DLBCL|Follicular Lymphoma Grade 3B
|
September 12, 2019 | Phase 1 |
NCT00002780 | St. Luke´s Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 1996 | Phase 1|Phase 2 |
NCT00002987 | Medical Research Council|National Cancer Institute (NCI) |
Lymphoma
|
January 1997 | Phase 3 |
NCT05244070 | Bristol-Myers Squibb |
Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma
|
September 14, 2022 | Phase 1 |
NCT03023358 | Nanfang Hospital of Southern Medical University |
Peripheral T Cell Lymphoma
|
February 2017 | Phase 3 |
NCT00199082 | Nicola Goekbuget|Goethe University |
Burkitt´s Lymphoma|Burkitt´s Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma
|
July 2002 | Phase 4 |
NCT00398554 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
June 2005 | Phase 2 |
NCT00481832 | Stanford University |
Lymphoma, Non-Hodgkin
|
January 2007 | Phase 2 |
NCT00093587 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia
|
August 2004 | Not Applicable |
NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis
|
July 9, 2015 | Phase 2 |
NCT02792114 | Memorial Sloan Kettering Cancer Center|United States Department of Defense |
Breast Cancer|Metastatic HER2-negative Breast
|
June 2016 | Phase 1 |
NCT00054327 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
November 2000 | Phase 2 |
NCT00513474 | Massachusetts General Hospital |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
January 2008 | Phase 1 |
NCT04221035 | Gustave Roussy, Cancer Campus, Grand Paris |
High-Risk Neuroblastoma
|
November 5, 2019 | Phase 3 |
NCT00005998 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
NCT00148681 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
|
May 2001 | Phase 2 |
NCT02894645 | National University Hospital, Singapore |
Acute Lymphoblastic Leukemia (ALL)
|
October 2008 | Phase 4 |
NCT01105650 | Masonic Cancer Center, University of Minnesota |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Breast Cancer
|
July 2010 | Phase 2 |
NCT05495464 | M.D. Anderson Cancer Center|Kite, A Gilead Company|Acerta Pharma, LLC |
Lymphoma|Mantle Cell Lymphoma
|
November 18, 2022 | Early Phase 1 |
NCT00129376 | Spanish Breast Cancer Research Group|Sanofi |
Breast Cancer
|
February 2003 | Phase 2 |
NCT01186640 | German CLL Study Group|Genzyme, a Sanofi Company|University of Cologne |
T-cell-prolymphocytic Leukemia
|
June 2010 | Phase 2 |
NCT00667329 | M.D. Anderson Cancer Center |
Lymphoma
|
July 9, 1999 | Phase 1 |
NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
NCT04049669 | Theodore S. Johnson|National Cancer Institute (NCI)|Augusta University|Emory University |
Glioblastoma|Medulloblastoma|Ependymoma|Diffuse Intrinsic Pontine Glioma
|
October 2, 2019 | Phase 2 |
NCT05479578 | Rashmi Verma, MD|National Cancer Institute (NCI)|University of California, Davis |
Castration-Resistant Prostate Carcinoma|Metastatic Prostate Adenocarcinoma|Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
|
June 29, 2022 | Phase 1 |
NCT00317785 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
May 2005 | Phase 2 |
NCT00608517 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
September 2005 | Not Applicable |
NCT01094548 | Merck KGaA, Darmstadt, Germany |
Multiple Myeloma
|
January 2008 | Phase 2 |
NCT02228772 | Massachusetts General Hospital|Millennium Pharmaceuticals, Inc. |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia
|
December 2014 | Phase 1 |
NCT03593902 | Northwestern University |
Systemic Sclerosis|Scleroderma
|
May 17, 2018 | Phase 2|Phase 3 |
NCT04551885 | Fate Therapeutics |
Solid Tumor, Adult
|
September 7, 2020 | Phase 1 |
NCT01527487 | SCRI Development Innovations, LLC|Eisai Inc. |
HER2 Negative Breast Cancer
|
June 2012 | Phase 2 |
NCT00285389 | French Innovative Leukemia Organisation|Hoffmann-La Roche |
Mantle Cell Lymphoma
|
February 2002 | Phase 2 |
NCT01457131 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer|Metastatic Melanoma|Metastatic Renal Cancer
|
October 6, 2011 | Phase 1 |
NCT02685059 | German Breast Group|AstraZeneca|Celgene |
Breast Cancer
|
June 2016 | Phase 2 |
NCT00003972 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 1998 | Phase 3 |
NCT00971763 | University College, London |
Lymphoma
|
March 2006 | Phase 2 |
NCT00536978 | M.D. Anderson Cancer Center |
Lymphoma|Leukemia
|
September 2007 | Phase 2 |
NCT02933775 | RenJi Hospital|CARsgen Therapeutics Co., Ltd. |
CD19 Positive Malignant B-cell Leukemia and Lymphoma
|
October 2016 | Phase 1 |
NCT01342289 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Hodgkin´s Lymphoma|Leukemia|Myelodysplastic Syndrome(MDS)|Multiple Myeloma|Non Hodgkin´s Lymphoma
|
August 2011 | Phase 1 |
NCT00004224 | Societe Internationale d´Oncologie Pediatrique|Children´s Cancer and Leukaemia Group|Italian Association for Pediatric Hematology Oncology|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
January 1999 | Phase 2 |
NCT02419170 | Washington University School of Medicine |
Carcinoma, Non-Small-Cell-Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer
|
July 2016 | Early Phase 1 |
NCT02582775 | Masonic Cancer Center, University of Minnesota |
Epidermolysis Bullosa
|
March 2016 | Phase 2 |
NCT03061656 | Samsung Medical Center|Ministry of Health, Republic of Korea |
High Risk Neuroblastoma
|
January 1, 2009 | Phase 2 |
NCT02282514 | Northwestern University |
Stiff-Person Syndrome
|
October 2014 | Phase 1|Phase 2 |
NCT04160195 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, B-Cell|Lymphoma, Non-hodgkins|Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia
|
December 20, 2019 | Phase 1 |
NCT03249831 | City of Hope Medical Center|California Institute for Regenerative Medicine (CIRM) |
Sickle Cell Disease|Sickle Cell Disorder|Hemoglobinopathies|Thalassemia|Anemia, Sickle Cell
|
January 4, 2019 | Phase 1 |
NCT00004036 | The Cleveland Clinic|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Drug+Agent Toxicity by Tissue+Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific
|
November 1997 | Phase 1 |
NCT01015456 | Chulalongkorn University|Clinical Research Collaborative Network|Health Intervention and Technology Assessment Program (HITAP) |
Lupus Nephritis
|
January 2010 | Phase 3 |
NCT05159193 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
December 20, 2021 | Phase 3 |
NCT00004006 | St. Jude Children´s Research Hospital|National Cancer Institute (NCI) |
Retinoblastoma
|
November 1997 | Phase 2 |
NCT01025778 | Lund University Hospital |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
December 2009 | Phase 2 |
NCT00101101 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Lymphoma Research Foundation|Novartis |
Lymphoma
|
July 2004 | Phase 2 |
NCT05442580 | University of Pennsylvania |
Acute Myeloid Leukemia (AML)|Multiple Myeloma (MM)
|
May 2023 | Phase 1 |
NCT03409198 | Oslo University Hospital|Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF|Jules Bordet Institute|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Centre Hospitalier Universitaire Dinant Godinne - UCL Namur |
Breast Cancer|Hormone Receptor Positive Tumor|Metastatic Breast Cancer
|
January 21, 2018 | Phase 2 |
NCT01416038 | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
|
December 2011 | Phase 1 |
NCT00546156 | Ian E. Krop, MD, PhD|Genentech, Inc.|Massachusetts General Hospital|Brigham and Women´s Hospital|New Hampshire Oncology-Hematology PA|Dana-Farber Cancer Institute |
Breast Cancer
|
October 2007 | Phase 2 |
NCT03690011 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma
|
August 2, 2021 | Phase 1 |
NCT02936375 | RenJi Hospital |
Lupus Nephritis
|
September 7, 2017 | Phase 2 |
NCT02049580 | Istituto Clinico Humanitas |
Lymphoma
|
July 2013 | Phase 2 |
NCT00025649 | European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1999 | Phase 2 |
NCT04243109 | Maimónides Biomedical Research Institute of Córdoba |
Multiple Myeloma
|
February 23, 2017 | Phase 2 |
NCT00719173 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer|Nausea and Vomiting
|
August 2005 | Phase 1 |
NCT00083161 | Gundersen Lutheran Health System |
Lung Cancer
|
June 2003 | Phase 2 |
NCT00129389 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb |
Breast Cancer
|
September 19, 2003 | Phase 3 |
NCT04083495 | UNC Lineberger Comprehensive Cancer Center |
Peripheral T Cell Lymphoma
|
September 17, 2019 | Phase 2 |
NCT04301076 | National Cancer Institute (NCI) |
Acute Adult T-Cell Leukemia+Lymphoma|Adult T-Cell Leukemia+Lymphoma|Chronic Adult T-Cell Leukemia+Lymphoma|HTLV-1 Infection
|
June 15, 2020 | Phase 1 |
NCT00185614 | Wen-Kai Weng|Stanford University |
Blood Cancer|Multiple Myeloma
|
August 2000 | Phase 2 |
NCT01849783 | Margarida Magalhaes-Silverman|National Cancer Institute (NCI)|University of Iowa |
Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
April 4, 2013 | Phase 2 |
NCT02225665 | Sangamo Therapeutics |
Human Immunodeficiency Virus (HIV)
|
August 2014 | Phase 1|Phase 2 |
NCT02287311 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Hodgkin Disease|Non-Hodgkin Lymphoma|Severe Chronic Active Epstein Barr Virus|T+NK-lymphoproliferative Disease|Nasopharyngeal Carcinoma|Smooth Muscle Tumor
|
February 2015 | Phase 1 |
NCT04978584 | M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma
|
March 3, 2022 | Phase 2 |
NCT05600686 | Joseph Tuscano|National Cancer Institute (NCI)|ADC Therapeutics|University of California, Davis |
Double-Expressor Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
|
December 1, 2022 | Phase 2 |
NCT00736450 | University of Nebraska|National Cancer Institute (NCI)|Genta Incorporated |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
July 2008 | Not Applicable |
NCT00038402 | M.D. Anderson Cancer Center|Genentech, Inc. |
Breast Cancer
|
April 2001 | Phase 3 |
NCT00174655 | Sanofi |
Breast Neoplasms
|
June 1998 | Phase 3 |
NCT03132584 | Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Sanofi |
Non Hodgkin Lymphoma|High-grade B-cell Lymphoma|Diffuse Large B Cell Lymphoma
|
July 30, 2017 | Phase 1 |
NCT01979536 | National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
|
November 8, 2013 | Phase 2 |
NCT00129935 | Spanish Breast Cancer Research Group|Sanofi|Hoffmann-La Roche|Pfizer |
Breast Cancer
|
February 2004 | Phase 3 |
NCT00036868 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
February 2002 | Phase 2 |
NCT03945591 | NYU Langone Health |
GVHD
|
June 20, 2019 | Phase 2 |
NCT00004197 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
June 1999 | Phase 2 |
NCT01106898 | University of Nebraska|National Cancer Institute (NCI) |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer
|
March 2010 | Phase 2 |
NCT04745949 | M.D. Anderson Cancer Center |
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
May 10, 2021 | Phase 2 |
NCT01192555 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Neuroblastoma
|
September 2010 | Phase 1|Phase 2 |
NCT04362293 | St. Jude Children´s Research Hospital |
Sickle Cell Disease
|
April 30, 2020 | Phase 2 |
NCT00719849 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
November 2005 | Phase 2 |
NCT00004464 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Aplastic Anemia|Paroxysmal Hemoglobinuria, Nocturnal
|
February 1996 | Phase 2 |
NCT00005578 | Children´s Oncology Group|National Cancer Institute (NCI) |
Cardiac Toxicity|Lymphoma
|
March 1997 | Phase 3 |
NCT00345865 | Masonic Cancer Center, University of Minnesota |
Lymphoma
|
August 24, 2005 | Phase 2 |
NCT01585415 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer|Melanoma
|
April 9, 2012 | Phase 1 |
NCT00379574 | Asan Medical Center|Janssen Korea, Ltd., Korea |
Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell
|
September 2006 | Phase 1|Phase 2 |
NCT00031590 | Children´s Hospital of Philadelphia|Stanford University|Emory University |
Brain Tumors|Central Nervous System Tumors|Medulloblastoma
|
April 2001 | Phase 2 |
NCT00005641 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
September 1997 | Phase 2 |
NCT05207722 | Celularity Incorporated |
Metastatic HER2 Positive Gastroesophageal Junction Cancer
|
April 14, 2022 | Phase 1|Phase 2 |
NCT00545714 | Hoffmann-La Roche |
Leukemia, Lymphocytic, Chronic, B-Cell
|
November 21, 2007 | Phase 2 |
NCT00002498 | Leiden University Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 1992 | Phase 2 |
NCT02414269 | Memorial Sloan Kettering Cancer Center|Bellicum Pharmaceuticals|United States Department of Defense |
Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer
|
May 2015 | Phase 1|Phase 2 |
NCT02861417 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid Cell Neoplasm|High Risk Acute Myeloid Leukemia|High Risk Myelodysplastic Syndrome|Lymphoproliferative Disorder|Myelodysplastic Syndrome|Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent High Risk Myelodysplastic Syndrome|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma
|
August 5, 2016 | Phase 2 |
NCT00017381 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia
|
April 2001 | Early Phase 1 |
NCT00629278 | Azienda Ospedaliero-Universitaria di Modena|National Cancer Institute (NCI) |
Breast Cancer
|
December 2007 | Phase 3 |
NCT01076556 | National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
April 2010 | Phase 1 |
NCT05463133 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Chronic Granulomatous Disease
|
July 8, 2022 | Phase 1|Phase 2 |
NCT00343785 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI) |
Aplastic Anemia
|
February 2006 | Phase 2 |
NCT00816595 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2009 | Phase 2 |
NCT00339118 | Sheba Medical Center |
Rhabdomyosarcoma
|
Phase 4 | |
NCT03017131 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 8, 2017 | Phase 1 |
NCT02388594 | University of Pennsylvania|National Institute of Allergy and Infectious Diseases (NIAID) |
Human Immunodeficiency Virus (HIV)
|
April 2015 | Phase 1 |
NCT02161692 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Testicular Neoplasms|Germ Cell Tumors
|
December 1996 | Phase 2 |
NCT02162420 | Masonic Cancer Center, University of Minnesota |
Dyskeratosis Congenita|Aplastic Anemia
|
January 2015 | Not Applicable |
NCT04437160 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Triple Negative Breast Cancer
|
February 1, 2020 | Phase 2 |
NCT01454596 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Malignant Glioma|Glioblastoma|Brain Cancer|Gliosarcoma
|
May 16, 2012 | Phase 1|Phase 2 |
NCT00002494 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 1992 | Phase 2 |
NCT03939026 | Allogene Therapeutics |
Relapsed+Refractory Large B Cell Lymphoma|Relapsed+Refractory Follicular Lymphoma
|
May 1, 2019 | Phase 1 |
NCT03215810 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Stand Up To Cancer|Iovance Biotherapeutics, Inc. |
Non-Small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas
|
October 11, 2017 | Phase 1 |
NCT04904185 | Inge Marie Svane|Technical University of Denmark|Herlev Hospital |
Malignant Melanoma
|
August 17, 2021 | Phase 1 |
NCT04715191 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor
|
July 3, 2023 | Phase 1 |
NCT02559154 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Multiple Myeloma
|
July 2010 | Phase 4 |
NCT03197584 | ImmunityBio, Inc. |
Ovarian Cancer
|
December 2017 | Phase 1|Phase 2 |
NCT03417154 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia|Higher Risk Myelodysplastic Syndrome
|
August 13, 2018 | Phase 2 |
NCT05537766 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Waldenstrom Macroglobulinemia|Relapsed+Refractory Richter Transformation|Relapsed+Refractory Burkitt Lymphoma|Relapsed+Refractory Hairy Cell Leukemia
|
November 1, 2022 | Phase 2 |
NCT01779050 | Washington University School of Medicine|Genentech, Inc. |
Breast Neoplasms
|
December 19, 2013 | Phase 2 |
NCT03530462 | First Affiliated Hospital of Zhejiang University |
Cognitive Impairment|Autoimmune Encephalitis
|
April 7, 2017 | |
NCT00077116 | European Organisation for Research and Treatment of Cancer - EORTC |
Leukemia|Myelodysplastic Syndromes
|
November 2003 | Phase 2 |
NCT00004125 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B |
Breast Cancer
|
October 1999 | Phase 3 |
NCT01857115 | European Myeloma Network|Fondazione EMN Italy Onlus |
Multiple Myeloma
|
April 2013 | Phase 1|Phase 2 |
NCT00533936 | Instituto Nacional de Cancerologia, Columbia|National Cancer Institute (NCI) |
Breast Cancer
|
September 2006 | Phase 2 |
NCT00354744 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
July 2006 | Phase 3 |
NCT00513604 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Malignant Melanoma|Melanoma, Experimental|Experimental Melanomas
|
June 2007 | Phase 2 |
NCT00683670 | University of Pennsylvania |
Melanoma
|
August 2008 | Phase 1 |
NCT02566304 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Aplastic Anemia|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Malignant Neoplasm|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ring Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
|
November 13, 2015 | Phase 2 |
NCT00433459 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
January 2007 | Phase 3 |
NCT00293384 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms|Nausea and Vomiting|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor
|
October 2004 | Not Applicable |
NCT00131053 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 2 |
NCT03654703 | Capital Research Institute of Pediatrics |
Hematopoietic System--Cancer
|
March 1, 2015 | Phase 2 |
NCT02694224 | Clinica Universidad de Navarra, Universidad de Navarra |
Breast Cancer
|
April 2016 | Phase 2 |
NCT00554788 | Children´s Oncology Group|National Cancer Institute (NCI) |
Extraocular Retinoblastoma
|
February 4, 2008 | Phase 3 |
NCT00775931 | Masonic Cancer Center, University of Minnesota |
Severe Osteopetrosis
|
August 2008 | Phase 2|Phase 3 |
NCT01265849 | CEL-SCI Corporation|Teva Branded Pharmaceutical Products R&D, Inc.|Orient Europharma Co., Ltd. |
Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate
|
December 2010 | Phase 3 |
NCT02228512 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma
|
August 15, 2014 | Phase 1|Phase 2 |
NCT00494897 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 1996 | Phase 4 |
NCT00801632 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Kidney Transplantation|Kidney Failure, Chronic
|
December 2008 | Phase 2 |
NCT00483119 | NYU Langone Health |
Pemphigus Vulgaris
|
April 2007 | Phase 2 |
NCT00309881 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
April 2003 | Phase 2 |
NCT01092962 | Assistance Publique - Hôpitaux de Paris |
Idiopathic Nephrotic Syndrome
|
September 2010 | Phase 3 |
NCT03704714 | Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI) |
Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 20, 2018 | Phase 1|Phase 2 |
NCT02761915 | Cancer Research UK |
Relapsed or Refractory Neuroblastoma
|
February 29, 2016 | Phase 1 |
NCT02125344 | German Breast Group|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma |
Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer
|
December 2014 | Phase 3 |
NCT02061800 | Diane George|Columbia University |
Chronic Myeloid Leukemia (CML)|Acute Myelogenous Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Juvenile Myelomonocytic Leukemia (JMML)|Acute Lymphoblastic Leukemia (ALL)|Lymphoma (Hodgkin´s and Non-Hodgkin´s)
|
June 3, 2013 | Phase 1|Phase 2 |
NCT00004903 | Robert H. Lurie Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
October 1999 | Phase 2 |
NCT00477035 | Sally Arai|Stanford University |
Leukemia|Multiple Myeloma
|
May 2006 | Phase 1 |
NCT04667663 | Cancer Trials Ireland|Janssen Pharmaceuticals|Celgene |
Multiple Myeloma
|
November 2021 | Phase 1 |
NCT00365417 | NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute |
Breast Cancer
|
August 2006 | Phase 2 |
NCT03017404 | Hebei Medical University Fourth Hospital |
Breast Cancer
|
May 2015 | Not Applicable |
NCT04594798 | University of Rochester|Genentech, Inc. |
DLBCL|Lymphoma, B-Cell
|
September 20, 2021 | Phase 2 |
NCT02828592 | Northside Hospital, Inc. |
Severe Aplastic Anemia
|
September 9, 2016 | Phase 2 |
NCT01537029 | Texas Tech University Health Sciences Center|University of Texas |
Breast Cancer|Obesity
|
February 2012 | Phase 4 |
NCT00194753 | University of Washington|Amgen|Bristol-Myers Squibb |
Breast Neoplasm
|
December 2001 | Phase 2 |
NCT03063983 | Grupo de Apoio ao Adolescente e a Crianca com Cancer |
Osteosarcoma
|
January 2, 2017 | Phase 2 |
NCT00595127 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Miltenyi Biotec, Inc. |
Fanconi Anemia
|
June 2001 | Not Applicable |
NCT02027220 | Second Affiliated Hospital of Soochow University |
Myeloma|Bortezomib|Cyclophosphamide|Dexamethasone|Granulocyte Colony-Stimulating Factor
|
December 2013 | Phase 2 |
NCT00871689 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
January 2009 | Phase 2 |
NCT02270307 | National Research Center for Hematology, Russia |
Leukemia|Multiple Myeloma
|
January 2014 | Phase 2|Phase 3 |
NCT03937544 | National University of Malaysia|Gaia Science |
Relapsed B Acute Lymphoblastic Leukaemia|Refractory B Acute Lymphoblastic Leukaemia
|
March 19, 2019 | Phase 2|Phase 3 |
NCT03043105 | Peking Union Medical College Hospital |
Multicentric Castleman Disease
|
January 1, 2017 | Phase 2 |
NCT01671319 | University of Wisconsin, Madison|Amgen |
Female Breast Cancer
|
June 2011 | Phase 2 |
NCT00959231 | Cancer Research UK|National Cancer Institute (NCI) |
Hematopoietic+Lymphoid Cancer
|
January 2009 | Phase 2 |
NCT00651755 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Lymphoma
|
March 2008 | Not Applicable |
NCT01836289 | Johns Hopkins University |
Crohn´s Disease|Crohn Disease
|
March 2015 | Phase 1|Phase 2 |
NCT00008008 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
September 1997 | Phase 2 |
NCT00963872 | Masonic Cancer Center, University of Minnesota|National Heart, Lung, and Blood Institute (NHLBI) |
Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes
|
March 2010 | Phase 1|Phase 2 |
NCT03602612 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myeloma-Multiple|Myeloma, Plasma-Cell
|
September 14, 2018 | Phase 1 |
NCT02449278 | Wuhan University |
Diffuse Large B-cell Lymphoma
|
October 2015 | Phase 3 |
NCT05153226 | DKMS gemeinnützige GmbH |
Graft Vs Host Disease|Peripheral Blood Stem Cell Transplantation|AML|MDS|MDS+MPN|CMML
|
March 2, 2022 | Phase 3 |
NCT00612222 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
January 2008 | Phase 2 |
NCT02176967 | Children´s Oncology Group|National Cancer Institute (NCI) |
Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Neuroblastoma
|
July 28, 2014 | Phase 3 |
NCT01027000 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Genentech, Inc.|Biologics, Inc. |
Leukemia|Lymphoma
|
February 2010 | Phase 2 |
NCT01493154 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Institute of Dental and Craniofacial Research (NIDCR)|Ichor Medical Systems Incorporated |
Head and Neck Cancer
|
April 2012 | Phase 1 |
NCT04193059 | Fudan University |
Breast Cancer
|
August 1, 2018 | Phase 3 |
NCT01045460 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Multiple Myeloma
|
January 15, 2010 | Phase 2 |
NCT00032019 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
February 2002 | Phase 2 |
NCT00003007 | University of Tennessee|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
July 1996 | Phase 2 |
NCT05492682 | Valo Therapeutics Oy |
Melanoma (Skin)|Triple-Negative Breast Cancer|Non-Small Cell Lung Cancer
|
August 2022 | Phase 1 |
NCT03286634 | National Hospital Organization Nagoya Medical Center |
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
|
April 18, 2017 | Phase 2 |
NCT00121199 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
June 2005 | Phase 2 |
NCT00053911 | UNICANCER |
Breast Cancer
|
November 2002 | Phase 3 |
NCT02518750 | St. Jude Children´s Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc |
Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin´s|Leukemia, T-Cell|Leukemia, B-Cell
|
November 23, 2016 | Phase 2 |
NCT00559845 | Hoffmann-La Roche |
Breast Cancer
|
February 2008 | Phase 2 |
NCT02639650 | Weiguo Lv|Shandong University|Huazhong University of Science and Technology|First Affiliated Hospital of Zhongshan Medical University|Women´s Hospital School Of Medicine Zhejiang University |
Gestational Trophoblastic Neoplasms
|
March 1, 2016 | Phase 3 |
NCT02111850 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cervical Cancer|Renal Cancer|Urothelial Cancer|Melanoma|Breast Cancer
|
February 7, 2014 | Phase 1|Phase 2 |
NCT03818334 | Hospital Israelita Albert Einstein |
Bone Marrow Transplant Complications|Graft Versus Host Disease|Infection Viral|Engraft Failure|Immunologic Suppression
|
November 6, 2018 | Phase 2|Phase 3 |
NCT02775292 | Jonsson Comprehensive Cancer Center|Stand Up To Cancer|Bristol-Myers Squibb|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Cancer Institute (NCI) |
Adult Solid Neoplasm|Childhood Solid Neoplasm|Metastatic Neoplasm
|
January 3, 2017 | Phase 1 |
NCT00136539 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Harvard Vanguard Medical Associates|Brigham and Women´s Hospital |
Breast Cancer
|
March 1999 | Phase 2 |
NCT00002961 | Children´s Hospital of Philadelphia |
Leukemia
|
October 1995 | Phase 3 |
NCT04670068 | UNC Lineberger Comprehensive Cancer Center|National Institutes of Health (NIH) |
Epithelial Ovarian Cancer
|
January 27, 2021 | Phase 1 |
NCT00615173 | Sun Yat-sen University |
Kidney Diseases|Lupus Nephritis|Tacrolimus|Induction Phase|Maintenance Phase
|
July 2006 | Phase 3 |
NCT00791037 | University of Washington|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
October 2008 | Phase 1|Phase 2 |
NCT00047281 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Schering-Plough|Celgene |
Brain and Central Nervous System Tumors
|
March 2004 | Phase 2 |
NCT00000899 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
NCT05371093 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Follicular Lymphoma
|
September 12, 2022 | Phase 3 |
NCT03136406 | ImmunityBio, Inc. |
Pancreatic Cancer
|
August 14, 2017 | Phase 1|Phase 2 |
NCT00002875 | Children´s Oncology Group|National Cancer Institute (NCI)|Pediatric Oncology Group |
Brain Tumors|Central Nervous System Tumors
|
December 1996 | Phase 3 |
NCT03677141 | Hoffmann-La Roche |
B-cell Non-Hodgkin Lymphoma
|
February 8, 2019 | Phase 1|Phase 2 |
NCT02881086 | Goethe University |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
August 2016 | Phase 3 |
NCT04994132 | Children´s Oncology Group |
Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Metastatic Embryonal Rhabdomyosarcoma|Metastatic Rhabdomyosarcoma|Solid Alveolar Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell+Sclerosing Rhabdomyosarcoma
|
September 13, 2021 | Phase 3 |
NCT00047099 | Ludwig-Maximilians - University of Munich|National Cancer Institute (NCI) |
Breast Cancer
|
August 2001 | Phase 3 |
NCT03492255 | University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Systemic Lupus Erythematosus (SLE)
|
April 12, 2018 | Not Applicable |
NCT03894007 | Renske Altena|Karolinska University Hospital |
Early-stage Breast Cancer|HER2-positive Breast Cancer
|
May 23, 2019 | Phase 2 |
NCT00925548 | EMD Serono |
Breast Cancer
|
September 2009 | Phase 3 |
NCT05302336 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer|Chemotherapeutic Toxicity
|
May 1, 2022 | Phase 4 |
NCT03175666 | ImmunityBio, Inc. |
Triple Negative Breast Cancer
|
December 2017 | Phase 1|Phase 2 |
NCT04061772 | Zhejiang Cancer Hospital |
Peripheral T Cell Lymphoma
|
August 12, 2019 | Phase 2 |
NCT01885013 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
|
September 2010 | Phase 2 |
NCT00726700 | Universität des Saarlandes |
Lymphoma
|
May 2004 | Phase 2 |
NCT00361621 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Millennium Pharmaceuticals, Inc. |
Non-Hodgkin´s Lymphoma
|
July 2006 | Phase 2 |
NCT00003309 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group |
Brain and Central Nervous System Tumors
|
July 1998 | Phase 2 |
NCT00002548 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group |
Multiple Myeloma
|
January 1994 | Phase 3 |
NCT04205240 | Srinivas Devarakonda|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma
|
May 27, 2020 | Phase 2 |
NCT03192059 | University Hospital, Ghent|Kom Op Tegen Kanker|Anticancer Fund, Belgium |
Cervical Cancer|Endometrial Cancer|Uterine Cancer
|
July 1, 2017 | Phase 2 |
NCT00003273 | NYU Langone Health |
Brain and Central Nervous System Tumors|Neuroblastoma|Retinoblastoma|Sarcoma
|
November 1997 | Phase 2 |
NCT00002580 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
June 1993 | Phase 3 |
NCT00610311 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
January 2008 | Phase 2 |
NCT00295893 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 14, 2005 | Phase 2 |
NCT00948090 | Otsuka Pharmaceutical Development & Commercialization, Inc.|Center for International Blood and Marrow Transplant Research |
Lymphoma
|
January 2010 | Phase 2 |
NCT03004287 | University of Arkansas|Janssen, LP |
Multiple Myeloma
|
July 1, 2017 | Phase 2 |
NCT00003578 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
January 1993 | Phase 3 |
NCT00499122 | University of Miami |
Breast Cancer
|
June 4, 2007 | Phase 2 |
NCT03247088 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
July 30, 2017 | Phase 1|Phase 2 |
NCT03412877 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Endocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Gastrointestinal+Genitourinary Cancers|Neuroendocrine Tumors|Multiple Myeloma
|
September 6, 2018 | Phase 2 |
NCT02425306 | Craig L Slingluff, Jr|Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|University of Virginia |
Melanoma
|
May 12, 2015 | Phase 1|Phase 2 |
NCT00792948 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia
|
September 1, 2009 | Phase 2 |
NCT00002634 | Memorial Sloan Kettering Cancer Center |
Neuroblastoma
|
February 1995 | Phase 2 |
NCT02757885 | Emory University |
Sickle Cell Disease
|
April 2016 | Phase 2 |
NCT03970096 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Undifferentiated Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Lymphoblastic Lymphoma|Mixed Phenotype Acute Leukemia|Acute Leukemia|Hematopoietic and Lymphoid Cell Neoplasm
|
November 19, 2019 | Phase 2 |
NCT00290641 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes
|
April 2001 | Not Applicable |
NCT05565105 | Baptist Health South Florida |
Leukemia, Myeloid, Acute|Leukemia, Lymphocytic, Acute
|
October 2022 | Phase 2 |
NCT01731886 | Columbia University |
Multiple Myeloma
|
September 2012 | Phase 4 |
NCT03085914 | Incyte Corporation |
Solid Tumor
|
May 2, 2017 | Phase 1|Phase 2 |
NCT01314833 | Fudan University|Chinese Anti-Cancer Association |
Primary Breast Cancer
|
June 1, 2010 | Phase 3 |
NCT04214626 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma
|
January 2, 2020 | Phase 2 |
NCT04674813 | Juno Therapeutics, a Subsidiary of Celgene |
Multiple Myeloma
|
February 24, 2021 | Phase 1 |
NCT00005867 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
January 1998 | Phase 3 |
NCT00003012 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
October 1996 | Phase 3 |
NCT01046487 | Centre Oscar Lambret |
Cancer
|
January 2009 | Phase 1 |
NCT00109837 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2005 | Phase 2 |
NCT00002809 | Temple University |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
August 1996 | Phase 2 |
NCT04661852 | Dana-Farber Cancer Institute |
Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma|Relapsed Osteosarcoma|Refractory Osteosarcoma
|
December 23, 2020 | Phase 1 |
NCT03733587 | Genexine, Inc. |
Solid Tumor
|
October 17, 2018 | Phase 1 |
NCT00429182 | M.D. Anderson Cancer Center |
Breast Cancer|Metastatic Breast Carcinoma|Invasive Breast Carcinoma
|
June 2007 | Phase 2 |
NCT00028886 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
March 2001 | Phase 3 |
NCT01503905 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer Nos Premenopausal
|
December 2011 | Not Applicable |
NCT00679029 | University of Nebraska|National Cancer Institute (NCI) |
HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
May 2008 | Phase 2 |
NCT04262843 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|High Risk Myelodysplastic Syndrome|Myelodysplastic Syndrome
|
February 7, 2020 | Phase 2 |
NCT00176852 | Masonic Cancer Center, University of Minnesota|National Marrow Donor Program |
Sickle Cell Disease|Thalassemia|Severe Congenital Neutropenia|Diamond-Blackfan Anemia|Shwachman-Diamond Syndrome
|
June 2002 | Phase 2|Phase 3 |
NCT03918499 | City of Hope Medical Center|National Cancer Institute (NCI) |
Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Recurrent Gastric Adenocarcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma
|
April 19, 2019 | Phase 1|Phase 2 |
NCT00196872 | German Breast Group |
Breast Cancer
|
July 2004 | Phase 3 |
NCT04892277 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia
|
July 14, 2022 | Phase 1 |
NCT00254163 | US Oncology Research|Astex Pharmaceuticals, Inc. |
B-Cell Chronic Lymphocytic Leukemia
|
December 2003 | Phase 3 |
NCT03755804 | St. Jude Children´s Research Hospital|Teva Pharmaceuticals USA|Seagen Inc. |
Hodgkin Lymphoma
|
December 12, 2018 | Phase 2 |
NCT05389514 | Providence Health & Services |
KRAS G12V Mutant Advanced Epithelial Cancers
|
||
NCT00433420 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Gruppo Italiano Mammella (GIM) |
Breast Cancer
|
April 2003 | Phase 3 |
NCT00198991 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research |
Adult Acute Lymphocytic Leukemia
|
April 2003 | Phase 4 |
NCT00176605 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Prostate Cancer
|
May 2005 | Phase 2 |
NCT01539174 | Fox Chase Cancer Center|Genentech, Inc. |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
Phase 2 | |
NCT00430118 | University Hospital Schleswig-Holstein |
Leukemia
|
July 2000 | Phase 3 |
NCT00438841 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
August 2006 | Phase 2 |
NCT00003288 | National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
August 1998 | Phase 1 |
NCT01175356 | Children´s Oncology Group|National Cancer Institute (NCI) |
Disseminated Neuroblastoma|Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma
|
October 2010 | Not Applicable |
NCT01862926 | Royal Brompton & Harefield NHS Foundation Trust|Imperial College London|University of East Anglia|University College London Hospitals |
Interstitial Lung Disease|Scleroderma|Idiopathic Inflammatory Myositis|Mixed Connective Tissue Disease
|
November 2014 | Phase 2|Phase 3 |
NCT00001426 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Neoplasm
|
February 3, 1995 | Phase 2 |
NCT00958256 | M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. |
Mantle Cell Lymphoma|Lymphoma
|
August 2009 | Phase 2 |
NCT00390156 | University of California, San Francisco|Novartis |
Unspecified Adult Solid Tumor
|
August 2006 | Phase 1 |
NCT00003204 | National Cancer Institute (NCI) |
Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Small Lymphocytic Lymphoma
|
March 1998 | Phase 3 |
NCT00001626 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Severe Aplastic Anemia (SAA)
|
June 2, 1997 | Phase 2 |
NCT04007029 | Jonsson Comprehensive Cancer Center|Parker Institute for Cancer Immunotherapy |
CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma
|
October 4, 2019 | Phase 1 |
NCT02624973 | Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca |
Breast Cancer
|
April 15, 2016 | Phase 2 |
NCT00157196 | Merck KGaA, Darmstadt, Germany |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms
|
April 2005 | Phase 2 |
NCT03556358 | Tanvex BioPharma USA, Inc. |
Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
June 28, 2018 | Phase 3 |
NCT00058578 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
Systemic Sclerosis
|
June 1999 | Phase 1 |
NCT00049517 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 2002 | Phase 3 |
NCT00002547 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
August 1987 | Phase 2 |
NCT02790515 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myeloid Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)
|
July 14, 2016 | Phase 2 |
NCT00003728 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
December 1998 | Phase 3 |
NCT01619761 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
May 3, 2013 | Phase 1 |
NCT00003870 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
February 1999 | Phase 2 |
NCT05531708 | Shanghai Pudong Hospital|UTC Therapeutics Inc. |
Mesothelin-positive Advanced Refractory Solid Tumors
|
April 2, 2021 | Phase 1 |
NCT00290628 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Diamond-blackfan Anemia|Fanconi Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
October 1999 | Not Applicable |
NCT02215967 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myeloma, Plasma-Cell|Myeloma-Multiple
|
August 12, 2014 | Phase 1 |
NCT04745728 | Peking Union Medical College Hospital |
Idiopathic Membranous Nephropathy
|
April 14, 2021 | Phase 3 |
NCT03153410 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme LLC|Eli Lilly and Company |
Pancreatic Cancer
|
September 27, 2018 | Early Phase 1 |
NCT00002542 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Breast Cancer
|
July 20, 1993 | Phase 3 |
NCT01690520 | Nohla Therapeutics, Inc.|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome
|
December 11, 2012 | Phase 2 |
NCT00580372 | University of Arkansas |
Multiple Myeloma
|
August 2002 | Phase 2 |
NCT03263559 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Sickle Cell Disease
|
October 3, 2017 | Phase 2 |
NCT00201318 | National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|National Cheng-Kung University Hospital|Taipei Veterans General Hospital, Taiwan|Chi Mei Medical Hospital |
Non-Hodgkin´s Lymphoma
|
September 2001 | Phase 2 |
NCT00003389 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 1999 | Phase 3 |
NCT02153905 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Cervical Cancer|Renal Cancer|Melanoma|Bladder Cancer
|
July 3, 2014 | Phase 1|Phase 2 |
NCT04099797 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Faris Foundation |
Diffuse Intrinsic Pontine Glioma|High Grade Glioma|Embryonal Tumor|Ependymal Tumor
|
February 3, 2020 | Phase 1 |
NCT03218852 | Guangdong Provincial People´s Hospital |
IgA Nephropathy
|
December 2016 | Phase 4 |
NCT00002643 | National Cancer Institute (NCI)|Children´s Cancer Group |
Neutropenia|Sarcoma
|
April 1995 | Phase 2 |
NCT00258206 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 2004 | Phase 2 |
NCT02830724 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer
|
April 6, 2017 | Phase 1|Phase 2 |
NCT02139280 | Dartmouth-Hitchcock Medical Center |
Hematologic Malignancies
|
December 2013 | Phase 2 |
NCT03259516 | St. Petersburg State Pavlov Medical University |
Myelodysplastic Syndromes
|
May 25, 2017 | Phase 1|Phase 2 |
NCT01060410 | Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University |
Lupus Erythematosus, Systemic|Adverse Effects
|
May 2010 | |
NCT00482391 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline |
Breast Cancer
|
March 2007 | Phase 2 |
NCT00276848 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
July 1999 | Phase 3 |
NCT02630368 | Institut Bergonié|National Cancer Institute, France|Fondation ARC|Merck Sharp & Dohme LLC|Transgene |
Solid Tumors|Soft-tissue Sarcoma|Breast Cancer
|
September 18, 2015 | Phase 1|Phase 2 |
NCT04303520 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Hrain Biotechnology Co., Ltd.|First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Nanchang University |
CD19-positive ALL
|
May 3, 2018 | Phase 1 |
NCT05182073 | Fate Therapeutics |
Multiple Myeloma|Myeloma
|
November 24, 2021 | Phase 1 |
NCT00924326 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell
|
February 17, 2009 | Phase 1|Phase 2 |
NCT00053989 | Roswell Park Cancer Institute |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Fanconi Anemia|Aplastic Anemia
|
January 29, 2002 | Phase 2 |
NCT04139304 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Montefiore Medical Center|Memorial Sloan Kettering Cancer Center|AIDS and Cancer Specimen Resource|The Emmes Company, LLC |
Plasmablastic Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
May 24, 2021 | Early Phase 1 |
NCT00002590 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
July 1994 | Phase 2 |
NCT01451515 | St. Jude Children´s Research Hospital|National University, Singapore |
Lymphoblastic Lymphoma
|
May 25, 2012 | Phase 2 |
NCT00203372 | Translational Oncology Research International|Genentech, Inc. |
Breast Cancer
|
May 2005 | Phase 2 |
NCT00017225 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
May 1997 | Phase 2 |
NCT00057005 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
LEUKEMIA
|
February 2003 | Phase 1 |
NCT02306161 | National Cancer Institute (NCI) |
Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
|
December 8, 2014 | Phase 3 |
NCT01883323 | University Health Network, Toronto |
Metastatic, Stage III or Stage IV, Melanoma
|
June 2013 | Phase 2 |
NCT03761056 | Kite, A Gilead Company|Gilead Sciences |
B-cell Lymphoma
|
January 29, 2019 | Phase 2 |
NCT02664103 | Sanofi |
Breast Cancer Metastatic
|
January 23, 2016 | Phase 2 |
NCT00666484 | University College, London |
Lymphoma|Neurotoxicity
|
March 2008 | Phase 2 |
NCT01033552 | Masonic Cancer Center, University of Minnesota |
Epidermolysis Bullosa
|
January 2010 | Phase 1|Phase 2 |
NCT01652014 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
January 2014 | Phase 2 |
NCT02957968 | Virginia Commonwealth University|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor- Negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2+Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive Tumor|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Triple-negative Breast Carcinoma
|
January 24, 2017 | Phase 2 |
NCT01670500 | Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute |
Breast Cancer
|
October 2012 | Phase 2 |
NCT02132949 | Hoffmann-La Roche |
Breast Cancer
|
July 14, 2014 | Phase 2 |
NCT01177371 | Case Comprehensive Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myeloid Leukemia in Remission|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Acute Promyelocytic Leukemia (M3)|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|De Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
March 1988 | Phase 2 |
NCT00008034 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
February 2000 | Phase 1 |
NCT00005854 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
December 1999 | Phase 2 |
NCT01020734 | Asan Medical Center |
Leukemia
|
May 2011 | Phase 2 |
NCT05131893 | National Institute of Oncology, Hungary |
Breast Cancer
|
March 2022 | |
NCT00121134 | Harold J. Burstein, MD, PhD|Genentech, Inc.|Beth Israel Deaconess Medical Center|Indiana University School of Medicine|University of California, San Francisco|University of North Carolina|Dana-Farber Cancer Institute |
Breast Cancer
|
June 2005 | Not Applicable |
NCT00338377 | M.D. Anderson Cancer Center|Prometheus Laboratories|Key Biologics, LLC|National Cancer Institute (NCI)|Adelson Medical Research |
Melanoma
|
February 1, 2006 | Phase 2 |
NCT04214886 | Loyola University|Leukemia Research Foundation |
B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent
|
December 31, 2019 | Phase 1 |
NCT00590785 | National Cancer Institute (NCI)|Cancer and Leukemia Group B |
High Risk|Breast Cancer|Positive Nodes|Cyclophosphamide|Doxorubicin
|
August 13, 1996 | Phase 3 |
NCT00006734 | Children´s Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group |
Sarcoma
|
May 2001 | Phase 3 |
NCT00577629 | Duke University|GlaxoSmithKline |
Lymphoma, B-Cell
|
June 18, 2005 | Phase 2 |
NCT05395052 | Fate Therapeutics |
Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer
|
May 31, 2022 | Phase 1 |
NCT04285567 | Hoffmann-La Roche |
Chronic Lymphocytic Leukemia (CLL)
|
May 28, 2020 | Phase 3 |
NCT00822120 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Nonneoplastic Condition
|
July 2009 | Phase 2 |
NCT02737475 | Bristol-Myers Squibb |
Advanced Cancer
|
June 17, 2016 | Phase 1|Phase 2 |
NCT04945096 | The First Affiliated Hospital of Soochow University |
Engraft Failure|Relapse|GVHD
|
July 1, 2021 | Phase 3 |
NCT00288002 | German Breast Group|National Cancer Institute (NCI) |
Breast Cancer
|
January 2005 | Phase 3 |
NCT00005891 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Fanconi´s Anemia
|
March 2000 | Not Applicable |
NCT03731832 | GWT-TUD GmbH |
Refractory Multiple Myeloma
|
September 20, 2018 | Phase 2 |
NCT01777152 | Seagen Inc.|Millennium Pharmaceuticals, Inc. |
Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma
|
January 31, 2013 | Phase 3 |
NCT03219450 | Dana-Farber Cancer Institute|Oncovir, Inc.|BioNTech SE|Merck Sharp & Dohme LLC |
Lymphocytic Leukemia
|
August 18, 2021 | Phase 1 |
NCT03858322 | Dana-Farber Cancer Institute|Mayo Clinic |
Breast Cancer
|
March 21, 2019 | Phase 1 |
NCT01025089 | Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|M.D. Anderson Cancer Center|City of Hope National Medical Center |
Thymoma|Thymic Carcinoma|Clinical Masaoka Stage II to IVA
|
December 2009 | Phase 2 |
NCT04626791 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
August 3, 2021 | Phase 2 |
NCT04106219 | Eli Lilly and Company|New Approaches to Neuroblastoma Therapy Consortium (NANT)|Innovative Therapies for Children with Cancer in Europe (ITCC) |
Neuroblastoma
|
June 11, 2020 | Phase 1 |
NCT02722668 | Masonic Cancer Center, University of Minnesota |
Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia+Lymphoma|Burkitt´s Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Large-cell Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Relapsed Chronic Lymphocytic Leukemia|Relapsed Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-cell Lymphoma|Prolymphocytic Leukemia|Bone Marrow Failure Syndromes|Myeloproliferative Neoplasms+Myelofibrosis|Biphenotypic+Undifferentiated+Prolymphocytic Leukemias|MRD Positive Leukemia|Leukemia or MDS in Aplasia|Relapsed T-Cell Lymphoma|Relapsed Multiple Myeloma|Plasma Cell Leukemia
|
May 15, 2017 | Phase 2 |
NCT00939653 | Therapeutic Advances in Childhood Leukemia Consortium|Genzyme, a Sanofi Company |
Relapsed Acute Myelogenous Leukemia
|
July 10, 2009 | Phase 2 |
NCT00005612 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Ovarian Cancer
|
August 1999 | Phase 1|Phase 2 |
NCT01358877 | Hoffmann-La Roche|Genentech, Inc.|Breast International Group |
Breast Cancer
|
November 8, 2011 | Phase 3 |
NCT00632827 | University of California, San Francisco|Eisai Inc.|Washington University School of Medicine |
Peripheral T-Cell Lymphoma
|
July 1, 2008 | Phase 2 |
NCT04162756 | Kite, A Gilead Company|Gilead Sciences |
Relapse+Refractory Mantle Cell Lymphoma
|
||
NCT00470301 | National Cancer Institute (NCI) |
Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
April 2007 | Phase 1|Phase 2 |
NCT00899847 | Stanford University |
Transplantation, Homologous|Transplantation, Autologous|Multiple Myeloma|Blood and Marrow Transplant (BMT)
|
May 2009 | Phase 2 |
NCT02845596 | Michael Pulsipher, MD|Children´s Hospital Los Angeles |
Severe Aplastic Anemia
|
August 2016 | Not Applicable |
NCT00712582 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University |
Non-Hodgkin´s Lymphoma
|
July 1, 2008 | Phase 2 |
NCT00073918 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
February 1999 | Phase 2 |
NCT03092453 | University of Pennsylvania |
Melanoma
|
May 1, 2017 | Phase 1 |
NCT00434031 | National Cancer Institute, Naples |
Breast Cancer
|
September 2007 | Phase 2 |
NCT05478837 | University of California, San Francisco|The V Foundation|Parker Institute for Cancer Immunotherapy |
Diffuse Midline Glioma, H3 K27M-Mutant
|
January 1, 2023 | Phase 1 |
NCT00960115 | Merck KGaA, Darmstadt, Germany|Merck Serono Co., Ltd., Japan |
Non-small Cell Lung Cancer
|
December 2008 | Phase 1|Phase 2 |
NCT00779129 | Merck Sharp & Dohme LLC|Princess Margaret Hospital, Canada |
Breast Neoplasm
|
March 2003 | Phase 2 |
NCT04205838 | Jonsson Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Progressive Disease|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
March 4, 2020 | Phase 2 |
NCT00129922 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb|Pfizer|Hoffmann-La Roche |
Breast Cancer
|
November 1999 | Phase 3 |
NCT00284271 | University of Cologne |
Hodgkin´s Lymphoma
|
January 2004 | Phase 2 |
NCT01369888 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
May 2011 | Phase 1|Phase 2 |
NCT00003386 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer
|
July 1999 | Phase 2 |
NCT05436418 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Peripheral Blood Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation
|
November 18, 2022 | Phase 1|Phase 2 |
NCT00869232 | University of Arkansas |
Multiple Myeloma
|
October 2008 | Phase 2 |
NCT04151706 | Stanford University|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Acute Leukemia|Chronic Myeloid Leukemia
|
February 27, 2020 | Phase 2 |
NCT04024761 | Dana-Farber Cancer Institute|The Leukemia and Lymphoma Society |
Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Juvenile Myelomonocytic Leukemia
|
August 31, 2019 | Phase 1 |
NCT00446173 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 2007 | Phase 2 |
NCT03505762 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
B-Cell Non-Hodgkin Lymphoma
|
July 19, 2018 | Phase 2 |
NCT00002757 | Children´s Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children´s Cancer and Leukaemia Group |
Leukemia|Lymphoma
|
June 2001 | Phase 3 |
NCT04440267 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
Acute Leukemia of Ambiguous Lineage
|
June 20, 2020 | Phase 2 |
NCT00866749 | M.D. Anderson Cancer Center |
Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
September 12, 2006 | Phase 2 |
NCT01285817 | Assistance Publique Hopitaux De Marseille |
Solid Tumours.
|
November 2010 | Phase 2 |
NCT01700946 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|Assisi Foundation |
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma
|
April 15, 2013 | Phase 2 |
NCT03263767 | Nantes University Hospital |
Graft Versus Host Disease
|
January 15, 2018 | Phase 2 |
NCT00987480 | Memorial Sloan Kettering Cancer Center|Boston Children´s Hospital|Children´s Hospital Medical Center, Cincinnati|Children´s Hospital and Health System Foundation, Wisconsin|Rockefeller University|Fred Hutchinson Cancer Center |
Aplastic Anemia|Leukemia|Myelodysplastic Syndrome
|
September 25, 2009 | Phase 2 |
NCT00941928 | M.D. Anderson Cancer Center |
Leukemia|Pediatric Cancer
|
July 2009 | Phase 2 |
NCT00004181 | Northwestern University|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Plasma Cell Neoplasm
|
October 1999 | Phase 2 |
NCT04231877 | University of Washington|Genentech, Inc. |
Aggressive Non-Hodgkin Lymphoma|ALK-Positive Large B-Cell Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
October 27, 2020 | Phase 1 |
NCT00562965 | Pfizer|UCB Pharma |
Lymphoma, Follicular
|
November 2007 | Phase 3 |
NCT00233987 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 2005 | Phase 2 |
NCT00897026 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
July 2008 | |
NCT03023046 | University of Washington|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
February 23, 2017 | Phase 2 |
NCT00028730 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
August 2001 | Phase 2 |
NCT03161379 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb |
Pancreatic Cancer
|
February 2, 2018 | Phase 2 |
NCT03248427 | SOLTI Breast Cancer Research Group|Novartis |
Breast Cancer
|
July 13, 2017 | Phase 2 |
NCT00494780 | GlaxoSmithKline |
Lymphoma, Follicular
|
June 2007 | Phase 2 |
NCT02354547 | SynerGene Therapeutics, Inc. |
Neoplasm
|
December 2014 | Phase 1 |
NCT02348216 | Kite, A Gilead Company|Gilead Sciences |
Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma (TFL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|High Grade B-cell Lymphoma (HGBCL)
|
April 21, 2015 | Phase 1|Phase 2 |
NCT00358657 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Immunodeficiency Syndrome|Severe Aplastic Anemia|Genetic Disorder
|
May 24, 2006 | Phase 2 |
NCT00003396 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
September 1998 | Phase 2 |
NCT00007995 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
July 1999 | Phase 2 |
NCT03821610 | University of Birmingham |
Acute Lymphoblastic Leukemia
|
November 22, 2018 | Phase 2 |
NCT04989803 | Kite, A Gilead Company|Gilead Sciences |
Relapsed and+or Refractory B-cell Lymphoma
|
October 27, 2021 | Phase 1 |
NCT03527628 | King Abdullah International Medical Research Center |
Classical Hodgkin Lymphoma|Hodgkin Lymphoma (Category)|Hodgkin Disease|Hodgkin Lymphoma
|
January 1, 2018 | Phase 2 |
NCT02400567 | UNICANCER|Pfizer|NanoString Technologies, Inc. |
Neoadjuvant Operable Breast Cancer
|
January 2015 | Phase 2 |
NCT00833560 | Janssen-Cilag G.m.b.H |
Multiple Myeloma
|
March 2006 | Phase 2 |
NCT04216524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastic Plasmacytoid Dendritic Cell Neoplasm
|
May 29, 2020 | Phase 2 |
NCT04137640 | Shengjing Hospital |
Breast Cancer
|
July 19, 2021 | Phase 4 |
NCT04596033 | Genocea Biosciences, Inc. |
Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Renal Cell Carcinoma|Small-cell Lung Cancer|Cutaneous Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Merkel Cell Carcinoma
|
November 11, 2020 | Phase 1 |
NCT01271010 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
June 17, 2011 | Phase 4 |
NCT00039195 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc. |
Lymphoma
|
November 2006 | Phase 2 |
NCT00025324 | Children´s Hospital Los Angeles|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
December 2000 | Phase 2 |
NCT00107276 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
August 2005 | Phase 2 |
NCT00507442 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Multiple Myeloma
|
August 2007 | Phase 1|Phase 2 |
NCT00343798 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Damon Runyon Cancer Research Foundation |
Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma
|
April 2006 | Phase 1 |
NCT00605566 | University Health Network, Toronto |
Neuroendocrine Tumors
|
January 2008 | Phase 2 |
NCT02948101 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 31, 2018 | Phase 2 |
NCT03574649 | ImmunityBio, Inc. |
Non Small Cell Lung Cancer
|
September 2018 | Phase 2 |
NCT04232085 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Primary Immune Deficiency Disorder|Immune Deficiency Disease|Bone Marrow Failure
|
February 12, 2020 | Phase 2 |
NCT00002582 | Institute of Cancer Research, United Kingdom|Cancer Research Campaign Clinical Trials Centre|Scottish Cancer Therapy Network|Yorkshire Regional Clinical Trials Research Unit|National Cancer Institute (NCI) |
Breast Cancer
|
June 1993 | Phase 3 |
NCT01864018 | Mayo Clinic|National Cancer Institute (NCI) |
Amyloidosis|Plasma Cell Myeloma
|
August 20, 2013 | Phase 1|Phase 2 |
NCT03595592 | Fondazione Michelangelo|Hoffmann-La Roche |
Invasive Breast Cancer
|
September 7, 2018 | Phase 3 |
NCT00088881 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
December 2004 | Phase 2 |
NCT02049151 | EMD Serono |
Carcinoma, Non-Small-Cell Lung
|
March 2014 | Phase 3 |
NCT00006252 | Cancer and Leukemia Group B|National Cancer Institute (NCI)|Alliance for Clinical Trials in Oncology |
Leukemia|Lymphoma
|
February 2001 | Phase 2 |
NCT01043640 | Masonic Cancer Center, University of Minnesota |
Mucopolysaccharidosis|Hurler Syndrome|Hunter Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Adrenoleukodystrophy (ALD)|Krabbe Disease|Metachromatic Leukodystrophy (MLD)|Sphingolipidoses|Peroxisomal Disorders
|
December 2009 | Phase 2 |
NCT00303719 | Masonic Cancer Center, University of Minnesota |
Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
March 26, 2002 | Phase 2 |
NCT03680092 | Dimitrios Tzachanis, MD PhD|Bristol-Myers Squibb|University of California, San Diego |
GVHD|Hematologic Neoplasms
|
November 26, 2019 | Phase 2 |
NCT03236792 | Icahn School of Medicine at Mount Sinai|Millennium Pharmaceuticals, Inc. |
AL Amyloidosis
|
June 12, 2017 | Phase 1|Phase 2 |
NCT00915408 | King´s College Hospital NHS Trust |
Multiple Myeloma
|
September 2006 | Phase 1|Phase 2 |
NCT00333008 | The Alvin and Lois Lapidus Cancer Institute|Ortho Biotech Products, L.P. |
Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin
|
May 2006 | Phase 2 |
NCT00689845 | University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI) |
Lymphoma
|
June 2007 | Not Applicable |
NCT00002524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1993 | Phase 2 |
NCT05576181 | Fundamenta Therapeutics, Ltd.|The First Affiliated Hospital of Zhengzhou University |
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
|
October 15, 2022 | Phase 1 |
NCT01057225 | Mayo Clinic |
Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
March 2010 | Phase 1|Phase 2 |
NCT00020176 | National Cancer Institute (NCI) |
Breast Cancer
|
June 2000 | Phase 2 |
NCT00541034 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Astex Pharmaceuticals, Inc. |
Leukemia|Lymphoma
|
May 2005 | Phase 2 |
NCT03670966 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome With Excess Blasts|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Refractory Mixed Phenotype Acute Leukemia|Hematopoietic and Lymphoid Cell Neoplasm
|
July 10, 2019 | Phase 1|Phase 2 |
NCT00424489 | Northwestern University |
Myasthenia Gravis
|
February 2002 | Phase 1 |
NCT00062036 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Melanoma (Skin)
|
June 2003 | Phase 1|Phase 2 |
NCT00016302 | National Cancer Institute (NCI) |
T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
April 2001 | Not Applicable |
NCT01857934 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|CURE Childhood Cancer, Inc. |
Neuroblastoma
|
July 5, 2013 | Phase 2 |
NCT02481310 | Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. |
Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma
|
October 28, 2015 | Phase 1|Phase 2 |
NCT00697671 | St. Jude Children´s Research Hospital|Assisi Foundation |
Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin´s Lymphoma
|
March 2007 | Phase 1 |
NCT00005090 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B |
Lymphoma
|
April 2000 | Phase 3 |
NCT02046915 | University Hospital Tuebingen |
Relapsed or Refractory Multiple Myeloma
|
April 2014 | Phase 2 |
NCT03642626 | Masonic Cancer Center, University of Minnesota |
Acute Lymphoblastic Leukemia|Large B-cell Lymphoma
|
December 18, 2018 | |
NCT01279616 | Nationwide Children´s Hospital |
Sickle Cell Disease
|
September 2010 | Phase 2 |
NCT00070278 | Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI) |
Breast Cancer
|
January 2005 | Phase 3 |
NCT02080195 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Maryland Stem Cell Research Fund |
Lupus Erythematosus|Graft-versus-host Disease
|
September 13, 2016 | Phase 1|Phase 2 |
NCT00400075 | Hospices Civils de Lyon |
Polyarteritis Nodosa|Microscopic Polyangiitis
|
July 1996 | Phase 4 |
NCT03518112 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia
|
April 18, 2018 | Phase 2 |
NCT00482053 | Stanford University |
Lymphoma, B-cell|Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma (DLBCL)|Malignant Lymphoma, Non-Hodgkin
|
October 2006 | Phase 2 |
NCT00005089 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 2 |
NCT00280241 | University of Pittsburgh|Genentech, Inc.|Biogen |
Chronic Lymphocytic Leukemia
|
June 2004 | Phase 2 |
NCT02744742 | Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Institute of Hematology and Blood Diseases Hospital|Peking University People´s Hospital|First People´s Hospital of Chenzhou|Liuzhou Workers Hospital |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
April 18, 2016 | Phase 2|Phase 3 |
NCT01453140 | Hackensack Meridian Health |
Graft Versus Host Disease
|
August 2011 | Phase 1|Phase 2 |
NCT00003519 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|North Central Cancer Treatment Group|Cancer and Leukemia Group B |
Breast Cancer
|
August 1998 | Phase 3 |
NCT04835870 | The First Affiliated Hospital of Soochow University |
Non-GCB+ABC Diffuse Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
NCT03624036 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Chronic Lymphocytic Leukemia and Relapsed+Refractory Small Lymphocytic Lymphoma
|
November 15, 2018 | Phase 1 |
NCT00004237 | Royal Marsden NHS Foundation Trust|National Cancer Institute (NCI) |
Breast Cancer
|
October 1998 | Phase 2 |
NCT00381173 | Eisai Inc. |
Breast Cancer|Ovarian Cancer|Prostate Cancer|Colon Cancer|Renal Cancer
|
November 2006 | Phase 1 |
NCT03531736 | Memorial Sloan Kettering Cancer Center |
Myeloid Diseases
|
May 9, 2018 | Phase 1 |
NCT02502708 | NewLink Genetics Corporation|Lumos Pharma |
Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor
|
October 2015 | Phase 1 |
NCT04959175 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hematologic Neoplasms
|
September 23, 2021 | Phase 1|Phase 2 |
NCT00429143 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematologic Malignancies
|
January 2006 | Phase 1|Phase 2 |
NCT04696731 | Allogene Therapeutics |
Advanced+Metastatic Clear Cell Renal Cell Carcinoma
|
February 24, 2021 | Phase 1 |
NCT00135954 | Radboud University Medical Center |
Glomerulonephritis, Membranous
|
July 1997 | Phase 3 |
NCT01143545 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma
|
December 7, 2010 | Phase 1 |
NCT04022239 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid System Neoplasm
|
March 13, 2020 | Phase 1|Phase 2 |
NCT00656123 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
March 2008 | Phase 1 |
NCT02876679 | Assistance Publique - Hôpitaux de Paris |
Graft vs Host Disease
|
April 6, 2017 | Phase 2 |
NCT00740805 | National Cancer Institute (NCI) |
Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Solid Neoplasm
|
August 18, 2008 | Phase 1 |
NCT05165225 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|HER2-low-expressing Breast Cancer|Hormone Receptor-positive Breast Cancer|Neoadjuvant Therapy
|
May 19, 2021 | Phase 2 |
NCT02767674 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B Cell Lymphoma
|
May 2016 | Phase 3 |
NCT00003552 | National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI) |
Stage IV Melanoma|Recurrent Melanoma
|
January 1999 | Phase 1|Phase 2 |
NCT05389423 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Large Cell Lymphoma|Non-Hodgkin Lymphoma|Burkitt Lymphoma|Plasmablastic Lymphoma|B-Cell Neoplasm
|
November 28, 2022 | Phase 1 |
NCT00526175 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2001 | Phase 4 |
NCT04659551 | Istituto Oncologico Veneto IRCCS|University of Padova |
Breast Cancer
|
October 5, 2017 | Phase 2 |
NCT01078441 | National Cancer Institute (NCI) |
Refractory Multiple Myeloma
|
September 2010 | Phase 2 |
NCT00004474 | Roswell Park Cancer Institute|Office of Rare Diseases (ORD) |
Aplastic Anemia
|
September 1998 | Phase 3 |
NCT02143830 | Children´s Hospital Medical Center, Cincinnati|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Center |
Fanconi Anemia|Severe Marrow Failure|Myelodysplastic Syndrome (MDS)|Acute Myelogenous Leukemia (AML)
|
April 2014 | Phase 2 |
NCT03387111 | ImmunityBio, Inc. |
Squamous Cell Carcinoma
|
January 13, 2018 | Phase 1|Phase 2 |
NCT03328104 | Emory University |
Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
July 24, 2018 | Phase 1 |
NCT02684071 | Nicklaus Children´s Hospital f+k+a Miami Children´s Hospital |
Recurrent Childhood Medulloblastoma|Recurrent Childhood Ependymoma|Childhood Atypical Teratoid+Rhabdoid Tumor|Embryonal Tumor With Abundant Neuropil and True Rosettes|Metastatic Malignant Neoplasm to the Leptomeninges
|
February 2016 | Phase 2 |
NCT00556127 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS
|
June 2002 | Phase 2 |
NCT00820547 | UNICANCER |
Breast Cancer
|
January 2009 | Phase 2 |
NCT00849251 | University of Washington|National Cancer Institute (NCI) |
Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
November 2008 | Phase 1|Phase 2 |
NCT01415882 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 31, 2012 | Phase 2 |
NCT00266136 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research |
Acute Myeloid Leukemia
|
June 1999 | Phase 3 |
NCT05380713 | University Health Network, Toronto|OICR |
Mesothelioma, Malignant
|
May 9, 2022 | Phase 2 |
NCT03197935 | Hoffmann-La Roche |
Triple-negative Breast Cancer
|
July 24, 2017 | Phase 3 |
NCT04029038 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma
|
November 30, 2022 | Phase 1|Phase 2 |
NCT05069935 | Fate Therapeutics |
Solid Tumor, Adult
|
October 15, 2021 | Phase 1 |
NCT00018954 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
October 1992 | Phase 2 |
NCT04799275 | National Cancer Institute (NCI) |
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Grade 3b Follicular Lymphoma|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
March 19, 2021 | Phase 2|Phase 3 |
NCT03149679 | Haukeland University Hospital |
Colorectal Cancer Metastatic|Colorectal Cancer Stage IV|TP53 Gene Mutation
|
May 9, 2017 | Phase 2 |
NCT01527149 | Roswell Park Cancer Institute|National Comprehensive Cancer Network |
Stage I Mantle Cell Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma
|
December 6, 2011 | Phase 2 |
NCT00981799 | Therapeutic Advances in Childhood Leukemia Consortium|GlaxoSmithKline|Novartis |
Relapsed T-Cell Acute Lymphoblastic Leukemia|Relapsed T-Cell Lymphoblastic Lymphoma
|
June 2010 | Phase 1|Phase 2 |
NCT01265901 | Immatics Biotechnologies GmbH |
Metastatic Renal Cell Carcinoma
|
December 2010 | Phase 3 |
NCT00290667 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
February 2004 | Phase 2 |
NCT02324088 | UNICANCER |
Inflammatory Breast Cancer
|
October 2000 | Phase 3 |
NCT00209222 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association |
Lymphoma, Mantle-Cell
|
July 2004 | Phase 3 |
NCT05287308 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
March 2022 | Not Applicable |
NCT03318861 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Multiple Myeloma
|
October 20, 2017 | Phase 1 |
NCT00217503 | National Cancer Institute (NCI) |
Lymphoma
|
July 2005 | Phase 2 |
NCT04850495 | Yazeed Sawalha|Ohio State University Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 16, 2021 | Phase 1 |
NCT00072280 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
November 2004 | Phase 2 |
NCT03842696 | University of Michigan Rogel Cancer Center|National Institutes of Health (NIH) |
Hematologic Diseases|Acute Leukemia in Remission|Chronic Myelogenous Leukemia - Chronic Phase|Chronic Myelogenous Leukemia, Accelerated Phase|Chronic Myelogenous Leukemia, Blastic Phase|Myelodysplastic Syndromes|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma|Non Hodgkin Lymphoma|Graft Vs Host Disease|Graft-versus-host-disease
|
February 4, 2020 | Phase 1|Phase 2 |
NCT00671658 | M.D. Anderson Cancer Center |
Leukemia|Acute Lymphoblastic Leukemia
|
November 2002 | Phase 2 |
NCT03099356 | University of Michigan Rogel Cancer Center |
Metastatic Thyroid Cancer
|
April 27, 2017 | Phase 2 |
NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
November 1, 2016 | Phase 2 |
NCT01204437 | German Breast Group |
Breast Cancer
|
March 2009 | Phase 2|Phase 3 |
NCT01507103 | Merck KGaA, Darmstadt, Germany |
Rectal Cancer
|
February 2012 | Phase 2 |
NCT01028716 | Fred Hutchinson Cancer Center |
Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3+ITD Mutation|Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma|Hematopoietic Cell Transplant Recipient
|
February 8, 2010 | Phase 2 |
NCT00002700 | European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association |
Leukemia|Lymphoma
|
August 1995 | Phase 3 |
NCT00077285 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Sarcoma
|
October 2003 | Phase 2 |
NCT01705691 | NSABP Foundation Inc|Eisai Inc. |
Breast Cancer|HER2-negative Breast Cancer
|
September 2012 | Phase 2 |
NCT00030719 | University of Leicester|National Cancer Institute (NCI) |
Neuroblastoma
|
December 2001 | Phase 3 |
NCT04676997 | Shandong Cancer Hospital and Institute|Jiangsu HengRui Medicine Co., Ltd. |
Triple Negative Breast Cancer
|
May 20, 2020 | Phase 2 |
NCT00003659 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
September 1998 | Phase 2 |
NCT00165139 | Dana-Farber Cancer Institute|Boston Children´s Hospital|Children´s Hospital of Philadelphia |
Neuroblastoma|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma
|
January 1996 | Phase 2 |
NCT00002691 | Memorial Sloan Kettering Cancer Center |
Lymphoma
|
August 1995 | Phase 2 |
NCT02969980 | Asan Medical Center |
Myelodysplastic Syndromes
|
November 2016 | Phase 2 |
NCT00410631 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
October 2004 | Phase 3 |
NCT00476190 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Boston Children´s Hospital|NCIC Clinical Trials Group |
Acute Lymphoblastic Leukemia
|
April 2007 | Phase 2 |
NCT00960063 | Merck Sharp & Dohme LLC |
Neoplasms|Solid Tumors|Bone Cancer|Kidney Tumor|Neuroblastoma
|
November 11, 2009 | Phase 1 |
NCT00083551 | University of Arkansas|Celgene Corporation |
Multiple Myeloma
|
August 1998 | Phase 3 |
NCT00616122 | University of California, San Francisco|National Cancer Institute (NCI) |
Breast Cancer
|
March 1, 2006 | Phase 1|Phase 2 |
NCT00006451 | Masonic Cancer Center, University of Minnesota |
Graft Versus Host Disease|Leukemia|Lymphoma
|
April 1996 | Phase 3 |
NCT01976182 | Rennes University Hospital |
Large Granular Lymphocytes Leukemia
|
November 26, 2013 | Phase 2 |
NCT03864419 | Fred Hutchinson Cancer Center |
Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma
|
October 24, 2019 | Phase 1 |
NCT00004905 | Loyola University|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 2 |
NCT01685411 | Masonic Cancer Center, University of Minnesota |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
January 2013 | Not Applicable |
NCT00131963 | Duke University|National Cancer Institute (NCI) |
Breast Cancer
|
October 2003 | |
NCT00002829 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 1994 | Phase 2 |
NCT00417053 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
Phase 3 | |
NCT00003364 | London Lung Cancer Group|National Cancer Institute (NCI) |
Lung Cancer
|
January 1993 | Phase 3 |
NCT03018535 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia|University of Bari|Azienda Ospedaliera Brotzu|University of Messina|University of Milan|Universita di Verona|University of Chieti|University of Bologna|Azienda Sanitaria Locale Roma E|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Regione Piemonte|University of Modena and Reggio Emilia|University of Pisa|University of Milano Bicocca|Humanitas Hospital, Italy|Azienda Ospedaliera Universitaria Policlinico|Fondazione Salvatore Maugeri|University of Bern|University of Alberta|Istituto Giannina Gaslini |
Glomerulonephritis, Membranous
|
January 2012 | Phase 3 |
NCT00513955 | University Hospital Plymouth NHS Trust |
Lymphoma
|
June 2006 | Phase 2 |
NCT02065362 | Baylor College of Medicine|National Cancer Institute (NCI)|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
EBV-positive Nasopharyngeal Carcinoma
|
February 2015 | Phase 1 |
NCT02903524 | Hebei Medical University Fourth Hospital |
Breast Cancer
|
September 2016 | Phase 4 |
NCT03440411 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
February 18, 2016 | Phase 3 |
NCT00199095 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
February 1997 | Phase 4 |
NCT00002475 | St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI) |
Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer
|
April 1991 | Phase 2 |
NCT00873093 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2009 | Phase 2 |
NCT02285062 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
January 21, 2015 | Phase 3 |
NCT04688021 | Yi Luo|First Affiliated Hospital of Zhejiang University |
Leukemia|Graft-versus-host-disease
|
December 3, 2020 | Phase 2 |
NCT00002461 | Montefiore Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
April 1988 | Phase 2 |
NCT00002535 | St. Luke´s Medical Center|National Cancer Institute (NCI) |
Melanoma (Skin)
|
July 1993 | Phase 2 |
NCT00525876 | M.D. Anderson Cancer Center |
Lymphoma
|
January 2005 | Not Applicable |
NCT03349450 | Sunnybrook Health Sciences Centre|ImmunoVaccine Technologies, Inc. (IMV Inc.)|Merck Sharp & Dohme LLC |
Adult Diffuse Large Cell Lymphoma|Recurrent|Adult Refractory Diffuse Large B-Cell Lymphoma
|
March 13, 2018 | Phase 2 |
NCT01690702 | German Breast Group|Celgene|Amgen |
Breast Cancer
|
September 2012 | Phase 3 |
NCT01147016 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer
|
July 2010 | Phase 2 |
NCT00003764 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group |
Leukemia
|
December 1999 | Phase 3 |
NCT00278408 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
NCT00376519 | Masonic Cancer Center, University of Minnesota |
Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Secondary Myelofibrosis
|
May 2007 | Phase 1 |
NCT05449899 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|The Seventh Affiliated Hospital of Sun Yat-sen University |
Secondary Acute Myeloid Leukemia Evolving From MDS|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
July 2022 | Phase 2|Phase 3 |
NCT00652899 | Masonic Cancer Center, University of Minnesota |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
March 2008 | Phase 2 |
NCT00002531 | Johann Wolfgang Goethe University Hospital|National Cancer Institute (NCI) |
Leukemia
|
January 1993 | Phase 2 |
NCT01212887 | Cancer Research UK |
Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
August 2007 | Phase 1 |
NCT00003957 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 1998 | Phase 2 |
NCT04145349 | Eli Lilly and Company |
Desmoplastic Small Round Cell Tumor
|
January 22, 2020 | Phase 1|Phase 2 |
NCT02046070 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
March 5, 2014 | Phase 2 |
NCT04825496 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University |
Relapsed or Refractory Acute Lymphoblastic Leukemia
|
April 9, 2021 | Phase 1 |
NCT00003185 | The Cleveland Clinic|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
August 1997 | Phase 2 |
NCT05269381 | Mayo Clinic|National Cancer Institute (NCI) |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Merkel Cell Carcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Cervical Carcinoma|Locally Advanced Endometrial Carcinoma|Locally Advanced Gastric Adenocarcinoma|Locally Advanced Gastroesophageal Junction Adenocarcinoma|Locally Advanced Head and Neck Squamous Cell Carcinoma|Locally Advanced Hepatocellular Carcinoma|Locally Advanced Lung Non-Small Cell Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Merkel Cell Carcinoma|Locally Advanced Renal Cell Carcinoma|Locally Advanced Skin Squamous Cell Carcinoma|Locally Advanced Triple-Negative Breast Carcinoma|Locally Advanced Unresectable Breast Carcinoma|Locally Advanced Unresectable Cervical Carcinoma|Locally Advanced Unresectable Gastric Adenocarcinoma|Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma|Locally Advanced Unresectable Renal Cell Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Cervical Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IV Merkel Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Skin Squamous Cell Carcinoma|Stage III Cervical Cancer AJCC v8|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Cervical Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Cervical Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Cervical Cancer AJCC v8|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Cervical Carcinoma|Unresectable Endometrial Carcinoma|Unresectable Gastric Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Renal Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma|Unresectable Triple-Negative Breast Carcinoma|Unresectable Urothelial Carcinoma
|
March 31, 2022 | Phase 1 |
NCT05589896 | Ossium Health, Inc.|Center for International Blood and Marrow Transplant Research |
Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Biphenotypic Leukemia|Acute Undifferentiated Leukemia
|
March 2023 | Phase 1|Phase 2 |
NCT04577326 | Memorial Sloan Kettering Cancer Center|Atara Biotherapeutics |
Malignant Pleural Mesothelioma (MPM)
|
September 30, 2020 | Phase 1 |
NCT00270881 | Keio University |
Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome
|
January 2006 | Phase 1|Phase 2 |
NCT00028717 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lymphoma
|
February 2001 | Phase 3 |
NCT04322318 | Children´s Oncology Group|National Cancer Institute (NCI) |
Anaplastic Kidney Wilms Tumor|Recurrent Kidney Wilms Tumor|Stage II Kidney Wilms Tumor|Stage III Kidney Wilms Tumor|Stage IV Kidney Wilms Tumor
|
September 18, 2020 | Phase 2 |
NCT00336791 | M.D. Anderson Cancer Center|Breast Cancer Research Foundation |
Breast Cancer
|
September 2003 | Phase 3 |
NCT01526499 | Fudan University |
Breast Cancer
|
December 2011 | Phase 2 |
NCT00003136 | University of Chicago |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
December 1996 | Phase 1|Phase 2 |
NCT00064337 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma|Plasma Cell Myeloma
|
January 2004 | Phase 2 |
NCT01343043 | GlaxoSmithKline |
Neoplasms
|
September 27, 2012 | Phase 1 |
NCT00911183 | Institut Bergonié|National Cancer Institute, France |
Lymphoma
|
December 2, 2008 | Phase 2 |
NCT03139370 | Kite, A Gilead Company|Gilead Sciences |
Solid Tumor
|
December 27, 2017 | Phase 1 |
NCT00126191 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Burkitt Lymphoma|Non-Hodgkins Lymphoma|Atypical Burkitt Lymphoma
|
July 2005 | Phase 2 |
NCT03184194 | Amsterdam UMC, location VUmc|Erasmus Medical Center|UMC Utrecht|Maastricht University Medical Center|Meander Medical Center|St. Antonius Hospital|Isala|Albert Schweitzer Hospital|Radboud University Medical Center|University Medical Center Groningen|Rijnstate Hospital |
Myeloma
|
February 21, 2018 | Phase 2 |
NCT00002466 | Memorial Sloan Kettering Cancer Center |
Kidney Cancer|Sarcoma
|
May 1990 | Phase 2 |
NCT00923195 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Skin Cancer
|
December 2008 | Phase 2 |
NCT04317248 | Yuehua Huang|Sun Yat-sen University|Nanfang Hospital of Southern Medical University|Third Affiliated Hospital, Sun Yat-Sen University |
Hepatocellular Carcinoma
|
April 1, 2020 | Phase 2 |
NCT00787527 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Lymphoma
|
November 2008 | Phase 1|Phase 2 |
NCT00157209 | Merck KGaA, Darmstadt, Germany |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung
|
August 2000 | Phase 2 |
NCT01783535 | St. Jude Children´s Research Hospital |
Retinoblastoma
|
June 19, 2013 | Phase 2 |
NCT00493870 | US Oncology Research|Sanofi |
Breast Cancer
|
May 29, 2007 | Phase 3 |
NCT05027945 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Immunodeficiency|Hematopoietic Stem Cell Transplantation
|
November 28, 2022 | Phase 2 |
NCT00003414 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Graft Versus Host Disease|Lymphoma
|
October 1997 | Phase 3 |
NCT04119336 | Andrew Yee, MD|Bristol-Myers Squibb|Takeda Pharmaceuticals North America, Inc.|Massachusetts General Hospital |
Relapsed Multiple Myeloma|Refractory Multiple Myeloma
|
January 14, 2020 | Phase 2 |
NCT03190941 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Pancreatic Cancer|Gastric Cancer|Gastrointestinal Cancer|Colon Cancer|Rectal Cancer
|
September 21, 2017 | Phase 1|Phase 2 |
NCT04547049 | First Affiliated Hospital of Zhejiang University |
Leukemia
|
September 1, 2020 | Phase 3 |
NCT02210104 | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Melanoma|Sarcoma
|
December 2016 | Phase 1 |
NCT03396575 | University of Florida|Accelerate Brain Cancer Cure|Lyla Nsouli Foundation |
Diffuse Intrinsic Pontine Glioma (DIPG)|Brain Stem Glioma
|
May 17, 2018 | Phase 1 |
NCT02224872 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Severe Aplastic Anemia|Bone Marrow Failure Syndromes
|
August 2014 | Phase 2 |
NCT02027935 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Melanoma|Stage IV Cutaneous Melanoma AJCC v6 and v7
|
January 22, 2015 | Phase 2 |
NCT02310997 | University College, London|Cancer Research UK |
Leukaemia|Lymphoma|Other Haematological Diseases
|
July 2011 | Phase 2 |
NCT00002509 | Temple University|Fox Chase Cancer Center |
Breast Cancer
|
November 1991 | Phase 1|Phase 2 |
NCT02502864 | H. Lee Moffitt Cancer Center and Research Institute|Saladax Biomedical, Inc. |
Breast Cancer|Breast Cancer Female
|
February 9, 2016 | Phase 4 |
NCT03814447 | Shanghai 6th People´s Hospital|Hrain Biotechnology Co., Ltd. |
Ovarian Cancer
|
August 16, 2019 | Early Phase 1 |
NCT02214381 | West German Study Group|Teva Pharmaceuticals USA |
Early Primary Breast Cancer
|
July 2014 | Phase 3 |
NCT01871441 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Malignant Neoplasm
|
May 17, 2013 | Phase 2 |
NCT00911716 | Cancer Trials Ireland |
Breast Cancer
|
October 2008 | Not Applicable |
NCT00186797 | St. Jude Children´s Research Hospital |
Aplastic Anemia
|
December 2002 | Not Applicable |
NCT00446030 | Sanofi |
Breast Neoplasms
|
March 2007 | Phase 2 |
NCT02867332 | Peking University |
Metastatic Renal Cell Carcinoma
|
November 2016 | Phase 1 |
NCT01015443 | Merck KGaA, Darmstadt, Germany |
Non-Small Cell Lung Cancer
|
December 2009 | Phase 3 |
NCT00027885 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
November 2001 | Phase 2 |
NCT01193283 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Aplastic Anemia|Neutropenia|Pancytopenia|Severe Aplastic Anemia
|
August 2010 | Phase 1|Phase 2 |
NCT00770224 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2009 | Phase 2 |
NCT01640301 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Donor|Hematopoietic Cell Transplant Recipient|HLA-A*0201 Positive Cells Present|Recurrent Acute Myeloid Leukemia
|
December 6, 2012 | Phase 1|Phase 2 |
NCT02666898 | French Innovative Leukemia Organisation|Roche Pharma AG|Janssen-Cilag Ltd. |
Leukemia, Lymphocytic, Chronic, B-Cell
|
October 2015 | Phase 2 |
NCT02166463 | National Cancer Institute (NCI) |
Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma
|
March 16, 2015 | Phase 3 |
NCT01415336 | Peking Union Medical College Hospital |
Breast Cancer
|
March 2010 | Phase 2|Phase 3 |
NCT01681563 | Niguarda Hospital|Regione Lombardia|GlaxoSmithKline|Hospira, now a wholly owned subsidiary of Pfizer |
Chronic Lymphocytic Leukemia
|
September 2011 | Phase 2 |
NCT02794077 | The University of Hong Kong |
Recurrent Nasopharyngeal Undifferentiated Carcinoma|Stage IV Nasopharyngeal Undifferentiated Carcinoma
|
January 2008 | Phase 2 |
NCT01304797 | Merrimack Pharmaceuticals |
Breast Cancer
|
March 2011 | Phase 1 |
NCT00053768 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
April 2002 | Phase 3 |
NCT01205503 | Mara Chambers|University of Kentucky |
Breast Cancer|Non-Hodgkin´s Lymphoma
|
September 2010 | Phase 2 |
NCT00149214 | Eli Lilly and Company |
Breast Cancer
|
September 2005 | Phase 2 |
NCT04776850 | M.D. Anderson Cancer Center |
Beta Thalassemia Major|Sickle Beta 0 Thalassemia|Sickle Beta Plus Thalassemia|Sickle Beta Thalassemia|Sickle Cell Disease|Sickle Cell-SS Disease
|
December 29, 2020 | Early Phase 1 |
NCT03263208 | Henan Cancer Hospital|The Pregene (ShenZhen) Biotechnology Company, Ltd. |
B-cell Acute Lymphocytic Leukemia
|
August 16, 2017 | Phase 1|Phase 2 |
NCT04102436 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Endocrine+Neuroendocrine|Non-Small Cell Lung Cancer|Breast Cancer|Gastrointestinal+Genitourinary Cancers|Ovarian Cancer
|
November 28, 2022 | Phase 2 |
NCT00482911 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Intraocular Melanoma|Malignant Conjunctival Neoplasm
|
April 2007 | Phase 2 |
NCT02661503 | University of Cologne |
Classical Hodgkin Lymphoma
|
July 2016 | Phase 3 |
NCT02294552 | Ivan S Moiseev|St. Petersburg State Pavlov Medical University |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphoma|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Immune System Diseases
|
October 2014 | Phase 2 |
NCT04370301 | Fred Hutchinson Cancer Center |
Primary Myelofibrosis|Secondary Myelofibrosis
|
February 9, 2021 | Phase 2 |
NCT00002865 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Leukemia
|
April 1995 | Phase 2 |
NCT00278161 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
January 2005 | Phase 2 |
NCT00062140 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
April 2003 | Phase 1 |
NCT00025610 | European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1999 | Phase 2 |
NCT00235235 | Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Walther Cancer Institute |
Breast Cancer
|
September 2005 | |
NCT00662233 | Mayo Clinic|National Cancer Institute (NCI) |
Ovarian Cancer|Sarcoma
|
October 1991 | Early Phase 1 |
NCT04304352 | European Institute of Oncology |
Advanced Breast Cancer
|
July 29, 2011 | Phase 2 |
NCT04388839 | H. Lee Moffitt Cancer Center and Research Institute|National Pediatric Cancer Foundation |
Rhabdomyosarcoma
|
September 27, 2020 | Phase 2 |
NCT00753220 | Bostwick Laboratories|Prostate Institute of America|Community Memorial HealthCenter|HemaCare Corporation |
Prostate Cancer
|
August 2009 | Phase 1|Phase 2 |
NCT00002785 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 1996 | Phase 2 |
NCT00096382 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Melanoma (Skin)
|
September 2004 | Phase 2 |
NCT00110006 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 2004 | Not Applicable |
NCT00363090 | Toronto Sunnybrook Regional Cancer Centre|National Cancer Institute (NCI) |
Lymphoma
|
September 2006 | Phase 1|Phase 2 |
NCT00425438 | Hoffmann-La Roche |
Lupus Nephritis
|
March 2007 | Phase 3 |
NCT05294055 | Qiu Lugui|Jiangsu Hengrui Pharmaceuticals Co.,Ltd|Institute of Hematology & Blood Diseases Hospital |
Multiple Myeloma|Lymphoma
|
March 25, 2022 | Phase 2 |
NCT02029638 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Kidney Transplantation
|
January 7, 2014 | Phase 2 |
NCT03188172 | University of Leeds|Myeloma UK|Celgene|Janssen, LP |
Multiple Myeloma
|
September 28, 2017 | Phase 2 |
NCT00499083 | University of Nebraska|National Cancer Institute (NCI) |
Breast Cancer
|
May 2006 | Phase 2 |
NCT02880293 | Memorial Sloan Kettering Cancer Center |
Hematologic Malignancy
|
August 23, 2016 | Not Applicable |
NCT02094794 | City of Hope Medical Center|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia
|
May 12, 2014 | Phase 2 |
NCT04264039 | Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People´s Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|Central South University|The First Affiliated Hospital of Kunming Medical College|The General Hospital of Western Theater Command|Second Affiliated Hospital of Xi´an Jiaotong University|Nanfang Hospital of Southern Medical University|Fujian Medical University Union Hospital|The First Affiliated Hospital of Anhui Medical University|Tang-Du Hospital |
B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma
|
April 1, 2020 | Early Phase 1 |
NCT02472392 | University of Louisville |
EWINGS SARCOMA
|
April 2013 | Phase 1 |
NCT04154735 | Northwestern University |
Crohn´s Disease
|
November 2019 | Phase 2 |
NCT01306032 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Cancer|Primary Peritoneal Cancer|Serous Carcinoma Cancer|Triple-Negative Breast Cancer|Fallopian Tube Cancer
|
January 12, 2011 | Phase 2 |
NCT02362165 | Sun Yat-sen University |
Multiple Myeloma
|
April 2015 | Phase 3 |
NCT00003944 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
August 1998 | Phase 2 |
NCT00002905 | Centro di Riferimento Oncologico - Aviano|National Cancer Institute (NCI) |
Lymphoma
|
June 1995 | Phase 2 |
NCT01807182 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Metastatic Melanoma
|
August 20, 2013 | Phase 2 |
NCT02359162 | Sun Yat-sen University |
Lymphoma, Extranodal NK-T-Cell
|
May 2015 | Phase 3 |
NCT01412879 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2011 | Phase 2 |
NCT01036087 | M.D. Anderson Cancer Center|Celgene Corporation|Amgen |
Breast Cancer
|
November 2010 | Phase 2 |
NCT00002594 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumor|Central Nervous System Tumor
|
September 1994 | Phase 2 |
NCT01955460 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Melanoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7
|
October 15, 2014 | Phase 1 |
NCT01621477 | St. Jude Children´s Research Hospital|Assisi Foundation |
Acute Lymphoblastic Leukemia|Acute Myelocytic Leukemia|Chronic Myelocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hodgkin or Non-Hodgkin Lymphoma|Sarcoma, Myeloid
|
August 2012 | Phase 2 |
NCT02506777 | N.N. Petrov National Medical Research Center of Oncology |
Breast Cancer
|
July 2015 | Phase 2 |
NCT00003119 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
March 1998 | Phase 3 |
NCT02763475 | Instituto de Investigación Hospital Universitario La Paz|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Fundación Mutua Madrileña |
Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia
|
May 2016 | Phase 2 |
NCT00971737 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
July 2009 | Phase 2 |
NCT01220128 | GlaxoSmithKline |
Neoplasms, Breast
|
April 11, 2011 | Phase 2 |
NCT00003650 | UNICANCER |
Lymphoma
|
February 1997 | Phase 3 |
NCT00002581 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
June 1993 | Phase 3 |
NCT04639245 | Fred Hutchinson Cancer Center|SignalOne Bio, Inc. |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
July 19, 2021 | Phase 1|Phase 2 |
NCT00004092 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 1999 | Phase 2 |
NCT01729338 | Duke University|Millennium Pharmaceuticals, Inc.|Duke Cancer Institute |
Multiple Myeloma
|
December 19, 2012 | Phase 2 |
NCT00856180 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|Genentech, Inc. |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer
|
February 2009 | Phase 2 |
NCT00653068 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Atypical Teratoid+Rhabdoid Tumor
|
December 8, 2008 | Phase 3 |
NCT01072773 | Mayo Clinic |
Primary Systemic Amyloidosis
|
March 2010 | Phase 2 |
NCT03192397 | Roswell Park Cancer Institute |
Acute Myeloid Leukemia in Remission|Adult Acute Lymphoblastic Leukemia in Complete Remission|Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission|Chronic Myelomonocytic Leukemia in Remission|Graft Versus Host Disease|Hodgkin Lymphoma|Minimal Residual Disease|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|Severe Aplastic Anemia|Waldenstrom Macroglobulinemia
|
August 9, 2017 | Phase 1|Phase 2 |
NCT01749293 | University of Illinois at Chicago |
Hematologic Malignancies
|
August 30, 2012 | Phase 2 |
NCT00324831 | Favrille|National Cancer Institute (NCI) |
Lymphoma
|
Phase 3 | |
NCT02876510 | Immatics US, Inc.|M.D. Anderson Cancer Center |
Cancer|Solid Tumor
|
June 30, 2017 | Phase 1 |
NCT01341262 | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
Multiple Myeloma
|
March 2002 | Phase 2 |
NCT01181258 | Masonic Cancer Center, University of Minnesota |
Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
August 2010 | Phase 2 |
NCT00667927 | St. Jude Children´s Research Hospital |
Acute Myeloid Leukemia
|
March 1991 | Phase 1 |
NCT04579523 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
May 1, 2023 | Phase 1 |
NCT00049036 | National Cancer Institute (NCI) |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma
|
March 2003 | Phase 2 |
NCT01790737 | Kuopio University Hospital|Helsinki University Central Hospital|Tampere University Hospital|Turku University Hospital|Oulu University Hospital|Mikkeli Central Hospital|Kymenlaakso Central Hospital Kotka Finland|Jyväskylä Central Hospital|Kanta-Häme Central Hospital|Satakunta Central Hospital|Kainuu Central Hospital, Kajaani|Celgene Corporation |
Multiple Myeloma
|
January 2013 | Phase 2 |
NCT00433511 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group |
Breast Adenocarcinoma
|
November 2, 2007 | Phase 3 |
NCT04318678 | St. Jude Children´s Research Hospital |
AML|B-ALL|T-ALL|BPDCN|MDS
|
May 27, 2020 | Phase 1 |
NCT00908232 | Janssen-Cilag International NV |
Multiple Myeloma
|
May 2008 | Phase 2 |
NCT05201248 | AbbVie|Genmab |
B-Cell Non-Hodgkin Lymphoma
|
March 10, 2022 | Phase 1 |
NCT02932956 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Cancer Prevention Research Institute of Texas|The V Foundation|Cookies for Kids´ Cancer|Curing Kids´ Cancer Foundation |
Liver Cancer
|
December 17, 2018 | Phase 1 |
NCT00812669 | Cancer Trials Ireland |
Leukemia
|
August 2008 | Phase 2 |
NCT00003700 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
January 1999 | Phase 2 |
NCT02176213 | Ajai Chari|Celgene Corporation|Icahn School of Medicine at Mount Sinai |
Multiple Myeloma in Relapse|Multiple Myeloma, Refractory
|
June 2014 | Phase 2 |
NCT00343369 | Universitätsklinikum Hamburg-Eppendorf|National Cancer Institute (NCI) |
Leukemia
|
January 2003 | Not Applicable |
NCT00006669 | Medstar Health Research Institute |
Lymphoma
|
September 1999 | Phase 2 |
NCT00003573 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumors|Central Nervous System Tumors
|
November 1998 | Phase 2 |
NCT05250973 | Janssen Research & Development, LLC |
Amyloidosis
|
March 1, 2022 | Phase 2 |
NCT02629809 | M.D. Anderson Cancer Center |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
March 18, 2016 | Phase 2 |
NCT00025259 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma|Childhood Mixed Cellularity Classical Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Classical Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
September 2002 | Phase 3 |
NCT04127019 | Fudan University |
Primary Breast Cancer
|
June 1, 2010 | Phase 3 |
NCT00669890 | New York Medical College |
Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome
|
May 2004 | Phase 1 |
NCT00409188 | EMD Serono|Merck KGaA, Darmstadt, Germany |
Non-small Cell Lung Cancer
|
January 2007 | Phase 3 |
NCT02955810 | National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland |
Multiple Myeloma
|
November 2016 | Phase 1 |
NCT00574080 | University of Arkansas |
Multiple Myeloma
|
July 2006 | Phase 3 |
NCT00039130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 2002 | Phase 2 |
NCT01071239 | Medical College of Wisconsin|Memorial Sloan Kettering Cancer Center |
Fanconi Anemia
|
April 2009 | Phase 2 |
NCT02446431 | Miller Children´s & Women´s Hospital Long Beach|Children´s Hospital of Orange County |
Solid Tumor
|
July 2014 | Early Phase 1 |
NCT03273595 | Xijing Hospital |
Neoplasms, Breast
|
July 2016 | Phase 2 |
NCT04432714 | The First Affiliated Hospital with Nanjing Medical University |
DLBCL|Untreated|MYC Gene Rearrangement
|
June 9, 2020 | Phase 1|Phase 2 |
NCT00007982 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Head and Neck Cancer|Lymphoma
|
April 1999 | Phase 2 |
NCT04227990 | BeyondSpring Pharmaceuticals Inc. |
Chemotherapy-induced Neutropenia
|
November 27, 2017 | Phase 2 |
NCT03817853 | Hoffmann-La Roche |
Advanced Follicular Lymphoma
|
February 26, 2019 | Phase 4 |
NCT00005893 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Neutropenia|Sickle Cell Anemia|Thalassemia Major|Red-Cell Aplasia, Pure
|
June 2000 | Not Applicable |
NCT00352027 | St. Jude Children´s Research Hospital |
Hodgkin´s Lymphoma
|
July 20, 2006 | Phase 2 |
NCT02499367 | The Netherlands Cancer Institute|Bristol-Myers Squibb |
Breast Cancer
|
August 2015 | Phase 2 |
NCT01005914 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Leukemia
|
June 2009 | Phase 2 |
NCT03289819 | Institut fuer Frauengesundheit|Merck Sharp & Dohme LLC|Celgene Corporation |
Malignant Neoplasm of Breast
|
March 23, 2018 | Phase 2 |
NCT03531281 | City of Hope Medical Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient
|
December 30, 2018 | Phase 1 |
NCT01495572 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Skin Cancer
|
December 2011 | Phase 2 |
NCT00500890 | M.D. Anderson Cancer Center |
Choroid Plexus Tumors
|
September 2, 2005 | Phase 3 |
NCT01855828 | Yale University|Genentech, Inc. |
Her2-Positive Breast Cancer
|
September 2013 | Phase 2 |
NCT01539902 | CytoMed & Beike |
Lupus Nephritis
|
February 2012 | Phase 2 |
NCT00033293 | Children´s Oncology Group|National Cancer Institute (NCI) |
Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma
|
March 15, 2004 | Phase 3 |
NCT02298283 | The Lymphoma Academic Research Organisation |
Hodgkin Lymphoma
|
April 2015 | Phase 2 |
NCT00801931 | Columbia University |
Leukemia|Lymphoma|Neuroblastoma|Immunodeficiencies|Anemia
|
September 6, 2007 | Phase 1|Phase 2 |
NCT00048737 | M.D. Anderson Cancer Center|Biogen |
Lymphoma|Leukemia
|
October 2002 | Phase 1|Phase 2 |
NCT00002898 | Societe Internationale d´Oncologie Pediatrique|National Cancer Institute (NCI) |
Childhood Malignant Fibrous Histiocytoma of Bone|Sarcoma
|
January 1995 | Phase 3 |
NCT03888677 | Henrik Lindman|Scandinavian Breast Group|Danish Breast Cancer Cooperative Group|Swedish Cancer Society|Swedish Cancer Foundation|Pharmacia Pharmaceutical Company|Swedish Breast Cancer Group|Uppsala University Hospital |
Breast Cancer
|
February 2001 | Phase 3 |
NCT00073879 | Baylor College of Medicine |
Kidney Cancer
|
April 2003 | Not Applicable |
NCT02622074 | Merck Sharp & Dohme LLC |
Triple Negative Breast Neoplasms
|
January 27, 2016 | Phase 1 |
NCT02627248 | Shandong University |
Breast Cancer
|
October 2015 | Phase 4 |
NCT02086942 | Yongping Zhai|Jinling Hospital, China |
Multiple Myeloma
|
August 2013 | Phase 2 |
NCT00705120 | St. Jude Children´s Research Hospital |
Osteogenesis Imperfecta
|
November 1995 | Phase 1 |
NCT00501995 | Johns Hopkins University |
Scleroderma
|
February 2001 | Phase 3 |
NCT02855359 | Seagen Inc. |
Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma + DLBCL
|
August 2016 | Phase 2 |
NCT05195619 | Centre Hospitalier Universitaire Vaudois |
Non-small Cell Lung Cancer
|
December 10, 2021 | Phase 1 |
NCT00828009 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
December 22, 2010 | Phase 2 |
NCT00242996 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
March 2004 | Phase 2 |
NCT00003679 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
November 1998 | Phase 3 |
NCT03380039 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|CARsgen Therapeutics Co., Ltd. |
Refractory or Relapsed Multiple Myeloma
|
October 13, 2017 | Not Applicable |
NCT03167177 | ImmunityBio, Inc. |
Melanoma
|
December 2017 | Phase 1|Phase 2 |
NCT00496665 | Dana-Farber Cancer Institute|AstraZeneca|Massachusetts General Hospital|Brigham and Women´s Hospital |
Metastatic Breast Cancer
|
July 2007 | Phase 1 |
NCT01918124 | Fan Ming|Fudan University |
Prosthesis Survival
|
January 2008 | Phase 2 |
NCT05177796 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
|
March 11, 2022 | Phase 2 |
NCT01187017 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Aplastic Anemia|Neutropenia|Pancytopenia|Severe Aplastic Anemia
|
August 2010 | Phase 1|Phase 2 |
NCT02118311 | Masonic Cancer Center, University of Minnesota|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Hematologic Malignancies
|
June 2016 | Phase 2 |
NCT00002784 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
June 1996 | Phase 3 |
NCT00698009 | M.D. Anderson Cancer Center |
Neuroblastoma
|
June 2008 | Phase 2 |
NCT03190265 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Aduro Biotech, Inc.|Bristol-Myers Squibb|National Cancer Institute (NCI) |
Pancreatic Cancer
|
December 14, 2017 | Phase 2 |
NCT01464359 | Masonic Cancer Center, University of Minnesota |
Acute Myelogenous Leukemia|Refractory Acute Myelogenous Leukemia
|
October 2011 | Phase 2 |
NCT01106235 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Stage IV Melanoma
|
April 2010 | Phase 1 |
NCT04172259 | Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer|Neoadjuvant Chemotherapy
|
January 10, 2019 | Phase 2 |
NCT00002610 | Children´s Oncology Group|National Cancer Institute (NCI) |
Kidney Cancer
|
January 1996 | Phase 3 |
NCT00634179 | Emory University|Millennium Pharmaceuticals, Inc. |
Lymphoma, B-Cell|Follicular Lymphoma
|
February 2008 | Phase 1|Phase 2 |
NCT00253552 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Sarcoma
|
May 2004 | Not Applicable |
NCT02251821 | Fred Hutchinson Cancer Center|Incyte Corporation|National Cancer Institute (NCI) |
Primary Myelofibrosis|Secondary Myelofibrosis
|
October 20, 2014 | Phase 2 |
NCT03706547 | Peng Liu|Hrain Biotechnology|Shanghai East Hospital|Shanghai Zhongshan Hospital |
Multiple Myeloma in Relapse|Multiple Myeloma Progression
|
October 30, 2018 | Phase 1 |
NCT00068601 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|ETOP IBCSG Partners Foundation |
Breast Cancer|Infertility|Menopausal Symptoms
|
October 2003 | Phase 3 |
NCT00182793 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2005 | Phase 2 |
NCT03093168 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Hrain Biotechnology Co., Ltd.|First Affiliated Hospital of Wenzhou Medical University|Shanghai Changzheng Hospital |
Multiple Myeloma
|
February 15, 2017 | Phase 1 |
NCT05577000 | Thomas Martin, MD|Actavis Inc.|University of California, Davis|Eugia Pharma Specialities Limited|University of California, San Francisco |
Refractory Multiple Myeloma|Relapsed Multiple Myeloma
|
March 1, 2023 | Phase 1 |
NCT00195871 | Centre Henri Becquerel |
Lymphoblastic Lymphoma
|
February 2004 | Phase 2 |
NCT00551265 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer
|
October 2007 | Not Applicable |
NCT03925233 | Xijing Hospital |
Breast Cancer Organoids
|
January 2, 2019 | |
NCT01595321 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The Skip Viragh Foundation |
Pancreatic Cancer
|
October 29, 2012 | Not Applicable |
NCT00016887 | German Low Grade Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Studio Linfomi|Lymphoma Study Association|National Cancer Institute (NCI) |
Lymphoma
|
December 2000 | Phase 3 |
NCT01707004 | University of Wisconsin, Madison|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
May 16, 2013 | Phase 2 |
NCT00004061 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Oral Complications
|
May 1999 | Phase 2 |
NCT03733327 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Guangzhou First People´s Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University |
Primary Central Nervous System Lymphoma|Autologous Hematopoietic Stem Cell Transplantation|Conditioning
|
November 2018 | Phase 2|Phase 3 |
NCT00004135 | University of Chicago|National Cancer Institute (NCI) |
Kidney Cancer|Melanoma (Skin)
|
February 1999 | Phase 2 |
NCT00688740 | Sanofi|Cancer International Research Group (CIRG) |
Breast Cancer
|
June 1997 | Phase 3 |
NCT00006455 | Gustave Roussy, Cancer Campus, Grand Paris |
Lymphoma
|
November 26, 1999 | Phase 3 |
NCT00002953 | Medical Research Council|National Cancer Institute (NCI) |
Breast Cancer
|
December 1996 | Phase 3 |
NCT00278564 | Northwestern University |
MYOPATHY
|
September 2005 | Phase 1 |
NCT00238368 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
NCT04083963 | University of Illinois at Chicago |
Triple Negative Breast Cancer
|
August 9, 2019 | Phase 2 |
NCT00412360 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Natural Killer Cell Lymphoblastic Leukemia+Lymphoma
|
December 2006 | Phase 3 |
NCT03164993 | Oslo University Hospital|Hoffmann-La Roche|Norwegian Cancer Society|St. Olavs Hospital|Helse Stavanger HF|Rigshospitalet, Denmark|Vejle Hospital|NanoString Technologies, Inc.|Technical University of Denmark|Karolinska Institutet |
Cancer, Breast|Triple Negative Breast Cancer
|
June 1, 2017 | Phase 2 |
NCT01943188 | Stanford University|National Cancer Institute (NCI) |
Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer
|
May 2014 | Phase 1 |
NCT04796688 | Wuhan Union Hospital, China|Chengdu USino Technology Biology Co., Ltd |
Acute Lymphoblastic Leukemia|Chronic Lymphoblastic Leukemia|B-cell Lymphoma
|
March 10, 2021 | Phase 1 |
NCT00377637 | Hoffmann-La Roche|Aspreva Pharmaceuticals |
Lupus Nephritis
|
July 2005 | Phase 3 |
NCT00228358 | University of Washington|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor
|
June 2003 | Phase 1 |
NCT00388349 | Stanford University|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID) |
Hodgkin Disease|Hodgkin´s Lymphoma|Lymphoma
|
September 2001 | Phase 2 |
NCT04648046 | Steven Deeks|Caring Cross|University of California, San Francisco |
HIV Infections
|
March 1, 2021 | Phase 1|Phase 2 |
NCT02467010 | University Medical Center Groningen |
Multiple Myeloma
|
September 2008 | Phase 2 |
NCT01354522 | Peking Union Medical College Hospital |
Breast Cancer
|
May 2011 | Phase 3 |
NCT00002819 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B|GOG Foundation |
Ovarian Cancer
|
November 1996 | Phase 3 |
NCT01630538 | University of Manitoba |
Antibody Mediated Rejection
|
June 2013 | Phase 2 |
NCT01697293 | Prescient Therapeutics, Ltd.|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor Positive|HER2+Neu Negative|Recurrent Breast Carcinoma|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
January 2012 | Phase 1|Phase 2 |
NCT01362790 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms
|
May 11, 2011 | Phase 1|Phase 2 |
NCT04239092 | Actuate Therapeutics Inc. |
Refractory Cancer|Refractory Neoplasm|Cancer Pediatric|Refractory Tumor|Pediatric Cancer|Pediatric Brain Tumor|Neuroblastoma|Neuroblastoma Recurrent|Pediatric Lymphoma|Pediatric Meningioma|Diffuse Intrinsic Pontine Glioma
|
June 5, 2020 | Phase 1 |
NCT00006123 | Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute |
Breast Cancer
|
July 2000 | Phase 1|Phase 2 |
NCT00331552 | University of Washington|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
February 2006 | Phase 1|Phase 2 |
NCT00003398 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
September 1998 | Phase 4 |
NCT00084695 | Milton S. Hershey Medical Center|National Cancer Institute (NCI) |
Childhood Langerhans Cell Histiocytosis|Fanconi Anemia|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific
|
September 2003 | Phase 2 |
NCT00977691 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Sickle Cell Anemia
|
December 14, 2009 | Phase 1|Phase 2 |
NCT02114229 | St. Jude Children´s Research Hospital|Millennium Pharmaceuticals, Inc.|Takeda Pharmaceuticals U.S.A., Inc. |
Malignant Rhabdoid Tumor|Atypical Teratoid Rhabdoid Tumor
|
May 14, 2014 | Phase 2 |
NCT05200312 | The First Affiliated Hospital with Nanjing Medical University |
Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma
|
February 1, 2022 | Phase 2 |
NCT04166565 | European Myeloma Network|Janssen, LP |
Multiple Myeloma|Extramedullary Plasmacytoma
|
October 31, 2019 | Phase 2 |
NCT00091611 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Kidney Neoplasms
|
September 2004 | Phase 1 |
NCT00022126 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 2 |
NCT00093795 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
October 2004 | Phase 3 |
NCT04177004 | City of Hope Medical Center|National Cancer Institute (NCI) |
Allogeneic Hematopoietic Stem Cell Transplant Recipient|Hematopoietic and Lymphoid Cell Neoplasm
|
April 30, 2021 | Phase 1 |
NCT04023071 | Fate Therapeutics |
Acute Myelogenous Leukemia|B-cell Lymphoma
|
October 4, 2019 | Phase 1 |
NCT01822652 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|Solving Kids´ Cancer|The Evan Foundation|National Cancer Institute (NCI)|Kids Cancer Research Foundation |
Neuroblastoma
|
August 2013 | Phase 1 |
NCT00002789 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
May 1996 | Phase 3 |
NCT00199069 | Johann Wolfgang Goethe University Hospital|Deutsche Krebshilfe e.V., Bonn (Germany) |
Adult Acute Lymphocytic Leukemia
|
April 1993 | Phase 4 |
NCT05003895 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hepatocellular Carcinoma|Hepatocellular Cancer|Metastatic Hepatocellular Carcinoma
|
December 8, 2021 | Phase 1 |
NCT00315705 | Genzyme, a Sanofi Company|Sanofi |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Relapsed Leukemia
|
March 2006 | Phase 1|Phase 2 |
NCT02057770 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
February 28, 2014 | Phase 1 |
NCT01606241 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Breast Cancer|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Breast Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Breast Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Breast Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer
|
July 24, 2012 | Phase 1 |
NCT04653493 | Sabz Biomedicals|Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran|Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran |
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)|Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
|
August 2021 | Phase 1 |
NCT00628732 | Children´s Medical Center Dallas|Metabolic Solutions Inc.|Simmons Cancer Center |
Solid Tumors
|
January 2005 | Phase 2 |
NCT02379520 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Human Papillomavirus-Related Carcinoma|Human Papillomavirus Positive Oropharyngeal Carcinoma|Human Papillomavirus Positive Cervical Carcinoma|Human Papillomavirus Positive Anal Carcinoma|Human Papillomavirus Positive Vulvar Carcinoma|Human Papillomavirus Positive Penile Carcinoma
|
September 2015 | Phase 1 |
NCT02349178 | Medical College of Wisconsin|American Family Children´s Hospital|Nationwide Children´s Hospital |
Leukemia, Acute Lymphoblastic|Acute Myeloid Leukemia
|
December 8, 2014 | Phase 2 |
NCT02005783 | Shanghai Jiao Tong University School of Medicine |
Grade 3+4 Neutropenia|Febrile Neutropenia
|
October 2013 | Phase 2 |
NCT00925652 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Translational Breast Cancer Research Consortium|Genentech, Inc. |
Breast Cancer
|
September 2010 | Phase 2 |
NCT03564704 | Nanfang Hospital of Southern Medical University |
Leukemia|Leukemia, Acute|Adult Lymphoblastic Lymphoma|Leukemia, Lymphoblastic|Leukemia, T Cell|Adult Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoblastic Leukemia
|
February 14, 2016 | Phase 2|Phase 3 |
NCT00004904 | Northwestern University|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous+Nonmalignant Condition|Small Intestine Cancer
|
October 1999 | Phase 1 |
NCT00331097 | National Cancer Institute, Naples |
Breast Cancer
|
July 2003 | Phase 3 |
NCT02987244 | Peking Union Medical College Hospital|Chinese PLA General Hospital|Peking University First Hospital|Peking University Third Hospital|Peking University Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital |
T Cell Non-Hodgkin´s Lymphoma
|
March 2016 | Phase 1|Phase 2 |
NCT04224558 | Cedars-Sinai Medical Center |
Crohn Disease
|
December 15, 2020 | Phase 1|Phase 2 |
NCT04534218 | Centre Hospitalier Universitaire de Besancon|Bayer |
Colo-rectal Cancer|Metastatic Cancer
|
October 16, 2020 | Phase 2 |
NCT03497702 | National Cancer Center, Korea |
Breast Cancer|Invasive Breast Cancer
|
May 8, 2017 | Phase 2 |
NCT04243616 | Medical College of Wisconsin |
Invasive Breast Cancer
|
March 5, 2020 | Phase 2 |
NCT01313429 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies
|
March 4, 2011 | Phase 1 |
NCT02032277 | AbbVie|German Breast Group|NSABP Foundation Inc|Grupo Español de Investigación del Cáncer de Mama|US Oncology Research |
Triple Negative Breast Cancer
|
April 2, 2014 | Phase 3 |
NCT01014767 | Tufts Medical Center |
Brain Cancer|Choroid Plexus Tumors
|
November 2009 | Phase 3 |
NCT04392037 | Amsterdam UMC, location VUmc|Celgene |
Multiple Myeloma
|
February 17, 2021 | Phase 2 |
NCT03328026 | BriaCell Therapeutics Corporation|LumaBridge |
Breast Cancer|Breast Neoplasm|Metastatic Breast Cancer|Breast Cancer Metastatic
|
March 16, 2018 | Phase 1|Phase 2 |
NCT02096614 | Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd. |
Solid Tumors
|
April 2014 | Phase 1 |
NCT03756090 | Zhejiang Cancer Hospital |
Breast Cancer|Breast Diseases|Breast Neoplasms
|
December 1, 2018 | Not Applicable |
NCT00399399 | Hospices Civils de Lyon |
Churg-Strauss Syndrome
|
July 1996 | Phase 4 |
NCT00580333 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Genentech, Inc. |
Breast Cancer
|
September 2007 | Phase 2 |
NCT03571321 | University of Chicago|Incyte Corporation |
Acute Lymphoblastic Leukemia|ALL, Childhood|ALL
|
May 28, 2019 | Phase 1 |
NCT03449108 | M.D. Anderson Cancer Center|Iovance Biotherapeutics, Inc.|National Cancer Institute (NCI) |
Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Triple Negative Breast Cancer
|
April 27, 2018 | Phase 2 |
NCT00390793 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|t(9;22)
|
September 28, 2006 | Phase 2 |
NCT00003392 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 1997 | Phase 2 |
NCT00281918 | Hoffmann-La Roche|German CLL Study Group |
Leukemia
|
July 2003 | Phase 3 |
NCT00002740 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
May 1996 | Phase 1 |
NCT01855750 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
September 3, 2013 | Phase 3 |
NCT03692663 | Allife Medical Science and Technology Co., Ltd.|Tianjin People´s Hospital |
Metastatic Castration-resistant Prostate Cancer
|
December 1, 2018 | Early Phase 1 |
NCT00095862 | Wiseman Research Initiatives LLC|National Cancer Institute (NCI) |
Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
November 2004 | Phase 1|Phase 2 |
NCT00597519 | Memorial Sloan Kettering Cancer Center |
Cancer|Leukemia|Myelodysplastic Syndrome|Non-Hodgkin´s Lymphoma
|
March 2006 | Phase 2 |
NCT03206671 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Mature B-cell Non-Hodgkin Lymphoma
|
August 3, 2017 | Phase 3 |
NCT03676504 | University Hospital Heidelberg |
Acute Lymphoblastic Leukemia, Adult|Acute Lymphoblastic Leukemia, Pediatric|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma
|
September 7, 2018 | Phase 1|Phase 2 |
NCT03536039 | Andres J. M. Ferreri|AGC Biologics S.p.A.|IRCCS San Raffaele |
Lymphoma, Large B-Cell, Diffuse
|
January 27, 2016 | Phase 2 |
NCT00293410 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic+Myeloproliferative Diseases
|
November 2005 | Phase 1 |
NCT03725059 | Merck Sharp & Dohme LLC |
Breast Cancer
|
December 27, 2018 | Phase 3 |
NCT04498793 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|First Affiliated Hospital Xi´an Jiaotong University|Wuhan Union Hospital, China|Beijing Huanxing Cancer Hospital |
HER2-negative Breast Cancer
|
September 2020 | Phase 2 |
NCT03935347 | Roswell Park Cancer Institute|Iovance Biotherapeutics, Inc. |
Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Unresectable Renal Pelvis Urothelial Carcinoma|Unresectable Ureter Urothelial Carcinoma
|
June 20, 2019 | Phase 2 |
NCT05370547 | Chinese PLA General Hospital |
Non Hodgkin´s Lymphoma
|
May 25, 2022 | Phase 1|Phase 2 |
NCT01804634 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Refractory and+or Relapsed Metastatic Solid Tumors
|
March 27, 2013 | Phase 2 |
NCT00718549 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
July 21, 2009 | Phase 3 |
NCT00004145 | University of Chicago|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
November 1998 | Phase 2 |
NCT01974518 | Uprety Shraddha|Postgraduate Institute of Medical Education and Research |
Pemphigus
|
November 2013 | Phase 3 |
NCT00005804 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous+Nonmalignant Condition|Small Intestine Cancer
|
October 1999 | Phase 2 |
NCT00908869 | Institut Paoli-Calmettes |
Advanced Neoplasm
|
May 2006 | Phase 1 |
NCT00813150 | Janssen-Cilag G.m.b.H |
Multiple Myeloma
|
January 2009 | Phase 3 |
NCT00190671 | Eli Lilly and Company |
Breast Cancer
|
June 2005 | Phase 1|Phase 2 |
NCT03285607 | Washington University School of Medicine|Novartis Pharmaceuticals |
Breast Cancer|Cancer of Breast
|
September 30, 2018 | Phase 1 |
NCT05323201 | The Affiliated Hospital of Xuzhou Medical University|Xuzhou Medical University|IIT MediTech Co. Ltd |
Hepatocellular Carcinoma
|
February 10, 2022 | Phase 1|Phase 2 |
NCT02538926 | University of Washington|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia+Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 1, 2018 | Phase 2 |
NCT01055301 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma|Plasma Cell Myeloma
|
July 2011 | Phase 2 |
NCT00054587 | UNICANCER |
Breast Cancer
|
June 2001 | Phase 3 |
NCT03896737 | European Myeloma Network|EMN Research Italy |
Multiple Myeloma
|
April 16, 2019 | Phase 2 |
NCT00255710 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
July 2002 | Phase 1 |
NCT02951728 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
October 2016 | Phase 1|Phase 2 |
NCT01435499 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The John P. Hussman Foundation |
Melanoma
|
September 2011 | Phase 1 |
NCT03219359 | Aaron Etra|Icahn School of Medicine at Mount Sinai |
Crohn Disease
|
July 12, 2017 | Phase 2 |
NCT05518383 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Non-hodgkin Lymphoma,B Cell|Burkitt Lymphoma|Primary Mediastinal Lymphoma|Primary CNS Lymphoma|Diffuse Large B-cell Lymphoma
|
May 25, 2022 | Phase 4 |
NCT00087178 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
May 2004 | Phase 3 |
NCT05155215 | Beijing Immunochina Medical Science & Technology Co., Ltd. |
Lymphoma|Lymphoma, Mantle-Cell|Neoplasms by Histologic Type|Neoplasms|Lymphoproliferative Disorders
|
December 31, 2021 | Phase 1|Phase 2 |
NCT00003910 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 16, 1999 | Phase 2 |
NCT00001212 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
Nephrotic Syndrome|Systemic Lupus Erythematosus
|
November 1986 | Phase 2 |
NCT03344705 | Beijing Immunochina Medical Science & Technology Co., Ltd. |
Hematological Malignancies
|
August 21, 2017 | Phase 1 |
NCT01105273 | Asan Medical Center |
Aplastic Anemia
|
July 2009 | Phase 1|Phase 2 |
NCT01190787 | European Myeloma Network|Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2010 | Phase 2 |
NCT00445900 | Mayo Clinic|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Secondary Myelofibrosis
|
October 2004 | Phase 2 |
NCT02441803 | M.D. Anderson Cancer Center |
Leukemia
|
September 14, 2015 | Phase 2 |
NCT00793845 | Samsung Medical Center |
Neuroblastoma
|
August 2008 | Phase 2 |
NCT02752815 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 4 |
NCT00002822 | Medical Research Council|National Cancer Institute (NCI) |
Lung Cancer
|
March 1996 | Phase 3 |
NCT03412643 | NSABP Foundation Inc|Celcuity, LLC|Genentech, Inc. |
HER2-negative Breast Cancer
|
May 14, 2018 | Phase 2 |
NCT02441491 | Johns Hopkins University |
ROHHAD Syndrome
|
March 2015 | Not Applicable |
NCT00005852 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
June 1996 | Phase 2 |
NCT04011033 | Beijing YouAn Hospital |
Hepatocellular Carcinoma
|
March 1, 2019 | Phase 2|Phase 3 |
NCT00801281 | Polish Lymphoma Research Group |
Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma
|
February 2007 | Phase 3 |
NCT00004088 | City of Hope Medical Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
April 13, 1999 | Phase 2 |
NCT02390063 | University of Oxford |
Prostate Cancer
|
June 2015 | Phase 1 |
NCT00003141 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumors|Central Nervous System Tumors|Neuroblastoma|Sarcoma
|
March 1998 | Phase 1 |
NCT00376805 | Masonic Cancer Center, University of Minnesota |
Breast Cancer
|
April 2006 | Phase 2 |
NCT00002788 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
October 1995 | Phase 1 |
NCT02786719 | Baylor College of Medicine |
Neuroblastoma
|
June 2016 | Not Applicable |
NCT00066417 | National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic+Myeloproliferative Diseases
|
Phase 2 | |
NCT01697527 | Jonsson Comprehensive Cancer Center |
Malignant Neoplasm
|
November 2, 2012 | Phase 2 |
NCT02626455 | Bayer |
Lymphoma, Non-Hodgkin
|
January 6, 2016 | Phase 3 |
NCT01740557 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Melanoma|Stage III Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7
|
January 28, 2015 | Phase 1|Phase 2 |
NCT01909752 | UbiVac|National Cancer Institute (NCI)|Providence Cancer Center, Earle A. Chiles Research Institute|Providence Health & Services|Mayo Clinic|Louisiana State University Health Sciences Center in New Orleans |
Carcinoma, Non-Small-Cell Lung
|
July 2013 | Phase 2 |
NCT01040871 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Diffuse Large B-Cell Lymphoma
|
January 2010 | Phase 2 |
NCT00005803 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Prolymphocytic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia
|
September 1999 | Phase 1|Phase 2 |
NCT01758120 | Guangdong Provincial People´s Hospital |
IgA Nephropathy
|
December 2012 | Phase 4 |
NCT05283720 | AbbVie|Genmab |
Non-Hodgkin Lymphoma
|
June 14, 2022 | Phase 2 |
NCT02105766 | National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sickle Cell Disease|Thalassemia|Stem Cell Transplantation|Graft vs Host Disease
|
April 21, 2014 | Phase 2 |
NCT03617432 | Peking University|Peking University International Hospital|Shandong Tumor Hospital|Jiangxi Provincial Cancer Hospital |
Experimental Tumor
|
August 28, 2018 | Phase 2 |
NCT00093834 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
January 2004 | Phase 1 |
NCT03704298 | Kite, A Gilead Company|Pfizer|Gilead Sciences |
Relapsed+Refractory Large B-cell Lymphoma
|
November 20, 2018 | Phase 1 |
NCT00025402 | III. Medizinische Klinik Mannheim|National Cancer Institute (NCI) |
Leukemia
|
July 1997 | Phase 3 |
NCT00448019 | M.D. Anderson Cancer Center|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
February 2007 | Phase 2 |
NCT00039377 | National Cancer Institute (NCI) |
Adult Acute Lymphoblastic Leukemia in Remission
|
April 2002 | Phase 2 |
NCT00769522 | German CLL Study Group|Roche Pharma AG|Mundipharma Pte Ltd. |
Chronic Lymphocytic Leukemia
|
October 2, 2008 | Phase 3 |
NCT00041132 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2002 | Phase 2 |
NCT00053092 | Institute of Cancer Research, United Kingdom|Australasian Leukaemia and Lymphoma Group|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
NCT00578864 | Baylor College of Medicine |
Neuroblastoma
|
March 2007 | Phase 2 |
NCT00589316 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|CD45-Positive Neoplastic Cells Present|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Refractory Anemia With Excess Blasts|Refractory Anemia With Ring Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
|
October 5, 2007 | Phase 1 |
NCT01818063 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Thomas Jefferson University |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer
|
April 25, 2013 | Phase 2 |
NCT03044743 | Yang Yang|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma
|
April 7, 2017 | Phase 1|Phase 2 |
NCT00199004 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
April 2004 | Phase 4 |
NCT00923390 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Renal Cancer|Kidney Cancer
|
March 2, 2009 | Phase 1 |
NCT01946373 | Karolinska University Hospital |
Melanoma
|
October 2013 | Phase 1 |
NCT02531308 | Rush University Medical Center |
Diffuse Large B-Cell Lymphoma
|
July 2015 | Phase 2 |
NCT00296010 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
August 2005 | Phase 3 |
NCT03745326 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Gastrointestinal Cancer|Pancreatic Cancer|Gastric Cancer|Colon Cancer|Rectal Cancer
|
May 16, 2019 | Phase 1|Phase 2 |
NCT03336073 | PETHEMA Foundation |
Multiple Myeloma
|
December 18, 2017 | Phase 2 |
NCT04732845 | Benjamin Tomlinson|Case Comprehensive Cancer Center |
Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia
|
April 26, 2021 | Phase 1 |
NCT00499616 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
October 8, 2007 | Phase 3 |
NCT00075582 | Children´s Oncology Group|National Cancer Institute (NCI) |
Adult Rhabdomyosarcoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Previously Untreated Childhood Rhabdomyosarcoma
|
September 4, 2004 | Phase 3 |
NCT00566696 | St. Jude Children´s Research Hospital |
Leukemia, Acute Lymphocytic (ALL)|Leukemia, Myeloid, Acute(AML)|Leukemia, Myeloid, Chronic(CML)|Juvenile Myelomonocytic Leukemia (JMML)|Hemoglobinuria, Paroxysmal Nocturnal (PNH)|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin (NHL)|Myelodysplastic Syndrome (MDS)
|
December 14, 2007 | Phase 2 |
NCT00365287 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Breast Cancer|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
June 2000 | Phase 1|Phase 2 |
NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
February 2023 | Phase 2 |
NCT00553683 | Rutgers, The State University of New Jersey |
Breast Cancer|Colorectal Cancer|Gastric Cancer|Liver Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer
|
October 2007 | Phase 1|Phase 2 |
NCT00075387 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Malignant Glioma
|
March 7, 2003 | Phase 2 |
NCT00438984 | Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Recurrent Melanoma|Stage IV Melanoma
|
December 2006 | Phase 1 |
NCT00004921 | EBMT Solid Tumors Working Party|National Cancer Institute (NCI) |
Ovarian Cancer
|
September 1998 | Phase 3 |
NCT00004039 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
June 1998 | Phase 2 |
NCT00003114 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
July 1997 | Phase 2 |
NCT00245089 | Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI) |
Sarcoma
|
May 2004 | Phase 2 |
NCT00003727 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Leukemia
|
March 1999 | Phase 2 |
NCT00820690 | Barretos Cancer Hospital|University of Sao Paulo |
Breast Cancer
|
July 2008 | |
NCT00309920 | Heinrich-Heine University, Duesseldorf|National Cancer Institute (NCI) |
Breast Cancer
|
January 2004 | Not Applicable |
NCT01904136 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia With Gene Mutations|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Therapy-Related Acute Myeloid Leukemia
|
April 22, 2014 | Phase 1|Phase 2 |
NCT00963729 | Imperial College London|National Cancer Institute (NCI) |
Breast Cancer
|
September 2008 | Phase 3 |
NCT00002854 | City of Hope Medical Center|National Cancer Institute (NCI) |
Cancer
|
December 1994 | Phase 1 |
NCT01019174 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Multiple Myeloma
|
November 2009 | Phase 1|Phase 2 |
NCT00010400 | Johns Hopkins University|Office of Rare Diseases (ORD) |
Systemic Lupus Erythematosus|Antiphospholipid Antibody Syndrome
|
April 1997 | Not Applicable |
NCT03336632 | Sichuan University |
Leukemia, Acute|MDS
|
January 1, 2019 | Phase 2 |
NCT00000658 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 3 | |
NCT02724163 | University of Birmingham|Assistance Publique - Hôpitaux de Paris|Cancer Research UK|National Cancer Institute, France|Pfizer |
Acute Myeloid Leukaemia
|
April 2016 | Phase 3 |
NCT02457650 | Shenzhen Second People´s Hospital|Shenzhen Institute for Innovation and Translational Medicine |
Bladder Carcinoma|Breast Cancer|Esophagus Carcinoma|Lung Cancer|Melanoma|Multiple Myeloma|Neuroblastoma|Ovarian Cancer|Synovial Sarcoma|Other Metastatic Solid Cancers
|
April 2015 | Phase 1 |
NCT01432600 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Myeloma
|
November 2011 | Phase 1|Phase 2 |
NCT00555048 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
September 2007 | Phase 1|Phase 2 |
NCT02605915 | Hoffmann-La Roche |
HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer
|
December 31, 2015 | Phase 1 |
NCT03168438 | GlaxoSmithKline|Merck Sharp & Dohme LLC |
Neoplasms
|
August 18, 2017 | Phase 1 |
NCT00581776 | University of Wisconsin, Madison |
Mantle Cell Lymphoma
|
May 2005 | Phase 2 |
NCT00109031 | Swedish Orphan Biovitrum|Amgen |
Cancer|Lymphoma|Leukemia
|
January 2005 | Phase 3 |
NCT00002556 | National Cancer Institute (NCI) |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
July 1994 | Phase 3 |
NCT03371095 | Assistance Publique - Hôpitaux de Paris |
Behcet´s Disease|Vasculitis
|
March 15, 2018 | Phase 3 |
NCT00314977 | Radboud University Medical Center|Sanofi|Amgen |
Breast Cancer
|
February 2006 | Phase 3 |
NCT00005024 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
Phase 3 | |
NCT02199184 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|Atypical Burkitt+Burkitt-Like Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
January 14, 2015 | Phase 2 |
NCT00006721 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group |
Lymphoma
|
March 2001 | Phase 3 |
NCT00618813 | Children´s Oncology Group|National Cancer Institute (NCI) |
Ewing Sarcoma of Bone|Localized Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor
|
March 2008 | Not Applicable |
NCT00427245 | Anglo Celtic Cooperative Oncology Group|National Cancer Institute (NCI) |
Breast Cancer|Infertility|Menopausal Symptoms
|
August 2004 | Phase 3 |
NCT02595242 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Diffuse Large B Cell Lymphoma
|
June 2015 | Phase 1 |
NCT00789776 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|The Wayne D. Kuni and Joan E. Kuni Foundation |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Previously Treated Myelodysplastic Syndrome|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia
|
October 13, 2008 | Phase 1|Phase 2 |
NCT02276300 | Technical University of Munich |
Gastric Cancer|Breast Cancer
|
December 2014 | Phase 1 |
NCT00028665 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 2 |
NCT01132807 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2010 | Phase 2 |
NCT00258960 | Spanish Breast Cancer Research Group|Schering-Plough |
Breast Cancer
|
February 15, 2006 | Phase 2 |
NCT00784927 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
November 2008 | Phase 2 |
NCT02876302 | Dana-Farber Cancer Institute|Incyte Corporation |
Inflammatory Breast Cancer (IBC)
|
April 26, 2017 | Phase 2 |
NCT00005834 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma
|
April 2000 | Phase 3 |
NCT02323230 | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Diffuse Large B-Cell Lymphoma
|
January 2015 | Phase 2 |
NCT02167958 | Rafic Farah, MD|University of Pittsburgh |
Leukemia|MDS|Myelofibrosis|Lymphoma
|
February 11, 2015 | Phase 1 |
NCT00017095 | European Organisation for Research and Treatment of Cancer - EORTC|Swedish Breast Cancer Group|Swiss Group for Clinical Cancer Research|Anglo Celtic Cooperative Oncology Group |
Breast Cancer
|
March 2001 | Phase 3 |
NCT03032783 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematopoietic and Lymphoid Cell Neoplasm
|
January 31, 2017 | Phase 2 |
NCT00448266 | The Netherlands Cancer Institute |
Breast Cancer
|
May 2007 | Phase 2|Phase 3 |
NCT00278213 | German CLL Study Group |
Prolymphocytic Leukemia
|
September 2002 | Phase 2 |
NCT03125642 | Masonic Cancer Center, University of Minnesota |
Non-Hodgkin Lymphoma|Hodgkin Lymphoma
|
April 20, 2017 | Phase 2 |
NCT02048813 | National Cancer Institute (NCI) |
Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
February 20, 2014 | Phase 3 |
NCT00061945 | National Cancer Institute (NCI) |
Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2003 | Phase 1|Phase 2 |
NCT00656669 | Indiana University|Pfizer |
Breast Cancer
|
April 2008 | Not Applicable |
NCT01309789 | Seagen Inc.|Millennium Pharmaceuticals, Inc. |
Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell
|
February 2011 | Phase 1 |
NCT00002836 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 26, 1995 | Phase 3 |
NCT00004323 | National Center for Research Resources (NCRR)|University of California, Los Angeles |
Aplastic Anemia
|
February 1995 | Phase 2 |
NCT00924170 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Adult T-Cell Leukemia (ATL)
|
October 31, 2008 | Phase 1|Phase 2 |
NCT02846428 | Hoffmann-La Roche |
Breast Cancer
|
March 2004 | Phase 2 |
NCT00002802 | Children´s Hospital Medical Center, Cincinnati|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1990 | Phase 3 |
NCT01338987 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia
|
April 19, 2011 | Phase 2 |
NCT00238173 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug+Agent Toxicity by Tissue+Organ|Long-term Effects Secondary to Cancer Therapy in Children
|
December 2004 | Phase 1 |
NCT02706405 | Fred Hutchinson Cancer Center|AstraZeneca|Juno Therapeutics, Inc.|MedImmune LLC|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
November 15, 2016 | Phase 1 |
NCT00941720 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
June 11, 2009 | Phase 2 |
NCT05115630 | M.D. Anderson Cancer Center |
Myeloid Malignancies|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia
|
April 8, 2022 | Phase 1|Phase 2 |
NCT04529772 | Acerta Pharma BV|AstraZeneca |
Diffuse Large B-Cell Lymphoma
|
October 8, 2020 | Phase 3 |
NCT00669877 | M.D. Anderson Cancer Center |
Burkitt´s Lymphoma|Burkitt´S-like Lymphoma
|
August 2002 | Phase 2 |
NCT00281931 | German CLL Study Group |
Prolymphocytic Leukemia
|
September 1999 | Phase 2 |
NCT05510323 | Air Force Military Medical University, China |
Glomerulonephritis, IGA
|
August 2022 | Phase 3 |
NCT03919526 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
MRD-positive|Acute Lymphoblastic Leukemia
|
August 11, 2019 | Phase 1 |
NCT05590221 | Peking University Cancer Hospital & Institute|Shanghai Ming Ju Biotechnology Co., Ltd. |
B-cell Lymphoma
|
December 10, 2022 | Phase 2 |
NCT00209209 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|Nordic Lymphoma Group |
Lymphoma, Mantle-Cell
|
January 14, 2004 | Phase 3 |
NCT00005945 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 2000 | Phase 3 |
NCT03128359 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Leukemia|Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Hodgkin Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Myelodysplastic Syndrome
|
May 30, 2017 | Phase 2 |
NCT01283386 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
April 27, 2011 | Phase 4 |
NCT02014506 | Asan Medical Center |
Haploidentical Hematopoietic Stem Cell Transplantation|Malignant Disease|Non-malignant Disease
|
January 2017 | Phase 1|Phase 2 |
NCT00049114 | National Cancer Institute (NCI) |
Inflammatory Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
February 2003 | Phase 2 |
NCT00054236 | Case Comprehensive Cancer Center |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
May 2002 | Phase 1 |
NCT02723994 | Incyte Corporation|Children´s Oncology Group |
Leukemia
|
September 30, 2016 | Phase 2 |
NCT00107198 | Children´s Oncology Group|National Cancer Institute (NCI) |
Ann Arbor Stage I Childhood Hodgkin Lymphoma|Ann Arbor Stage II Childhood Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
January 2, 2006 | Phase 2 |
NCT02107963 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma
|
February 28, 2014 | Phase 1 |
NCT05582590 | NexImmune Inc. |
Oropharyngeal Cancer|Human Papilloma Virus|Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma|Oropharyngeal Cancer, Metastatic|Head and Neck Cancer Metastatic|HPV-Related Squamous Cell Carcinoma|HPV-Related Mucosal Head and Neck Squamous Cell Carcinoma|Relapsed Oropharyngeal SCC|Refractory Oropharyngeal Squamous Cell Carcinoma
|
December 30, 2022 | Phase 1 |
NCT00003605 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
May 1998 | Phase 2 |
NCT02465983 | University of Pennsylvania|University of California, San Francisco |
Pancreatic Cancer
|
May 2015 | Phase 1 |
NCT03197571 | ImmunityBio, Inc. |
Urothelial Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT00274846 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
March 2005 | Phase 2 |
NCT00003549 | Southwest Oncology Group|National Cancer Institute (NCI) |
Neuroendocrine Carcinoma of the Skin
|
October 1998 | Phase 2 |
NCT00005092 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
May 28, 1999 | Phase 1 |
NCT02670616 | Samsung Medical Center |
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
|
May 1, 2016 | Phase 2 |
NCT00003311 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
May 20, 1998 | Phase 2 |
NCT00002792 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic+Myeloproliferative Diseases
|
June 1996 | Phase 2 |
NCT00006055 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Purpura, Schoenlein-Henoch|Graft Versus Host Disease|Anemia, Hemolytic, Autoimmune|Rheumatoid Arthritis|Churg-Strauss Syndrome|Hypersensitivity Vasculitis|Wegener´s Granulomatosis|Systemic Lupus Erythematosus|Giant Cell Arteritis|Pure Red Cell Aplasia|Juvenile Rheumatoid Arthritis|Polyarteritis Nodosa|Autoimmune Thrombocytopenic Purpura|Takayasu Arteritis
|
March 2000 | Not Applicable |
NCT01351909 | National Cancer Institute (NCI) |
Locally Advanced Unresectable Breast Carcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
May 2, 2011 | Phase 1 |
NCT02532777 | Nanjing Children´s Hospital |
Henoch-Schoenlein Purpura Nephritis
|
August 2015 | Phase 2 |
NCT01417000 | Aduro Biotech, Inc.|Johns Hopkins University |
Metastatic Pancreatic Cancer
|
September 21, 2011 | Phase 2 |
NCT02873819 | Gliknik Inc. |
Squamous Cell Carcinoma of the Oral Cavity
|
March 30, 2017 | Phase 2 |
NCT05622318 | Medical College of Wisconsin |
Graft-versus-host Disease
|
January 15, 2023 | Phase 2 |
NCT00003042 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 30, 1997 | Phase 2 |
NCT00192764 | Rambam Health Care Campus |
Non-Hodgkin´s Lymphoma
|
December 1996 | Phase 2 |
NCT02379195 | Inge Marie Svane|Herlev Hospital |
Metastatic Melanoma
|
November 2014 | Phase 1|Phase 2 |
NCT00177047 | Masonic Cancer Center, University of Minnesota |
Multiple Myeloma
|
April 20, 2004 | Phase 2|Phase 3 |
NCT05293509 | M.D. Anderson Cancer Center |
Stem Cell Transplantation
|
September 30, 2022 | Phase 2 |
NCT03786783 | National Cancer Institute (NCI) |
Ganglioneuroblastoma|High Risk Neuroblastoma
|
January 14, 2019 | Phase 2 |
NCT00637832 | University of Southampton |
Lymphoma
|
April 1, 2008 | Phase 2 |
NCT02145039 | Masonic Cancer Center, University of Minnesota |
Acute Leukemias|Burkitt´s Lymphoma|Chronic Myelogenous Leukemia
|
October 2014 | Not Applicable |
NCT04389229 | Immetacyte Ltd |
Ovarian Cancer Metastatic
|
July 1, 2020 | Phase 1|Phase 2 |
NCT00096460 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Follicular Lymphoma
|
August 2004 | Phase 2|Phase 3 |
NCT03716856 | First Affiliated Hospital of Zhejiang University|CARsgen Therapeutics Co., Ltd. |
Refractory or Relapsed Multiple Myeloma
|
March 23, 2018 | Phase 1 |
NCT00003399 | University of Maryland, Baltimore |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1998 | Phase 2 |
NCT00276705 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Liver Cancer
|
June 2005 | Phase 2 |
NCT04023669 | St. Jude Children´s Research Hospital|Eli Lilly and Company |
Brain Tumor|Brain Tumor, Recurrent|Brain Tumor, Refractory|Brain Tumor, Pediatric|Medulloblastoma|Medulloblastoma Recurrent|Medulloblastoma, Non-WNT+Non-SHH|Medulloblastoma, Non-WNT+Non-SHH, Group 3|Medulloblastoma, Non-WNT+Non-SHH, Group 4|Brain Cancer|CNS Cancer|CNS Tumor|CNS Neoplasm
|
August 8, 2019 | Phase 1 |
NCT00002481 | St. Luke´s Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
March 1990 | Phase 2 |
NCT00028964 | University of California, San Francisco|National Cancer Institute (NCI) |
Breast Cancer|Drug+Agent Toxicity by Tissue+Organ
|
February 2001 | Phase 1|Phase 2 |
NCT00049504 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic+Lymphoid Cancer|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
January 2002 | Phase 2 |
NCT00897871 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
February 2007 | |
NCT01384513 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Aplastic Anemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Mastocytosis|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia
|
August 4, 2011 | Phase 2 |
NCT01592981 | University College, London |
Waldenstrom´s Macroglobulinaemia
|
January 2013 | Phase 2 |
NCT02488967 | NRG Oncology|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
July 2015 | Phase 3 |
NCT03185429 | BGI, China|Fujian Cancer Hospital |
Tumor Gastric|Tumor, Colorectal
|
December 2017 | Not Applicable |
NCT00002477 | Medical Research Council|National Cancer Institute (NCI) |
Ovarian Cancer
|
April 1991 | Phase 3 |
NCT01795976 | Fiona Thistlethwaite|The Christie NHS Foundation Trust|Erasmus Medical Center|Ospedale San Raffaele|University College London Hospitals|Karolinska University Hospital|The Netherlands Cancer Institute |
Oesophageal Cancer
|
October 2014 | Phase 2 |
NCT03101709 | Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd. |
B Cell Lymphoma
|
August 2016 | Phase 1 |
NCT03773744 | Turnstone Biologics, Corp. |
Metastatic Melanoma|Squamous Cell Skin Carcinoma
|
February 15, 2020 | Phase 1 |
NCT00003846 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Neuroblastoma
|
July 1999 | Phase 2 |
NCT03088709 | Loyola University |
Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Non-hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
January 18, 2017 | Phase 2 |
NCT03502577 | Fred Hutchinson Cancer Center|Juno Therapeutics, Inc.|The Leukemia and Lymphoma Society |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
May 23, 2018 | Phase 1 |
NCT00594308 | Indiana University |
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin´s|Mantle-Cell Lymphoma|Hodgkin´s Disease|Multiple Myeloma|Myelofibrosis
|
October 2007 | Not Applicable |
NCT00003336 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
January 1998 | Phase 2 |
NCT03103971 | Fred Hutchinson Cancer Center|Juno Therapeutics, Inc. |
Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
|
November 3, 2017 | Phase 1 |
NCT04656262 | Istituto Oncologico Veneto IRCCS|Ministry of Health, Italy |
Soft Tissue Sarcoma Adult
|
September 10, 2018 | Phase 3 |
NCT00562068 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma|Small Intestine Cancer
|
May 2007 | Phase 1 |
NCT01796197 | Dana-Farber Cancer Institute |
Breast Cancer
|
August 2013 | Phase 2 |
NCT02204241 | European Myeloma Network|Fondazione EMN Italy Onlus |
Multiple Myeloma
|
June 2014 | Phase 1|Phase 2 |
NCT00303810 | Universitätsklinikum Hamburg-Eppendorf |
Brain and Central Nervous System Tumors
|
January 2001 | Not Applicable |
NCT04083170 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI) |
Acute Erythroid Leukemia|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid Cell Neoplasm|HIV Infection|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Refractory Anemia
|
October 6, 2022 | Phase 2 |
NCT00006056 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Chediak-Higashi Syndrome|Graft Versus Host Disease|X-Linked Lymphoproliferative Syndrome|Familial Erythrophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|Virus-Associated Hemophagocytic Syndrome
|
March 2000 | Not Applicable |
NCT02838342 | Centre Hospitalier Universitaire de Besancon |
Neuroendocrine Tumors
|
May 19, 2015 | Phase 2 |
NCT02455141 | Shanghai Jiao Tong University School of Medicine |
Breast Neoplasm
|
July 2015 | Phase 3 |
NCT01788020 | University of Ulm|Centre Hospitalier de Lens, Unité de Recherche Clinique, Lens (Co-Sponsor) |
Waldenström´s Macroglobulinemia
|
November 2013 | Phase 3 |
NCT01005537 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Melanoma (Skin)
|
June 2009 | |
NCT00040482 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
Multiple Sclerosis
|
April 1999 | Phase 2 |
NCT00354835 | Children´s Oncology Group|National Cancer Institute (NCI) |
Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Botryoid-Type Embryonal Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Non-Metastatic Childhood Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma
|
December 2006 | Phase 3 |
NCT00041119 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
May 2002 | Phase 3 |
NCT03203005 | National Cancer Institute, Naples|Immatics Biotechnologies GmbH|CureVac|European Commission -FP7-Health-2013-Innovation-1 |
Hepatocellular Carcinoma
|
September 18, 2017 | Phase 1|Phase 2 |
NCT01848132 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. |
Diffuse, Large B-Cell, Lymphoma
|
October 3, 2013 | Phase 2 |
NCT01106950 | Masonic Cancer Center, University of Minnesota |
Leukemia, Myelogenous, Acute
|
July 2010 | Phase 2 |
NCT00014573 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
August 1998 | Phase 2 |
NCT00005898 | University of Minnesota|Office of Rare Diseases (ORD) |
Fanconi´s Anemia
|
February 2000 | Phase 1|Phase 2 |
NCT01966471 | Hoffmann-La Roche |
Breast Cancer
|
January 31, 2014 | Phase 3 |
NCT04245722 | Fate Therapeutics |
Lymphoma, B-Cell|Chronic Lymphocytic Leukemia
|
March 19, 2020 | Phase 1 |
NCT05508009 | Alice Bertaina|Stanford University |
SIOD With CKD Stage 3 Through 5|Cystinosis With CKD Stage 3 Through 5|FSGS With CKD Stage 3 Through 5|SLE Nephritis With CKD Stage 3 Through 5
|
October 2022 | Phase 1|Phase 2 |
NCT03710772 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
May 1, 2019 | Phase 2 |
NCT01993719 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma
|
December 12, 2013 | Phase 2 |
NCT00681993 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Breast Cancer Research Foundation |
Breast Cancer
|
April 2008 | Not Applicable |
NCT00003859 | Societe Internationale d´Oncologie Pediatrique|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
April 1992 | Phase 3 |
NCT01334502 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2012 | Phase 1 |
NCT00278109 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
July 2004 | Phase 1|Phase 2 |
NCT01424982 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia
|
October 5, 2011 | Phase 2 |
NCT02298348 | New Approaches to Neuroblastoma Therapy Consortium|University of California, San Francisco|Children´s Hospital Los Angeles|Lucile Packard Children´s Hospital|Children´s Hospital Medical Center, Cincinnati|University of Michigan|Seattle Children´s Hospital|Dana-Farber Cancer Institute|The Hospital for Sick Children|Children´s Healthcare of Atlanta|University of Chicago|Cook Children´s Health Care System|Children´s Hospital Colorado |
Neuroblastoma
|
April 2015 | Phase 1 |
NCT02054104 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Thoracic Sarcomas|Thorasic Cancers|Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura|Sarcoma|Melanoma
|
September 3, 2014 | Phase 1|Phase 2 |
NCT04697940 | Han weidong|Chinese PLA General Hospital |
Relapsed and Refractory B-cell Non-Hodgkin´s Lymphoma|Decitabine-primed Tandem CD19+CD20 CAR T Cells
|
December 15, 2020 | Phase 1|Phase 2 |
NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
April 2, 2012 | Phase 2 |
NCT04536922 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
|
January 27, 2021 | Phase 2 |
NCT00526318 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
January 2007 | Not Applicable |
NCT04626726 | Hebei Senlang Biotechnology Inc., Ltd. |
Adult B Acute Lymphoblastic Leukemia
|
April 1, 2020 | Early Phase 1 |
NCT00496873 | M.D. Anderson Cancer Center|Astex Pharmaceuticals, Inc.|Pharmatech |
Lymphoma
|
June 2005 | Phase 2 |
NCT00017628 | Northwestern Memorial Hospital|Office of Rare Diseases (ORD) |
Multiple Sclerosis
|
April 2001 | Phase 1 |
NCT00516295 | National Cancer Institute (NCI) |
Ewing Sarcoma of Bone|Extraosseous Ewing Sarcoma|Peripheral Primitive Neuroectodermal Tumor|Recurrent Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor
|
February 2008 | Phase 2 |
NCT01653717 | M.D. Anderson Cancer Center |
Advanced Cancers|Leukemia
|
June 11, 2013 | Phase 1 |
NCT02727803 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Acute Myeloid Leukemia With Variant MLL Translocations|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chemotherapy-Related Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Gene Mutation|Myelodysplastic+Myeloproliferative Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
May 19, 2016 | Phase 2 |
NCT00005613 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Lymphoma
|
March 1996 | Phase 2 |
NCT03322735 | Henan Cancer Hospital|The Pregene (ShenZhen) Biotechnology Company, Ltd. |
Multiple Myeloma
|
December 8, 2017 | Phase 1|Phase 2 |
NCT03899337 | University of Birmingham|Bloodwise|Acerta Pharma, LLC |
Richter Syndrome
|
April 2019 | Phase 2 |
NCT02427620 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastoid Variant Mantle Cell Lymphoma|Mantle Cell Lymphoma|Pleomorphic Variant Mantle Cell Lymphoma
|
June 3, 2015 | Phase 2 |
NCT03841110 | Fate Therapeutics |
Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma
|
February 15, 2019 | Phase 1 |
NCT00302003 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma
|
February 2006 | Phase 3 |
NCT03759093 | National University Hospital, Singapore|National University, Singapore |
Multiple Myeloma
|
March 1, 2020 | Phase 2|Phase 3 |
NCT01675765 | Aduro Biotech, Inc. |
Malignant Pleural Mesothelioma
|
September 3, 2014 | Phase 1 |
NCT04479267 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma w+MYC & BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma w+MYC, BCL2 & BCL6 Rearrangements
|
August 21, 2020 | Phase 2 |
NCT03272477 | Palleos Healthcare GmbH|Roche Pharma AG|WSG WOMEN´S HEALTHCARE STUDY GROUP|Cankado GmbH |
Breast Neoplasms
|
October 5, 2017 | Phase 2 |
NCT00006261 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 2000 | Phase 2 |
NCT03017820 | Mayo Clinic|National Cancer Institute (NCI) |
Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Plasma Cell Myeloma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Plasma Cell Myeloma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma
|
April 4, 2017 | Phase 1 |
NCT04836507 | Curocell Inc. |
Relapsed Large B-cell Lymphoma|Refractory Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Transformed Follicular Lymphoma (TFL)
|
March 2, 2021 | Phase 1|Phase 2 |
NCT00356928 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
October 2006 | Phase 1 |
NCT00006126 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer|Kidney Cancer|Lung Cancer|Melanoma (Skin)|Testicular Germ Cell Tumor
|
September 1999 | Phase 1 |
NCT03225924 | The Lymphoma Academic Research Organisation |
DLBCL
|
July 26, 2017 | Phase 1|Phase 2 |
NCT03758989 | University of Rochester |
DLBCL
|
May 8, 2019 | Phase 2 |
NCT04877275 | Chunyan Sun, MD|Wuhan Union Hospital, China |
Multiple Myeloma
|
May 21, 2021 | Phase 2 |
NCT01889069 | Hoffmann-La Roche |
Lymphoma
|
July 31, 2013 | Phase 3 |
NCT00003340 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
November 1997 | Phase 2 |
NCT01057069 | The Netherlands Cancer Institute |
Breast Cancer
|
January 2010 | Phase 2|Phase 3 |
NCT00002831 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
August 1, 1995 | Phase 1|Phase 2 |
NCT02833805 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Severe Aplastic Anemia|Aplastic Anemia|Bone Marrow Failure|Immunosuppression
|
September 2016 | Phase 2 |
NCT02863913 | Peking University |
Invasive Bladder Cancer Stage IV
|
September 2016 | Phase 1 |
NCT01120171 | Hellenic Oncology Research Group |
Breast Cancer
|
September 2009 | Phase 2 |
NCT03742258 | Northwestern University|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
March 13, 2019 | Phase 1 |
NCT05455697 | University of Washington |
Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|High Grade B-Cell Lymphoma
|
December 15, 2022 | Phase 1|Phase 2 |
NCT00040872 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Neuroblastoma
|
June 2000 | Phase 2 |
NCT01341301 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematologic Malignancy
|
May 2010 | Phase 2 |
NCT05453552 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|The Seventh Affiliated Hospital of Sun Yat-sen University |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
July 2022 | Phase 2|Phase 3 |
NCT03602898 | Fred Hutchinson Cancer Center |
Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
June 1, 2021 | Phase 2 |
NCT00199056 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
October 1999 | Phase 4 |
NCT04109066 | Bristol-Myers Squibb |
Breast Cancer
|
December 2, 2019 | Phase 3 |
NCT00002471 | Memorial Sloan Kettering Cancer Center |
Leukemia|Lymphoma
|
February 1990 | Phase 2 |
NCT02917083 | Baylor College of Medicine|The Methodist Hospital Research Institute |
Hodgkin´s Lymphoma|Non-Hodgkin Lymphoma
|
May 8, 2017 | Phase 1 |
NCT05453500 | University of Washington|Incyte Corporation |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
January 1, 2023 | Phase 2 |
NCT00002995 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
August 1997 | Phase 3 |
NCT00004132 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Oral Complications|Radiation Toxicity
|
January 2000 | Phase 2 |
NCT00004172 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer
|
October 1999 | Phase 2 |
NCT00704938 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific
|
June 2008 | Phase 2 |
NCT00000596 | National Heart, Lung, and Blood Institute (NHLBI) |
Lung Diseases|Pulmonary Fibrosis|Sarcoidosis
|
June 1978 | Phase 2 |
NCT01880385 | Association Tunisienne de lutte Contre le Cancer|Hoffmann-La Roche|Sanofi |
Inflammatory Breast Cancer
|
March 2011 | Phase 1 |
NCT03563170 | ImmunityBio, Inc. |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent
|
May 25, 2018 | Phase 1|Phase 2 |
NCT04922567 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|Xinqiao Hospital of Chongqing|Union hospital of Fujian Medical University|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Southern Medical University, China|Shandong Provincial Hospital|Huashan Hospital|First Hospital of China Medical University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Henan Provincial People´s Hospital|First Affiliated Hospital Xi´an Jiaotong University|Changhai Hospital|The Affiliated Hospital of Xuzhou Medical University|Wuhan Union Hospital, China|RenJi Hospital|Zhongda Hospital|The First Affiliated Hospital of Anhui Medical University|Hunan Cancer Hospital|First Affiliated Hospital of Harbin Medical University|Xiangya Hospital of Central South University|The First Affiliated Hospital of Dalian Medical University|Jilin Provincial Tumor Hospital|Shanxi Province Cancer Hospital|Zhongshan Hospital Xiamen University |
Peripheral T-Cell Lymphoma|Lenalidomide|CHOP
|
April 1, 2021 | Phase 2 |
NCT03699475 | Bellicum Pharmaceuticals |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
December 27, 2018 | Phase 2|Phase 3 |
NCT02774291 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
HLA-A2 Positive Cells Present|Metastatic Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain
|
August 2016 | Early Phase 1 |
NCT00576979 | City of Hope Medical Center|National Cancer Institute (NCI) |
Leukemia
|
March 4, 2008 | Phase 1|Phase 2 |
NCT00630032 | UNICANCER |
Breast Cancer
|
September 2007 | Phase 3 |
NCT00080925 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
February 2004 | Phase 1 |
NCT00003068 | University of Arizona|National Cancer Institute (NCI) |
Breast Cancer|Drug+Agent Toxicity by Tissue+Organ
|
June 1997 | Phase 2 |
NCT00309569 | Austrian Breast & Colorectal Cancer Study Group |
Early Stage Breast Cancer
|
October 1991 | Phase 3 |
NCT00002870 | UNICANCER |
Breast Cancer
|
December 1994 | Phase 3 |
NCT00003868 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
February 1999 | Phase 2 |
NCT03450122 | M.D. Anderson Cancer Center |
HLA-A*0201 Positive Cells Present|NY-ESO-1 Positive Tumor Cells Present|Recurrent Myxoid Liposarcoma|Recurrent Synovial Sarcoma
|
September 13, 2018 | Phase 1 |
NCT02498912 | Memorial Sloan Kettering Cancer Center|Stanford University|Juno Therapeutics, Inc. |
Solid Tumors
|
August 2015 | Phase 1 |
NCT05110742 | M.D. Anderson Cancer Center |
Hematological Malignancy
|
June 30, 2022 | Phase 1|Phase 2 |
NCT00025077 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
January 2000 | Phase 2 |
NCT01660750 | Criterium, Inc.|Amgen |
Multiple Myeloma
|
January 2013 | Phase 1 |
NCT00002676 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
July 1995 | Phase 2 |
NCT03622788 | M.D. Anderson Cancer Center |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aplastic Anemia|Bone Marrow Failure|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Myeloma
|
August 8, 2019 | Phase 1|Phase 2 |
NCT01229605 | Tufts Medical Center |
Breast Cancer
|
October 2010 | Phase 2 |
NCT00577993 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 16, 1998 | Phase 3 |
NCT00140595 | Lymphoma Study Association|Amgen |
Diffuse Large-Cell Lymphoma
|
December 2003 | Phase 3 |
NCT03171220 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Advanced Malignant Solid Tumor
|
June 1, 2017 | Phase 1|Phase 2 |
NCT00027937 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific
|
August 2001 | Phase 2 |
NCT01746849 | Memorial Sloan Kettering Cancer Center|Swedish Orphan Biovitrum |
Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin´s Lymphoma
|
December 2012 | Phase 2 |
NCT03077542 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Sickle Cell Disease
|
April 6, 2017 | Phase 1|Phase 2 |
NCT00017641 | Northwestern Memorial Hospital|Office of Rare Diseases (ORD) |
Systemic Lupus Erythematosus
|
April 2001 | Phase 1 |
NCT00602693 | Masonic Cancer Center, University of Minnesota |
Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
July 23, 2007 | Phase 1 |
NCT01251107 | Fondazione Michelangelo |
Hodgkin Lymphoma
|
March 2000 | Phase 3 |
NCT00379015 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
Breast Cancer
|
January 2006 | Phase 2 |
NCT00193479 | SCRI Development Innovations, LLC|Genentech, Inc.|Amgen |
Non-Hodgkins Lymphoma
|
April 2003 | Phase 2 |
NCT00025363 | National Cancer Institute (NCI) |
Alveolar Childhood Rhabdomyosarcoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Rhabdomyosarcoma
|
November 2001 | Phase 2 |
NCT00080847 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
March 2004 | Phase 2 |
NCT02390843 | Emory University|Children´s Healthcare of Atlanta |
Retinoblastoma|Clear Cell Sarcoma|Renal Cell Carcinoma|Rhabdoid Tumor|Wilms Tumor|Hepatoblastoma|Neuroblastoma|Germ Cell Tumors|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Osteosarcoma|Rhabdomyosarcoma
|
February 2015 | Phase 1 |
NCT00382109 | Children´s Oncology Group|National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Graft Versus Host Disease|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2007 | Phase 3 |
NCT00003541 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1998 | Phase 1|Phase 2 |
NCT02500576 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Melanoma|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7
|
August 7, 2015 | Phase 2 |
NCT02158091 | Dana-Farber Cancer Institute|Secura Bio, Inc. |
Chronic Lymphocytic Leukemia
|
June 27, 2014 | Phase 1|Phase 2 |
NCT00665990 | St. Jude Children´s Research Hospital |
Refractory Solid Tumors|Leukemia
|
November 2007 | Phase 1 |
NCT02753647 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 2 |
NCT03030976 | Shanghai GeneChem Co., Ltd.|RenJi Hospital |
Systemic Lupus Erythematosus (SLE)
|
March 2017 | Phase 1 |
NCT02809573 | Chipscreen Biosciences, Ltd. |
Peripheral T-cell Lymphoma
|
August 11, 2016 | Phase 1 |
NCT01878617 | St. Jude Children´s Research Hospital|Genentech, Inc.|National Cancer Institute (NCI) |
Medulloblastoma
|
June 23, 2013 | Phase 2 |
NCT01477021 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Liposarcoma|Adult Synovial Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma
|
January 2012 | Phase 1 |
NCT00625729 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
January 2008 | Phase 1|Phase 2 |
NCT01798004 | Children´s Oncology Group|National Cancer Institute (NCI) |
Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma
|
April 8, 2013 | Not Applicable |
NCT00621452 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
August 2007 | Phase 1 |
NCT00017290 | Genitope Corporation|National Cancer Institute (NCI) |
Lymphoma
|
November 2000 | Phase 3 |
NCT01207297 | Zhejiang University |
SLE|Lupus Nephritis|Renal Insufficiency|End-stage Renal Disease
|
March 2003 | Phase 1 |
NCT02390739 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Thyroid Cancer
|
March 2, 2015 | Phase 1|Phase 2 |
NCT04872595 | Memorial Sloan Kettering Cancer Center |
Acute Myeloid Leukemia (AML)|Acute Lymphoid Leukemia (ALL)|Myelodysplastic Syndromes (MDS)
|
April 30, 2021 | Phase 2 |
NCT03007147 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia
|
July 28, 2017 | Phase 3 |
NCT00311636 | Gruppo Italiano Mammella (GIM)|National Cancer Institute (NCI) |
Breast Cancer
|
September 2003 | Phase 3 |
NCT00002707 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
December 1995 | Phase 3 |
NCT01594177 | German Breast Group|Boehringer Ingelheim |
Unilateral HER2 Positive Breast Cancer
|
May 2012 | Phase 2 |
NCT05621668 | M.D. Anderson Cancer Center |
Soft Tissue Sarcoma|Bone Sarcoma
|
May 30, 2023 | Phase 1 |
NCT03391466 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
|
January 25, 2018 | Phase 3 |
NCT02257697 | Asahi Kasei Pharma Corporation |
Nephrotic Syndrome
|
November 2014 | Phase 3 |
NCT00055653 | Roswell Park Cancer Institute|National Heart, Lung, and Blood Institute (NHLBI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic-Myeloproliferative Diseases
|
January 2003 | Phase 2 |
NCT00994968 | Yonsei University|National Cancer Institute (NCI) |
Breast Cancer
|
July 2009 | Phase 2 |
NCT02274506 | M.D. Anderson Cancer Center |
Blood And Marrow Transplantation|Leukemia|Lymphoma
|
October 20, 2014 | Phase 1 |
NCT00039351 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
March 2002 | Phase 2 |
NCT00003187 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
May 1995 | Phase 2|Phase 3 |
NCT00976131 | Columbia University |
Breast Cancer
|
September 2009 | Phase 1 |
NCT01005758 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
January 2009 | Phase 2 |
NCT04762810 | Peking Union Medical College Hospital |
Idiopathic Retroperitoneal Fibrosis
|
January 3, 2020 | Phase 4 |
NCT00003211 | St. Jude Children´s Research Hospital|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
October 1996 | Phase 2 |
NCT05418088 | Sumithira Vasu|Ohio State University Comprehensive Cancer Center |
Recurrent Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent High Grade B-Cell Lymphoma|Recurrent Indolent Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory High Grade B-Cell Lymphoma|Refractory Indolent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia
|
June 30, 2022 | Phase 1 |
NCT02870907 | Institut Curie |
Retinoblastoma
|
March 2010 | Phase 2 |
NCT01953900 | Baylor College of Medicine|National Cancer Institute (NCI)|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Osteosarcoma|Neuroblastoma
|
April 2014 | Phase 1 |
NCT00002510 | Temple University|Fox Chase Cancer Center |
Lymphoma
|
April 1992 | Phase 1|Phase 2 |
NCT03498716 | Hoffmann-La Roche|Breast International Group|Alliance Foundation Trials (AFT)|Institut Jules Bordet+Clinical Trials Support Unit (IJB+CTSU)|Frontier Science & Technology Research Foundation, Inc. |
Triple Negative Breast Cancer
|
August 2, 2018 | Phase 3 |
NCT04380831 | City of Hope Medical Center|National Cancer Institute (NCI) |
Systemic Scleroderma
|
February 24, 2022 | Early Phase 1 |
NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
NCT00392327 | Children´s Oncology Group|National Cancer Institute (NCI) |
Anaplastic Medulloblastoma|Medulloblastoma
|
March 26, 2007 | Phase 3 |
NCT02134262 | Jichi Medical University|Takara Bio Inc. |
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
May 2014 | Phase 1|Phase 2 |
NCT03173417 | Beijing Immunochina Medical Science & Technology Co., Ltd. |
Leukemia
|
May 23, 2017 | Phase 1|Phase 2 |
NCT00003829 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
August 1999 | Phase 2 |
NCT04123392 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital |
TP53|Myeloid Tumors|Conditioning|Allogeneic Hematopoietic Stem Cell Transplantation
|
October 2019 | Phase 2|Phase 3 |
NCT01010217 | M.D. Anderson Cancer Center |
Blood Stem Cell Transplant Failure|Leukemia|Hematologic Malignancies
|
November 5, 2009 | Phase 2 |
NCT02785250 | ImmunoVaccine Technologies, Inc. (IMV Inc.)|Incyte Corporation |
Recurrent Epithelial Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Peritoneal Cancer
|
April 2016 | Phase 1|Phase 2 |
NCT00890656 | M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc. |
Acute Lymphoblastic Leukemia
|
June 2003 | Phase 2 |
NCT01148446 | Fondazione Italiana Linfomi ONLUS |
Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL)
|
January 2003 | Phase 3 |
NCT00324467 | British Columbia Cancer Agency|Hoffmann-La Roche |
Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin´s Lymphoma
|
August 2006 | Phase 2 |
NCT03113500 | City of Hope Medical Center|National Cancer Institute (NCI) |
Adult T-Cell Leukemia+Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified
|
May 25, 2017 | Phase 2 |
NCT00012207 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 2000 | Phase 1 |
NCT05359211 | Fred Hutchinson Cancer Center|Nektar Therapeutics |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 18, 2022 | Phase 1 |
NCT05582499 | Fudan University |
Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
October 2022 | Phase 1|Phase 2 |
NCT01762202 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
B-cell Lymphoid Leukemia|Young Patients
|
November 5, 2013 | Phase 2 |
NCT00929591 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group|Cancer and Leukemia Group B|NCIC Clinical Trials Group |
Breast Cancer
|
May 1989 | Phase 3 |
NCT00258180 | Johns Hopkins University|National Cancer Institute (NCI) |
Diarrhea|Gastrointestinal Complications|Unspecified Childhood Solid Tumor, Protocol Specific
|
August 15, 2005 | Phase 2 |
NCT02280525 | M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation |
Leukemia
|
March 5, 2015 | Phase 1 |
NCT03294577 | BeyondSpring Pharmaceuticals Inc. |
Chemotherapy-induced Neutropenia
|
October 23, 2019 | Phase 3 |
NCT00334672 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Nonneoplastic Condition
|
March 2006 | Phase 3 |
NCT00002552 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
October 1993 | Phase 2 |
NCT04009525 | First Affiliated Hospital of Guangxi Medical University|Peking University People´s Hospital|Ruijin Hospital|The 923th Hospital of People´s Liberation Army|Fourth Affiliated Hospital of Guangxi Medical University|Liuzhou General Hospital|Hainan General Hospital|The Affiliated Hospital Of Guizhou Medical University|The First People´s Hospital of Yunnan |
Thalassemia Major
|
June 1, 2019 | Phase 4 |
NCT02405676 | Children´s Cancer Group, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China|Nanjing Children´s Hospital|West China Second University Hospital|Xiangya Hospital of Central South University|Qilu Hospital of Shandong University|Children´s Hospital Of Soochow University|Tianjin Medical University Cancer Institute and Hospital |
Mature B-cell Non-Hodgkin Lymphoma
|
January 2015 | Phase 2|Phase 3 |
NCT03721068 | UNC Lineberger Comprehensive Cancer Center|United States Department of Defense|Bellicum Pharmaceuticals|University Cancer Research Fund at Lineberger Comprehensive Cancer Center |
Neuroblastoma|Osteosarcoma
|
February 19, 2019 | Phase 1 |
NCT04083183 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI) |
Non-Malignant Neoplasm
|
June 16, 2020 | Phase 1|Phase 2 |
NCT03152318 | Dana-Farber Cancer Institute|National Institutes of Health (NIH)|Candel Therapeutics, Inc. |
Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic+Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme
|
July 18, 2017 | Phase 1 |
NCT00278512 | Northwestern University |
Vasculitis
|
August 2003 | Phase 1 |
NCT01464606 | Children´s Hospitals and Clinics of Minnesota |
Pleuropulmonary Blastoma
|
December 22, 2009 | Not Applicable |
NCT03608618 | MaxCyte, Inc.|CTI Clinical Trial and Consulting Services |
Peritoneal Mesothelioma|Fallopian Tube Adenocarcinoma|Adenocarcinoma of the Ovary|Primary Peritoneal Carcinoma
|
August 27, 2018 | Phase 1 |
NCT02439788 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Alex´s Lemonade Stand Foundation |
Neuroblastoma
|
August 2017 | Phase 1 |
NCT00004898 | Northwestern University|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
October 1999 | Phase 1|Phase 2 |
NCT02423915 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cancer Prevention Research Institute of Texas |
Leukemia|Lymphoma
|
July 30, 2015 | Phase 1 |
NCT00410163 | GlaxoSmithKline |
Leukaemia, Lymphocytic, Chronic
|
January 2007 | Phase 2 |
NCT02561832 | AstraZeneca |
Breast Cancer
|
November 6, 2015 | Phase 1 |
NCT05605899 | Kite, A Gilead Company|Gilead Sciences |
High-risk Large B-cell Lymphoma (LBCL)
|
November 2022 | Phase 3 |
NCT00002571 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 1994 | Phase 2 |
NCT02623582 | University of Pennsylvania |
Relapsed or Refractory Acute Myeloid Leukemia
|
December 2015 | Early Phase 1 |
NCT01159236 | M.D. Anderson Cancer Center |
Breast Cancer
|
September 2010 | Not Applicable |
NCT00049439 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
March 1998 | Phase 2 |
NCT03146533 | Shenzhen Second People´s Hospital|The Beijing Pregene Science and Technology Company, Ltd. |
B Cell Lymphoma
|
May 2017 | Phase 1|Phase 2 |
NCT00002611 | Children´s Oncology Group|National Cancer Institute (NCI) |
Kidney Cancer
|
July 1995 | Phase 3 |
NCT04323956 | Mayo Clinic|National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Follicular Lymphoma|Ann Arbor Stage II Marginal Zone Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Indolent Non-Hodgkin Lymphoma
|
June 15, 2020 | Phase 1 |
NCT00630565 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
July 26, 2006 | Phase 2|Phase 3 |
NCT05364762 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Primary Myelofibrosis|Secondary Myelofibrosis
|
November 20, 2022 | Phase 2 |
NCT02613026 | 307 Hospital of PLA |
Breast Neoplasms
|
July 2009 | Phase 3 |
NCT04877821 | Guangdong Provincial People´s Hospital |
Triple Negative Breast Cancer
|
September 15, 2021 | Phase 2 |
NCT00432172 | Spanish Breast Cancer Research Group|Pfizer |
Breast Cancer
|
April 24, 2007 | Phase 2 |
NCT03387098 | ImmunityBio, Inc. |
Pancreatic Cancer
|
January 2, 2018 | Phase 1|Phase 2 |
NCT00002941 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 1998 | Phase 2 |
NCT00003960 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
April 1998 | Phase 2 |
NCT03610490 | M.D. Anderson Cancer Center|Bristol-Myers Squibb|Iovance Biotherapeutics|National Cancer Institute (NCI) |
Malignant Solid Neoplasm|Metastatic Colorectal Adenocarcinoma|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Ductal Adenocarcinoma|Platinum-Resistant Ovarian Carcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Ovarian Carcinosarcoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8
|
August 17, 2018 | Phase 2 |
NCT02339441 | University of Manchester |
Early Diffuse Cutaneous Systemic Sclerosis
|
June 2010 | |
NCT02259348 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myelogenous Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)
|
October 2014 | Phase 2 |
NCT00398489 | Technical University of Munich|National Cancer Institute (NCI) |
Breast Cancer
|
October 2006 | Phase 2 |
NCT04848064 | John Reneau|Ohio State University Comprehensive Cancer Center |
Recurrent Adult T-Cell Leukemia+Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Adult T-Cell Leukemia+Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
|
May 6, 2022 | Phase 1 |
NCT00399529 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|American Cancer Society, Inc.|Avon Foundation|Cancer Treatment Research Foundation|The Commonwealth Fund|United States Department of Defense|Genentech, Inc. |
Breast Neoplasms
|
September 2006 | Phase 2 |
NCT00193115 | SCRI Development Innovations, LLC|Aventis Pharmaceuticals |
Breast Cancer
|
March 2004 | Phase 2 |
NCT00101010 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ortho Biotech, Inc. |
Lymphoma
|
September 2005 | Phase 2 |
NCT02924753 | Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd. |
B-cell Acute Lymphoblastic Leukemia
|
July 18, 2016 | Phase 1 |
NCT03600909 | Memorial Sloan Kettering Cancer Center|Pediatric Brain Tumor Consortium |
Fanconi Anemia|Myelodysplastic Syndrome (MDS)|Acute Myelogenous Leukemia (AML)
|
May 15, 2018 | Phase 2 |
NCT00000801 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 2 | |
NCT01646034 | The Netherlands Cancer Institute |
Breast Cancer
|
September 2014 | Phase 3 |
NCT03577431 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Liver Transplant
|
March 29, 2019 | Phase 1|Phase 2 |
NCT03169777 | ImmunityBio, Inc. |
Colorectal Cancer
|
August 2018 | Phase 1|Phase 2 |
NCT05385705 | Vall d´Hebron Institute of Oncology|Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits |
Breast Neoplasms
|
May 11, 2022 | Phase 1 |
NCT05457556 | Children´s Oncology Group |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
November 23, 2022 | Phase 3 |
NCT00074490 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Leukemia|Myeloproliferative Disorders|Multiple Myleoma|Myelodysplastic Syndrome
|
January 1, 2004 | Phase 2 |
NCT00668564 | Masonic Cancer Center, University of Minnesota |
Hurler´s Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Sphingolipidoses|Krabbe Disease|Wolman´s Disease|Niemann-Pick Disease Type B|Niemann-Pick Disease, Type C
|
March 2008 | Phase 2 |
NCT02734771 | Patrick Reagan|Seagen Inc.|University of Rochester |
Diffuse Large B-Cell Lymphoma
|
June 2016 | Phase 2 |
NCT02629120 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Chronic Granulomatous Disease Transplant
|
December 17, 2015 | Phase 1|Phase 2 |
NCT00003116 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
May 1997 | Phase 2 |
NCT02845999 | Centre Hospitalier Universitaire de Besancon|National Cancer Institute, France |
Gastrointestinal Metastatic Cancer
|
November 2009 | Phase 1 |
NCT03283202 | Celgene |
Diffuse B-Cell Lymphoma
|
October 4, 2017 | Phase 1 |
NCT05470283 | M.D. Anderson Cancer Center |
Tumor|Metastatic Melanoma|Melanoma
|
September 7, 2022 | Phase 1 |
NCT01679119 | University College, London|Pfizer|Cancer Research UK |
Diffuse Large B Cell Lymphoma
|
October 2013 | Phase 2 |
NCT03332576 | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
|
August 23, 2013 | Phase 1 |
NCT01982682 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematopoietic+Lymphoid Cancer
|
November 4, 2013 | Phase 2 |
NCT00883129 | Michael Roth|National Heart, Lung, and Blood Institute (NHLBI)|Hoffmann-La Roche|University of California, Los Angeles |
Scleroderma|Interstitial Lung Disease
|
September 2009 | Phase 2 |
NCT03480360 | Dartmouth-Hitchcock Medical Center |
Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplasia|Myeloproliferative Disorder|Myelofibrosis|Lymphoma|Lymphoma, Non-Hodgkin|Plasma Cell Disorder
|
March 28, 2018 | Phase 3 |
NCT00003269 | Scripps Health |
Breast Cancer|Drug+Agent Toxicity by Tissue+Organ|Lung Cancer|Lymphoma|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
February 1998 | Phase 2 |
NCT00005824 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
Lymphoma
|
November 2000 | Phase 2 |
NCT05513612 | Shanghai Pudong Hospital|UTC Therapeutics Inc. |
Acute Myeloid Leukemia (AML)|B-cell Non-Hodgkin´s Lymphoma (B-NHL)|Multiple Myeloma (MM)|T-Cell Leukemia+Lymphoma, Adult|B-cell Acute Lymphoblastic Leukemia (B-ALL)
|
August 1, 2020 | Phase 1 |
NCT01370694 | Merck Sharp & Dohme LLC |
Follicular Lymphoma
|
August 19, 2011 | Phase 1 |
NCT00052923 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Lymphoma
|
March 2003 | Phase 3 |
NCT02614066 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory B-precursor Acute Lymphoblastic Leukemia
|
March 7, 2016 | Phase 1|Phase 2 |
NCT05618925 | ImmunityBio, Inc. |
NonHodgkin´s Lymphoma Refractory
|
November 15, 2022 | Phase 1 |
NCT00849472 | GlaxoSmithKline|NSABP Foundation Inc |
Neoplasms, Breast
|
July 2009 | Phase 2 |
NCT00513292 | National Cancer Institute (NCI) |
HER2+Neu Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
July 2007 | Phase 3 |
NCT02909751 | Vejle Hospital |
Breast Cancer
|
September 14, 2016 | Phase 2 |
NCT03356860 | Grand Hôpital de Charleroi|Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Breast Cancer|Triple Negative Breast Cancer|Luminal B
|
April 13, 2017 | Phase 1|Phase 2 |
NCT00950300 | Hoffmann-La Roche |
Breast Cancer
|
October 16, 2009 | Phase 3 |
NCT02593227 | Marker Therapeutics, Inc. |
Breast Cancer
|
April 2016 | Phase 2 |
NCT00557193 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Childhood T Acute Lymphoblastic Leukemia
|
January 14, 2008 | Phase 3 |
NCT01542255 | Dartmouth-Hitchcock Medical Center |
Metastatic Melanoma
|
June 2010 | Phase 2 |
NCT01263704 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
July 17, 2011 | Phase 2 |
NCT02661035 | Masonic Cancer Center, University of Minnesota |
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Lymphoblastic Lymphoma|Burkitt´s Lymphoma|Non-Hodgkin´s Lymphoma|Multiple Myeloma|Myeloproliferative Syndromes|Hematological Diseases
|
March 9, 2017 | Phase 2 |
NCT00379340 | Children´s Oncology Group|National Cancer Institute (NCI) |
Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q|Stage IV Wilms Tumor
|
February 26, 2007 | Phase 3 |
NCT01003054 | M.D. Anderson Cancer Center |
Chronic Myelogenous Leukemia
|
March 2005 | Phase 2 |
NCT00314106 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma
|
April 2006 | Phase 2 |
NCT03710421 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
February 13, 2019 | Phase 1 |
NCT02406222 | University of Leeds|Myeloma UK|Celgene |
Multiple Myeloma
|
March 2016 | Phase 2 |
NCT00876616 | Zhi-Hong Liu, M.D.|Ruijin Hospital|West China Hospital|RenJi Hospital|China Medical University, China|Huashan Hospital|The First Affiliated Hospital with Nanjing Medical University|Beijing Friendship Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Nanjing University School of Medicine |
Lupus Nephritis
|
April 2009 | Not Applicable |
NCT00085462 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Melanoma (Skin)
|
May 2004 | Phase 1 |
NCT04173988 | Children´s Hospital of Fudan University |
ALL, Childhood B-Cell
|
January 9, 2020 | Early Phase 1 |
NCT00025038 | National Cancer Institute (NCI) |
Juvenile Myelomonocytic Leukemia
|
June 2001 | Phase 2 |
NCT00005970 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group|Southwest Oncology Group |
Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7
|
May 19, 2000 | Phase 3 |
NCT00295997 | University of California, San Francisco|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2005 | Not Applicable |
NCT00074178 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
NCT00343447 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
August 2006 | Phase 2 |
NCT00254592 | University of California, Irvine |
Breast Cancer
|
October 2005 | Phase 2 |
NCT01231906 | Children´s Oncology Group|National Cancer Institute (NCI) |
Localized Extraskeletal Ewing Sarcoma|Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
|
November 22, 2010 | Phase 3 |
NCT01679041 | Seah Lim M.D.|Texas Oncology Cancer Center |
Multiple Sclerosis
|
November 2012 | Phase 2 |
NCT03126916 | Children´s Oncology Group|National Cancer Institute (NCI) |
Ganglioneuroblastoma|Neuroblastoma
|
May 9, 2018 | Phase 3 |
NCT03910452 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Chronic Granulomatous Disease
|
October 28, 2019 | Early Phase 1 |
NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
February 2005 | Phase 1|Phase 2 |
NCT01910870 | Centre Jean Perrin |
Metastatic Breast Cancer
|
July 2013 | Phase 2 |
NCT04196491 | Celgene |
Multiple Myeloma
|
May 27, 2020 | Phase 1 |
NCT01808911 | University Hospital, Rouen |
Acquired Haemophilia
|
May 2012 | Phase 3 |
NCT01749111 | Hospital Israelita Albert Einstein |
Acute Myelogenous Leukemia|Acute Lymphoid Leukemia|Myeloproliferative Disease|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia
|
December 2012 | Phase 3 |
NCT02449265 | Wuhan University |
Diffuse Large B-cell Lymphoma
|
October 2015 | Phase 3 |
NCT02938442 | University of Arkansas |
Triple Negative Breast Cancer|Breast Neoplasms
|
January 25, 2019 | Phase 1|Phase 2 |
NCT01022138 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer
|
February 2011 | Phase 2 |
NCT02784054 | Samsung Medical Center |
Intracranial Non-germinomatous Germ Cell Tumor
|
April 2014 | Phase 2 |
NCT02650986 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma
|
July 14, 2017 | Phase 1|Phase 2 |
NCT00686556 | Masonic Cancer Center, University of Minnesota |
Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Multiple Myeloma
|
August 2012 | Phase 1 |
NCT03448978 | Cartesian Therapeutics |
Multiple Myeloma
|
February 26, 2018 | Phase 1|Phase 2 |
NCT03770663 | Assistance Publique - Hôpitaux de Paris |
Antisynthetase Syndrome (ASS)|Interstitial Lung Disease
|
February 5, 2021 | Phase 3 |
NCT01985841 | Hellenic Oncology Research Group |
Breast Cancer
|
October 2011 | Phase 2 |
NCT00972478 | National Cancer Institute (NCI) |
Ann Arbor Stage II Non-Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma
|
November 15, 2010 | Phase 1|Phase 2 |
NCT01898793 | Washington University School of Medicine|American Society of Clinical Oncology|American Society of Hematology|Gabrielle´s Angel Foundation|The Leukemia and Lymphoma Society|National Cancer Institute (NCI)|ImmunityBio, Inc. |
Leukemia, Myeloid, Acute
|
August 11, 2014 | Phase 1|Phase 2 |
NCT00090051 | Hoffmann-La Roche|Biogen|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
July 31, 2003 | Phase 3 |
NCT03201965 | Janssen Research & Development, LLC |
Amyloidosis
|
October 5, 2017 | Phase 3 |
NCT03088293 | Hospices Civils de Lyon |
Idiopathic Refractory Scleritis
|
June 11, 2020 | Phase 3 |
NCT00114530 | National Institute of Allergy and Infectious Diseases (NIAID)|Rho Federal Systems Division, Inc. |
Scleroderma, Systemic|Sclerosis|Autoimmune Disease
|
June 2005 | Phase 2|Phase 3 |
NCT01359592 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2011 | Phase 2 |
NCT00916045 | King´s College Hospital NHS Trust |
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Lymphoblastic, Acute|Lymphoma, Non-Hodgkin|Hodgkin Disease|Chronic Lymphocytic Leukemia
|
September 2009 | Phase 2 |
NCT03808610 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia
|
April 3, 2019 | Phase 1|Phase 2 |
NCT00033683 | Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI) |
Breast Cancer
|
February 2001 | Phase 2 |
NCT03936829 | Children´s Hospital of Fudan University |
Lipodystrophy Acquired|Type1diabetes
|
April 28, 2019 | Not Applicable |
NCT01416974 | Memorial Sloan Kettering Cancer Center |
Leukemia
|
August 22, 2011 | Phase 1 |
NCT00002554 | Fred Hutchinson Cancer Center |
Leukemia
|
November 1993 | Phase 2 |
NCT01963481 | NYU Langone Health |
Metastatic Beast Cancer
|
September 2013 | Phase 2 |
NCT00002653 | Medical Research Council|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1993 | Phase 3 |
NCT02597062 | Canadian Cancer Trials Group|Amgen|Canadian Myeloma Research Group |
Multiple Myeloma
|
March 29, 2016 | Phase 2 |
NCT00867178 | National Cancer Institute (NCI) |
Medulloblastoma|Pineoblastoma|Supratentorial Embryonal Tumor, Not Otherwise Specified
|
February 25, 2009 | Phase 1 |
NCT02879513 | RenJi Hospital |
Invasive Ductal Breast Cancer|Tubular Breast Cancer|Mucinous Breast Cancer|Inflammatory Breast Cancer
|
January 2014 | Phase 3 |
NCT00878254 | University of Miami |
Mantle-Cell Lymphoma
|
March 25, 2009 | Phase 2 |
NCT00281905 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Neuroblastoma
|
June 1992 | Phase 2 |
NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myeloproliferative Disorders|Multiple Myeloma|Plasma Cell Neoplasm|Plasma Cell Dyscrasia|Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia|Plasma Cell Leukemia
|
December 2015 | Phase 2 |
NCT00002534 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
May 1993 | Phase 3 |
NCT02995330 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Prostate Cancer
|
February 9, 2017 | Phase 1 |
NCT01907529 | Hebei Medical University Fourth Hospital |
Stage III Breast Cancer
|
August 2019 | Phase 2|Phase 3 |
NCT03246906 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myelodysplastic+Myeloproliferative Neoplasm|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Hematologic and Lymphocytic Disorder|Blastic Plasmacytoid Dendritic Cell Neoplasm
|
September 11, 2017 | Phase 2 |
NCT02408016 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Advanced Pleural Malignant Mesothelioma|HLA-A*0201 Positive Cells Present|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage III Pleural Malignant Mesothelioma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7|Stage IV Pleural Malignant Mesothelioma AJCC v7|WT1 Positive
|
May 22, 2015 | Phase 1|Phase 2 |
NCT00944047 | University of Kansas Medical Center|Celgene Corporation |
Breast Cancer
|
July 2009 | Phase 2 |
NCT04038489 | University of Virginia |
Breast Cancer|Estrogen Receptor-positive Breast Cancer
|
October 18, 2019 | Phase 2 |
NCT03425656 | AryoGen Pharmed Co. |
Malignant Neoplasm of Breast
|
July 9, 2016 | Phase 3 |
NCT05300932 | Tongji Hospital |
Systemic Sclerosis
|
March 8, 2022 | Phase 4 |
NCT05366062 | Epitopoietic Research Corporation |
Glioma, Malignant
|
July 1, 2022 | Phase 2 |
NCT03434769 | Benjamin Tomlinson|Case Comprehensive Cancer Center |
Non-Hodgkin Lymphoma
|
July 9, 2018 | Phase 1 |
NCT04224922 | AZ-VUB|Universitaire Ziekenhuizen KU Leuven|Universitair Ziekenhuis Brussel |
Breast Cancer
|
May 2015 | Phase 2 |
NCT02162771 | Celltrion |
Lymphoma, Follicular
|
July 14, 2014 | Phase 3 |
NCT02412423 | Peking University People´s Hospital |
Hematopoietic Stem Cell Transplantation
|
March 2015 | Phase 4 |
NCT05157971 | City of Hope Medical Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Ph-Like Acute Lymphoblastic Leukemia
|
March 17, 2022 | Phase 1 |
NCT03068624 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Malignant Neoplasm in the Liver|Metastatic Uveal Melanoma
|
September 8, 2017 | Phase 1 |
NCT00002628 | St. Louis University|National Cancer Institute (NCI) |
Breast Cancer
|
November 1994 | Phase 1|Phase 2 |
NCT04339777 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoproliferative Disorders|Autoimmune Lymphoproliferative|Immune System Diseases|Common Variable Immunodeficiency|Primary T-cell Immunodeficiency Disorders
|
September 22, 2020 | Phase 2 |
NCT01760655 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Cytopenia With Multilineage Dysplasia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
December 24, 2012 | Phase 2 |
NCT04443348 | Alice Ho|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation|Translational Breast Cancer Research Consortium|Massachusetts General Hospital |
Triple Negative Breast Cancer|Hormone Receptor Positive (HR&addition;), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)
|
December 16, 2020 | Phase 2 |
NCT02017964 | Children´s Oncology Group|National Cancer Institute (NCI) |
Desmoplastic+Nodular Medulloblastoma|Medulloblastoma|Medulloblastoma With Extensive Nodularity|Nevoid Basal Cell Carcinoma Syndrome|Untreated Childhood Medulloblastoma
|
April 22, 2014 | Phase 2 |
NCT00740467 | Institut Paoli-Calmettes|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition
|
January 2008 | Phase 2 |
NCT01403285 | Immatics Biotechnologies GmbH|National Cancer Institute (NCI) |
Glioblastoma
|
August 2011 | Phase 1 |
NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) |
Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Hodgkin´s Lymphoma
|
August 2014 | Phase 2 |
NCT00256243 | Rita Sanghvi, Mehta|University of California, Irvine |
Breast Cancer
|
April 2004 | Phase 2 |
NCT00074282 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 16, 2004 | Phase 2 |
NCT00324623 | Prof. Serge Leyvraz|Centre Hospitalier Universitaire Vaudois |
Melanoma (Skin)
|
September 2005 | Phase 1 |
NCT00005960 | Amgen|National Cancer Institute (NCI) |
Pain|Prostate Cancer
|
October 1999 | Phase 2 |
NCT00564889 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 2007 | Phase 2 |
NCT01853631 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia
|
February 2014 | Phase 1 |
NCT00028600 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Multiple Myeloma|Plasma Cell Neoplasm
|
November 2001 | Phase 2 |
NCT03742986 | NYU Langone Health |
Breast Cancer
|
May 2, 2019 | Phase 2 |
NCT00255684 | University of Rochester |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
December 2003 | Not Applicable |
NCT00014222 | NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B|Canadian Cancer Trials Group |
Breast Cancer
|
December 4, 2000 | Phase 3 |
NCT00002675 | Memorial Sloan Kettering Cancer Center |
Retinoblastoma
|
May 1995 | Phase 2 |
NCT01339910 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Leukemia, Myelocytic, Acute
|
June 2011 | Phase 3 |
NCT00060385 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
March 2003 | Phase 2|Phase 3 |
NCT01216111 | Fudan University|Chinese Anti-Cancer Association |
Triple Negative Breast Cancer
|
January 1, 2011 | Phase 3 |
NCT04323657 | TCR2 Therapeutics |
Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma
|
March 27, 2020 | Phase 1|Phase 2 |
NCT04561557 | Tongji Hospital|Nanjing IASO Biotherapeutics Co.,Ltd |
Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Neuromyelitis Optica Spectrum Disorder|Myasthenia Gravis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Immune-Mediated Necrotizing Myopathy
|
September 22, 2020 | Early Phase 1 |
NCT00000689 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 1 | |
NCT00003715 | AVAX Technologies |
Melanoma (Skin)
|
December 1998 | Phase 2 |
NCT05243524 | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Platinum-resistant Epithelial Ovarian Cancer
|
July 2022 | Phase 2 |
NCT05020392 | Wuhan Union Hospital, China|Wuhan Si´an Medical Technology Co., Ltd |
Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Burkitt Lymphoma
|
September 14, 2021 | Phase 3 |
NCT03666000 | Precision BioSciences, Inc. |
Non-Hodgkin Lymphoma|B-cell Acute Lymphoblastic Leukemia
|
March 11, 2019 | Phase 1|Phase 2 |
NCT00131027 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 3 |
NCT04664972 | Henan Cancer Hospital |
Triple Negative Breast Cancer
|
November 23, 2018 | Phase 2 |
NCT00038610 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals |
Leukemia
|
March 2001 | Phase 2 |
NCT00807196 | Maisonneuve-Rosemont Hospital|Bayer |
Non-Hodgkins Lymphoma
|
September 2008 | Phase 1|Phase 2 |
NCT00275054 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
October 2005 | Phase 3 |
NCT04262427 | The Christie NHS Foundation Trust|Merck Sharp & Dohme LLC|Liverpool Clinical Trials Centre|University of Manchester |
Metastatic Renal Cell Carcinoma
|
April 28, 2021 | Phase 1|Phase 2 |
NCT01005979 | Emory University|Celgene Corporation |
Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic
|
July 2010 | Phase 1 |
NCT04202835 | McMaster University|Cell Therapy Transplant Canada|Sanofi|Ozmosis Research Inc. |
Acute Leukemia|Myelodysplasia|Chronic Graft-versus-host-disease
|
October 13, 2020 | Phase 2 |
NCT02771743 | Samsung Medical Center |
Newly Diagnosed High Risk Neuroblastoma
|
April 2015 | Phase 2 |
NCT03121001 | University of Illinois at Chicago |
Sickle Cell Disease
|
March 20, 2017 | Phase 2 |
NCT00118209 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Large B Cell Lymphoma
|
May 2005 | Phase 3 |
NCT00094380 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Erythematosus, Systemic|Lupus Nephritis
|
September 2004 | Phase 1|Phase 2 |
NCT03399448 | University of Pennsylvania|Parker Institute for Cancer Immunotherapy|Tmunity Therapeutics |
Multiple Myeloma|Melanoma|Synovial Sarcoma|Myxoid+Round Cell Liposarcoma
|
September 5, 2018 | Phase 1 |
NCT04416984 | Allogene Therapeutics |
Relapsed+Refractory Large B Cell Lymphoma
|
May 21, 2020 | Phase 1|Phase 2 |
NCT02965950 | Haukeland University Hospital |
Locally Advanced Breast Cancer|Metastatic Breast Carcinoma
|
October 2016 | Phase 2 |
NCT03084380 | Xinqiao Hospital of Chongqing |
Hepatocellular Carcinoma
|
June 1, 2017 | Phase 1|Phase 2 |
NCT04584112 | Hoffmann-La Roche |
Triple-Negative Breast Cancer
|
September 28, 2020 | Phase 1 |
NCT02805725 | Institut Bergonié|PharmaMar |
Soft-tissue Sarcomas
|
December 2015 | Phase 1|Phase 2 |
NCT00079144 | National Cancer Institute (NCI) |
Melanoma (Skin)
|
January 2004 | Phase 2 |
NCT00068523 | Case Comprehensive Cancer Center |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
June 2003 | Not Applicable |
NCT05491694 | The First Affiliated Hospital with Nanjing Medical University |
Breast Cancer|TNBC - Triple-Negative Breast Cancer
|
September 1, 2022 | Phase 2 |
NCT03385096 | Nanfang Hospital of Southern Medical University|Guangzhou First People´s Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University |
Autologous Hematopoietic Stem Cell Transplantation|Conditioning|Multiple Myeloma
|
January 2, 2018 | Phase 2|Phase 3 |
NCT00354172 | Masonic Cancer Center, University of Minnesota |
Leukemia|Myelodysplastic Syndromes
|
February 2006 | Phase 2 |
NCT02489266 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma
|
June 24, 2015 | Phase 1 |
NCT02414945 | University Health Network, Toronto |
Pleural Mesothelioma
|
June 2015 | Phase 1|Phase 2 |
NCT00006110 | UNC Lineberger Comprehensive Cancer Center |
Breast Cancer
|
December 1998 | Phase 2 |
NCT04789408 | Kite, A Gilead Company|Gilead Sciences |
Acute Myeloid Leukemia
|
July 19, 2021 | Phase 1 |
NCT05445011 | Wuhan Union Hospital, China|PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Acute Myeloid Leukemia
|
June 14, 2022 | Phase 1 |
NCT00027573 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Kidney Cancer
|
October 2001 | Phase 2 |
NCT02858310 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Papillomavirus Infections|Cervical Intraepithelial Neoplasia|Carcinoma In Situ|Vulvar Neoplasms|Vulvar Diseases
|
January 27, 2017 | Phase 1|Phase 2 |
NCT00416832 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
November 2002 | Phase 2 |
NCT00003852 | UNICANCER |
Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor
|
March 1998 | Phase 2 |
NCT04770272 | Palleos Healthcare GmbH|Roche Pharma AG|Phaon Scientific GmbH|University Hospital, Essen|University Hospital Erlangen |
Triple-negative Breast Cancer
|
March 1, 2021 | Phase 2 |
NCT01000285 | Washington University School of Medicine |
Leukemia-Lymphoma, Adult T-Cell
|
September 2010 | Phase 1|Phase 2 |
NCT00066469 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoproliferative Disorder
|
April 2004 | Phase 2 |
NCT03749018 | David Bond, MD|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center |
Aggressive Non-Hodgkin Lymphoma|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Indolent Non-Hodgkin Lymphoma|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma
|
January 2, 2019 | Phase 2 |
NCT00072007 | Swiss Group for Clinical Cancer Research |
Leukemia
|
June 2002 | Phase 2 |
NCT00275015 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
January 1998 | Phase 2 |
NCT02797717 | GALIA AVRAHAMI|University of Giessen|Rabin Medical Center |
Classical Hodgkins Lymphoma in Children and Adolescents.
|
November 2015 | Not Applicable |
NCT02118285 | Masonic Cancer Center, University of Minnesota|Incyte Corporation |
Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma
|
July 28, 2014 | Phase 1 |
NCT02213913 | University of Chicago|National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
July 29, 2014 | Phase 1|Phase 2 |
NCT00225173 | Stanford University|National Cancer Institute (NCI) |
Hodgkin Disease
|
October 2001 | Phase 2 |
NCT00003658 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 1998 | Phase 2 |
NCT02298946 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma
|
November 21, 2014 | Phase 1 |
NCT02660281 | University of Rochester |
Hematological Disease|Immune Deficiencies|Solid Tumors|Myelofibrosis|Multiple Myeloma|Lymphoma
|
October 2015 | Phase 1 |
NCT00896519 | French Innovative Leukemia Organisation|National Cancer Institute (NCI) |
Lymphoma
|
March 2009 | Phase 2 |
NCT00365755 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
Phase 3 | |
NCT03318900 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
COL6A3 Positive|HLA-A*0201 Positive Cells Present|PRAME Positive|Recurrent Ovarian Carcinoma
|
July 16, 2018 | Phase 1 |
NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
NCT01824693 | Children´s Oncology Group|National Cancer Institute (NCI) |
Juvenile Myelomonocytic Leukemia
|
June 24, 2013 | Phase 2 |
NCT03914625 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome
|
June 28, 2019 | Phase 3 |
NCT05334329 | City of Hope Medical Center|National Cancer Institute (NCI)|CytoImmune Therapeutics |
Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Refractory Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
July 20, 2022 | Phase 1 |
NCT05304585 | Children´s Oncology Group|National Cancer Institute (NCI) |
Embryonal Rhabdomyosarcoma|Fusion-Negative Alveolar Rhabdomyosarcoma|Spindle Cell+Sclerosing Rhabdomyosarcoma
|
June 22, 2022 | Phase 3 |
NCT00902044 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|Cancer Prevention Research Institute of Texas |
Sarcoma
|
February 11, 2010 | Phase 1 |
NCT03250325 | Takara Bio Inc. |
Synovial Sarcoma
|
September 20, 2017 | Phase 1|Phase 2 |
NCT00194779 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
October 2003 | Phase 2 |
NCT00040651 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|University of Pittsburgh|Amgen|Genzyme, a Sanofi Company |
Scleroderma|Systemic Sclerosis
|
July 2002 | Phase 1 |
NCT01724866 | Spectrum Pharmaceuticals, Inc |
Neutropenia
|
March 25, 2013 | Phase 2 |
NCT05459571 | Kite, A Gilead Company|Gilead Sciences |
Relapsed or Refractory Large B-cell Lymphoma
|
August 10, 2022 | Phase 2 |
NCT00005940 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
|
October 1999 | Phase 2 |
NCT00005964 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2000 | Phase 2 |
NCT01570348 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH) |
Crohn Disease
|
July 17, 2012 | Phase 2 |
NCT02561273 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma
|
October 2015 | Phase 1|Phase 2 |
NCT02013375 | Damiano Rondelli, MD|University of Illinois at Chicago |
Sickle Cell Disease
|
April 10, 2014 | Phase 2 |
NCT04638790 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
Hodgkin Lymphoma, Adult
|
February 1, 2020 | Phase 3 |
NCT02670252 | Nanfang Hospital of Southern Medical University|Guangzhou First People´s Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University|Xiangya Hospital of Central South University|The Seventh Affiliated Hospital of Sun Yat-sen University|The First Affiliated Hospital of Guangzhou Medical University|Guangdong Second Provincial General Hospital|The Affiliated Hospital of Qingdao University|First People´s Hospital of Chenzhou|Guangzhou Panyu Central Hospital |
Allogeneic Hematopoietic Stem Cell Transplantation|Busulfan|Total Body Irradiation|Acute Lymphocytic Leukemia
|
January 2016 | Phase 3 |
NCT01622439 | Lund University Hospital|Valcuria |
Diffuse Large B-cell Lymphoma
|
June 2012 | Phase 1|Phase 2 |
NCT03407144 | Merck Sharp & Dohme LLC |
Hodgkin Lymphoma
|
April 9, 2018 | Phase 2 |
NCT00004179 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland|Australasian Leukaemia and Lymphoma Group|NCIC Clinical Trials Group|Nordic Lymphoma Group |
Lymphoma
|
May 1999 | Phase 3 |
NCT00075634 | National Cancer Institute (NCI) |
Recurrent Neuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific
|
December 2003 | Phase 1 |
NCT00004896 | Northwestern University|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
October 1999 | Phase 2 |
NCT00016276 | National Cancer Institute (NCI) |
Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer
|
May 2001 | Phase 3 |
NCT00712881 | Cephalon, Inc.|Teva Branded Pharmaceutical Products R&D, Inc. |
Breast Cancer
|
October 13, 2008 | Phase 2 |
NCT02869217 | University Health Network, Toronto|Takara Bio Inc. |
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients|Synovial Sarcoma|Melanoma|Esophageal Cancer|Ovarian Cancer|Lung Cancer|Bladder Cancer|Liver Cancer
|
September 2016 | Phase 1 |
NCT00027846 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumor|Central Nervous System Tumor
|
August 2003 | Phase 2 |
NCT03167164 | ImmunityBio, Inc. |
Merkel Cell Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT03420963 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm
|
August 31, 2018 | Phase 1 |
NCT00003783 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 1999 | Phase 2 |
NCT00477412 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
April 3, 2007 | Phase 1|Phase 2 |
NCT00564512 | French Innovative Leukemia Organisation |
Leukemia
|
November 2007 | Phase 3 |
NCT01135329 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Lymphoma|Leukemia|Myelodysplastic Syndrome
|
August 2010 | Phase 2 |
NCT00578539 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Disorders
|
October 2007 | Not Applicable |
NCT01701674 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Iovance Biotherapeutics, Inc. |
Metastatic Melanoma
|
October 9, 2012 | Not Applicable |
NCT00085098 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumor|Central Nervous System Tumor
|
January 2007 | Phase 3 |
NCT04433156 | Henan Cancer Hospital |
Marginal Zone Lymphoma
|
April 22, 2020 | Phase 2 |
NCT02643420 | Spectrum Pharmaceuticals, Inc |
Neutropenia|Breast Cancer
|
January 19, 2016 | Phase 3 |
NCT01585428 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cervical Cancer|Oropharyngeal Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer
|
April 13, 2012 | Phase 2 |
NCT00665457 | University of Nebraska|National Cancer Institute (NCI) |
Breast Cancer
|
April 2004 | Phase 2 |
NCT00004900 | Hackensack Meridian Health|National Cancer Institute (NCI) |
Breast Cancer
|
October 1999 | Phase 2 |
NCT03426969 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Primary Myelofibrosis|Secondary Myelofibrosis
|
January 31, 2018 | Early Phase 1 |
NCT05275777 | National University Hospital, Singapore|Adagene Inc |
HER2-negative Breast Cancer|Advanced Solid Tumor
|
May 19, 2022 | Phase 1|Phase 2 |
NCT00003088 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
September 1997 | Phase 3 |
NCT00559104 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
October 1998 | Phase 2 |
NCT00578461 | Baylor College of Medicine |
Leukemia|Cancer|Lymphoma|Lymphoma, Hodgkin|Lymphoma, Non-Hodgkin
|
October 2007 | Not Applicable |
NCT00245141 | Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI) |
Sarcoma
|
May 2004 | Phase 2 |
NCT01410344 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Leukemia|Lymphoma|HIV
|
September 2011 | Phase 2 |
NCT03654040 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc. |
Liver Transplant
|
April 22, 2021 | Phase 1|Phase 2 |
NCT04927884 | ImmunityBio, Inc. |
Advanced Triple Negative Breast Cancer
|
September 27, 2021 | Phase 1|Phase 2 |
NCT00871481 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent Melanoma|Stage IV Melanoma
|
February 2009 | Phase 1|Phase 2 |
NCT02652468 | University of Wisconsin, Madison |
Lymphoma
|
March 10, 2016 | Not Applicable |
NCT00553202 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
January 2008 | Phase 2 |
NCT01847001 | Columbia University |
Locally Advanced Malignant Neoplasm|Breast Cancer
|
October 2012 | Phase 2 |
NCT00002529 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
May 1993 | Phase 3 |
NCT00466531 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 21, 2007 | Phase 1|Phase 2 |
NCT02345850 | National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) |
Acute Leukemia|Myelodysplasia
|
August 2015 | Phase 3 |
NCT01746173 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center |
T-cell Non-Hodgkin Lymphoma
|
July 2013 | Phase 2 |
NCT00510367 | M.D. Anderson Cancer Center |
Breast Cancer|Pregnancy
|
August 7, 2001 | Early Phase 1 |
NCT04546399 | National Cancer Institute (NCI) |
Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia
|
December 4, 2020 | Phase 2 |
NCT04884035 | Celgene |
Lymphoma, B-Cell
|
September 15, 2021 | Phase 1 |
NCT01537861 | Washington University School of Medicine |
Multiple Myeloma
|
June 2012 | Early Phase 1 |
NCT04904588 | Center for International Blood and Marrow Transplant Research|National Marrow Donor Program |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Mixed Phenotype Acute Leukemia|Acute Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Lymphoma
|
September 30, 2021 | Phase 2 |
NCT00003992 | National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 2 |
NCT02623972 | Dana-Farber Cancer Institute|Eisai Inc. |
Inflammatory Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
|
February 26, 2016 | Phase 2 |
NCT03171831 | First Affiliated Hospital of Guangxi Medical University |
Thalassemia Major
|
April 1, 2017 | Phase 4 |
NCT04290793 | Hebei Medical University Fourth Hospital |
Breast Cancer
|
March 1, 2020 | Phase 2|Phase 3 |
NCT05400109 | James Michael Martin|Case Comprehensive Cancer Center |
Non Hodgkin Lymphoma
|
October 2023 | Phase 1 |
NCT02293109 | Mehrdad Abedi, MD|Amgen|University of California, Davis |
Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia
|
December 17, 2015 | Phase 1 |
NCT04539366 | National Cancer Institute (NCI) |
Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Neuroblastoma|Refractory Osteosarcoma
|
June 11, 2021 | Phase 1 |
NCT00002549 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia
|
November 1993 | Phase 3 |
NCT01194791 | PETHEMA Foundation |
Primary Systemic Amyloidosis
|
October 2010 | Phase 2 |
NCT00135499 | Lymphoma Study Association|Fondation ARC |
Lymphoma, Large-Cell, Diffuse
|
October 16, 2001 | Phase 3 |
NCT01253460 | M.D. Anderson Cancer Center|Cyclacel Pharmaceuticals, Inc.|National Cancer Institute (NCI) |
Leukemia
|
August 22, 2011 | Phase 2 |
NCT04109482 | Mustang Bio |
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
February 17, 2020 | Phase 1|Phase 2 |
NCT02678143 | Washington University School of Medicine |
Sickle Cell Disease
|
April 26, 2016 | Phase 1 |
NCT00429416 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematologic Malignancies
|
March 2004 | Phase 1|Phase 2 |
NCT00002489 | Memorial Sloan Kettering Cancer Center |
Extragonadal Germ Cell Tumor|Ovarian Cancer
|
October 1991 | Phase 2 |
NCT00003194 | Seattle Children´s Hospital|National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
July 1997 | Phase 1 |
NCT00002701 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto|National Cancer Institute (NCI) |
Leukemia
|
October 1995 | Phase 3 |
NCT03123770 | Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Zhejiang University|Sir Run Run Shaw Hospital|Women´s Hospital School Of Medicine Zhejiang University|Zhejiang Cancer Hospital|Zhejiang Provincial People´s Hospital|Zhejiang Provincial Hospital of TCM|First People´s Hospital of Hangzhou|Hangzhou Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Wenzhou Medical University|Ningbo No. 1 Hospital|Jinhua Central Hospital |
Breast Cancer
|
December 2016 | Phase 4 |
NCT04629729 | Fate Therapeutics |
Lymphoma, B-Cell|Chronic Lymphocytic Leukemia|Precursor B-Cell Acute Lymphoblastic Leukemia
|
July 26, 2021 | Phase 1 |
NCT00455533 | Bristol-Myers Squibb |
Breast Cancer
|
October 2007 | Phase 2 |
NCT01091831 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2009 | Phase 3 |
NCT00450814 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 30, 2006 | Phase 1|Phase 2 |
NCT00004218 | Leukemia Research Fund|Medical Research Council|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 3 |
NCT00003437 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia
|
January 1997 | Phase 3 |
NCT00146562 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Lowell General Hospital|Brigham and Women´s Hospital|North Shore Medical Center |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer
|
July 2003 | Phase 2 |
NCT00003163 | Medical College of Wisconsin|National Cancer Institute (NCI) |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
September 1997 | Phase 2 |
NCT05008536 | Xinqiao Hospital of Chongqing|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Multiple Myeloma, Refractory
|
October 1, 2021 | Early Phase 1 |
NCT01438177 | NYU Langone Health|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
October 2011 | Phase 2 |
NCT05052528 | Mehrdad Abedi, MD|National Cancer Institute (NCI)|University of California, Davis |
Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
September 17, 2021 | Phase 1 |
NCT00578643 | Baylor College of Medicine |
Chronic Granulomatous Disease
|
March 2004 | Phase 2 |
NCT00501826 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 11, 2007 | Phase 2 |
NCT01247701 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Myeloid Hematological Malignancies
|
November 2010 | Not Applicable |
NCT01292603 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
April 18, 2011 | Phase 1 |
NCT01350232 | Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University |
Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia
|
September 2009 | Not Applicable |
NCT00048893 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Neoplasms|Metastases, Neoplasm
|
November 2002 | Phase 1|Phase 2 |
NCT00049595 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l´Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group |
Lymphoma
|
August 2002 | Phase 3 |
NCT04784052 | Rajni Agarwal|Stanford University |
Fanconi Anemia
|
December 7, 2021 | Phase 1|Phase 2 |
NCT00070174 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 2003 | Phase 2 |
NCT01193842 | National Cancer Institute (NCI) |
AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage I Grade 3 Follicular Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma
|
October 6, 2010 | Phase 1|Phase 2 |
NCT01959490 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
September 24, 2013 | Phase 2 |
NCT01093183 | University of Nebraska|National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer
|
March 2010 | Phase 1|Phase 2 |
NCT01974440 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
January 31, 2014 | Phase 3 |
NCT00025636 | German Hodgkin´s Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|EBMT Solid Tumors Working Party|National Cancer Institute (NCI) |
Lymphoma
|
July 2001 | Phase 3 |
NCT00309842 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|MDS|Refractory Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Non-Hodgkin´s Lymphoma|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes
|
July 28, 2005 | Phase 2 |
NCT03520647 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Severe Aplastic Anemia (SAA)|Hypo-Plastic Myelodysplastic Syndrome (MDS)|Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
February 19, 2019 | Phase 2 |
NCT01646736 | Peking Union Medical College Hospital |
Nephritis, Lupus
|
July 2012 | Phase 2|Phase 3 |
NCT01332968 | Hoffmann-La Roche|German Low Grade Lymphoma Study Group|Institute of Cancer Research, United Kingdom |
Non-Hodgkin´s Lymphoma
|
July 6, 2011 | Phase 3 |
NCT00872625 | Centre Antoine Lacassagne |
Breast Cancer
|
April 2007 | Phase 1 |
NCT03242460 | Kosin University Gospel Hospital |
Relapsed and+or refractorY Multiple Myeloma
|
May 12, 2015 | Phase 2 |
NCT01273181 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer|Metastatic Renal Cancer|Metastatic Melanoma
|
December 2010 | Phase 1|Phase 2 |
NCT00626197 | Genentech, Inc.|Roche Pharma AG |
Lupus Nephritis|Systemic Lupus Erythematosus
|
February 15, 2008 | Phase 3 |
NCT05092451 | M.D. Anderson Cancer Center |
B-Cell Lymphoma|Myelodysplastic Syndromes (MDS)|Acute Myeloid Leukemia (AML)
|
November 1, 2022 | Phase 1|Phase 2 |
NCT00412243 | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company |
Burkitt´s Lymphoma|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia
|
March 2006 | Phase 1|Phase 2 |
NCT01920737 | Memorial Sloan Kettering Cancer Center|Shire|Duke University|Weill Medical College of Cornell University|Lehigh Valley Health Network |
Leukemia
|
August 2013 | Phase 2 |
NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
January 29, 2018 | Phase 1|Phase 2 |
NCT00841828 | Spanish Breast Cancer Research Group|GlaxoSmithKline |
Breast Cancer
|
February 2009 | Phase 2 |
NCT04432506 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
July 27, 2020 | Phase 2 |
NCT00025428 | Societe Internationale d´Oncologie Pediatrique|Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
December 2000 | Phase 3 |
NCT04752163 | M.D. Anderson Cancer Center |
Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome
|
March 25, 2021 | Phase 1|Phase 2 |
NCT00630253 | Masonic Cancer Center, University of Minnesota |
Fanconi Anemia
|
February 17, 2000 | Phase 1|Phase 2 |
NCT02460588 | Assistance Publique - Hôpitaux de Paris |
Idiopathic Pulmonary Fibrosis
|
December 2015 | Phase 3 |
NCT00046852 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Infection|Multiple Myeloma and Plasma Cell Neoplasm
|
December 2001 | Phase 1|Phase 2 |
NCT02636322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma Unclassifiable
|
March 29, 2016 | Phase 2 |
NCT03477500 | Haukeland University Hospital |
Multiple Sclerosis
|
March 21, 2018 | Phase 3 |
NCT02959905 | BGI, China|Sun Yat-sen University |
Solid Cancer
|
December 22, 2016 | Phase 1 |
NCT02159495 | City of Hope Medical Center|National Cancer Institute (NCI)|Mustang Bio, Inc. |
Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 15, 2015 | Phase 1 |
NCT05225363 | City of Hope Medical Center|National Cancer Institute (NCI) |
Platinum-Resistant Ovarian Carcinoma
|
May 5, 2022 | Phase 1 |
NCT00005986 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
August 2000 | Phase 2 |
NCT00392886 | Children´s Hospital Los Angeles|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
March 2004 | Phase 3 |
NCT00003401 | University of Maryland, Baltimore |
Multiple Myeloma and Plasma Cell Neoplasm
|
January 1999 | Phase 2 |
NCT03229616 | Nanfang Hospital of Southern Medical University|Guangzhou First People´s Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Peking University People´s Hospital |
Autologous Hematopoietic Stem Cell Transplantation|Diffuse Large B-cell Lymphoma|Conditioning
|
July 5, 2017 | Phase 2|Phase 3 |
NCT00773695 | Hoffmann-La Roche|Norwegian Radium Hospital |
Breast Cancer
|
November 7, 2008 | Phase 2 |
NCT00404066 | George Albert Fisher|GlaxoSmithKline|Sanofi|Stanford University |
Breast Cancer|Metastatic Breast Cancer
|
October 2006 | Phase 2 |
NCT00387959 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2006 | Phase 2 |
NCT03103555 | Mahidol University|Ministry of Health, Thailand |
Adult-onset Immunodeficiency
|
February 27, 2017 | Phase 2 |
NCT01240538 | National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
December 2010 | Phase 1 |
NCT02549677 | Ruijin Hospital |
Breast Neoplasms
|
October 2015 | Phase 4 |
NCT04052334 | H. Lee Moffitt Cancer Center and Research Institute|Iovance Biotherapeutics, Inc.|The V Foundation for Cancer Research|National Cancer Institute (NCI) |
Sarcoma
|
September 27, 2019 | Phase 1 |
NCT02441270 | University Hospital, Ghent |
Radiotherapy|Immunology
|
April 2015 | Early Phase 1 |
NCT02821507 | Leiden University Medical Center |
Conventional Chondrosarcoma|Myxoid Liposarcoma|Mesenchymal Chondrosarcoma|Dedifferentiated Chondrosarcoma
|
June 2014 | Phase 2 |
NCT03712878 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematopoietic and Lymphoid Cell Neoplasm
|
September 19, 2018 | Phase 2 |
NCT00741455 | Dartmouth-Hitchcock Medical Center |
Hematologic Malignancies
|
June 2004 | Not Applicable |
NCT02215876 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Breast Cancer
|
September 2014 | Phase 2 |
NCT05495893 | Second Xiangya Hospital of Central South University|Peking Union Medical College Hospital|Children´s Hospital of Chongqing Medical University|Beijing Children´s Hospital|Jiangxi Province Children´s Hospital|The Affiliated Hospital of Qingdao University|Shenzhen Children´s Hospital|The First Affiliated Hospital of Zhengzhou University|The Children´s Hospital of Zhejiang University School of Medicine|The Second Hospital of Hebei Medical University |
Mycophenolate Mofetil|Cyclophosphamide|Lupus Nephritis
|
July 25, 2022 | Phase 4 |
NCT00743509 | University of Michigan Rogel Cancer Center |
Osteosarcoma
|
August 2008 | Phase 2 |
NCT03117751 | St. Jude Children´s Research Hospital|Incyte Corporation|Amgen|Servier |
Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma
|
March 29, 2017 | Phase 2|Phase 3 |
NCT04196413 | Crystal Mackall, MD|CureSearch|Stanford University |
Glioma of Spinal Cord|Glioma of Brainstem
|
June 4, 2020 | Phase 1 |
NCT02299999 | UNICANCER|Fondation ARC|AstraZeneca |
Metastatic Breast Cancer
|
April 7, 2014 | Phase 2 |
NCT01995344 | The Christie NHS Foundation Trust|National Institute for Health Research, United Kingdom |
Metastatic Melanoma
|
October 2013 | Phase 2 |
NCT00112827 | City of Hope Medical Center |
Refractory Multiple Myeloma|Smoldering Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
November 2004 | Phase 1|Phase 2 |
NCT03836352 | ImmunoVaccine Technologies, Inc. (IMV Inc.)|Merck Sharp & Dohme LLC |
Ovarian Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Bladder Cancer|Microsatellite Instability-High
|
December 21, 2018 | Phase 2 |
NCT02654119 | University of Nebraska|National Cancer Institute (NCI) |
HER2 Positive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7
|
December 11, 2015 | Phase 2 |
NCT02111863 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Skin Cancer
|
February 21, 2014 | Phase 2 |
NCT05088057 | Aiping Shi|Jilin University |
Triple Negative Breast Cancer (TNBC)
|
September 20, 2021 | Phase 2 |
NCT00016458 | Fred Hutchinson Cancer Center|Office of Rare Diseases (ORD) |
Systemic Sclerosis
|
June 2000 | Phase 2 |
NCT02443831 | University College, London |
Acute Lymphoblastic Leukemia|Burkitt Lymphoma
|
April 2016 | Phase 1 |
NCT02512679 | Children´s Hospital Los Angeles|Lucile Packard Children´s Hospital |
Stem Cell Transplantation|Bone Marrow Transplantation|Peripheral Blood Stem Cell Transplantation|Allogeneic Transplantation|Genetic Diseases|Thalassemia|Pediatrics|Diamond-Blackfan Anemia|Combined Immune Deficiency|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Lymphoproliferative Disease|Metabolic Diseases
|
February 2007 | Phase 2 |
NCT00575406 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Diffuse Large B-Cell Lymphoma
|
December 2007 | Phase 2 |
NCT00691015 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2008 | Phase 2 |
NCT00258427 | Masonic Cancer Center, University of Minnesota |
Fanconi Anemia
|
March 26, 2002 | Phase 2 |
NCT00002657 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
May 1995 | Phase 2 |
NCT04171843 | Precision BioSciences, Inc. |
Relapsed+Refractory Multiple Myeloma
|
April 30, 2020 | Phase 1|Phase 2 |
NCT00416676 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
Phase 3 | |
NCT05020444 | Marcela V. Maus, M.D.,Ph.D.|Massachusetts General Hospital |
Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma
|
October 5, 2021 | Phase 1 |
NCT01719835 | Royal Marsden NHS Foundation Trust|Cancer Research UK |
Peripheral T-cell Lymphoma NOS|Anaplastic Large Cell Lymphoma, ALK-Negative|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic Gamma+ Delta T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma
|
March 2012 | Phase 2 |
NCT00003958 | Children´s Oncology Group|National Cancer Institute (NCI) |
Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Alveolar Childhood Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Nonmetastatic Childhood Soft Tissue Sarcoma|Previously Untreated Childhood Rhabdomyosarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma
|
September 2002 | Phase 3 |
NCT00671034 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
July 21, 2008 | Phase 3 |
NCT00473551 | M.D. Anderson Cancer Center |
Leukemia|Lymphoma|Myeloma
|
May 2007 | Phase 1 |
NCT05579769 | St. Jude Children´s Research Hospital |
Hematologic Malignancy|Myeloid Malignancy
|
November 4, 2022 | Phase 2 |
NCT00002761 | Columbia University |
Leukemia
|
February 1996 | Phase 1|Phase 2 |
NCT03861403 | Leap Therapeutics, Inc.|Pfizer|Merck KGaA, Darmstadt, Germany |
Solid Tumors|Advanced Triple Negative Breast Cancer|Advanced Hormone Receptor Positive+Endocrine Refractory Breast Cancer|Advanced Metastatic Castration-Resistant Prostate Cancer|Advanced Platinum-Resistant Ovarian Cancer
|
May 20, 2019 | Phase 1|Phase 2 |
NCT04568161 | University of Sao Paulo General Hospital|Universidade Federal Fluminense|Hospital Israelita Albert Einstein |
Cardiotoxicity|Cardiovascular Disease|Neurovascular Disorder|Endothelial Disfunction|Breast Cancer
|
August 3, 2020 | Not Applicable |
NCT03467256 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
B-cell Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia, Pediatric
|
May 14, 2018 | Phase 1|Phase 2 |
NCT03303950 | University of Utah |
Anemia|ASXL1 Gene Mutation|EZH2 Gene Mutation|IDH1 Gene Mutation|IDH2 Gene Mutation|Plasma Cell Myeloma|Primary Myelofibrosis|Recurrent Plasma Cell Myeloma|Secondary Myelofibrosis|Thrombocytopenia
|
March 30, 2018 | Phase 2 |
NCT00103285 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
April 11, 2005 | Phase 3 |
NCT00041327 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
NCT00009997 | NYU Langone Health|National Cancer Institute (NCI) |
Breast Cancer
|
March 1999 | Phase 1 |
NCT01955187 | Hospital Universitario 12 de Octubre|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Universitario Fundación Alcorcón|Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre|Biobanco REDinREN|ERA-EDTA|REDinREN|Spanish Society of Nephrology|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|University Hospital, Aachen |
MEMBRANOUS NEPHROPATHY
|
January 2014 | Phase 3 |
NCT00723099 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Indolent Non-Hodgkin Lymphoma|Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia|Refractory Follicular Lymphoma|Refractory Hodgkin Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Non-Hodgkin Lymphoma
|
June 25, 2008 | Phase 2 |
NCT00002812 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 1996 | Phase 3 |
NCT03009058 | Immodulon Therapeutics Ltd |
Metastatic Cancer
|
May 24, 2017 | Phase 1|Phase 2 |
NCT04282174 | Baptist Health South Florida |
Hematologic Diseases|Hematologic Malignancy|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia
|
September 2022 | Phase 2 |
NCT01236573 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Skin Cancer|Metastatic Melanoma
|
October 2010 | Phase 1|Phase 2 |
NCT00003974 | Roswell Park Cancer Institute |
Lung Cancer|Malignant Mesothelioma
|
August 1997 | Phase 1 |
NCT03200002 | Chitwan Medical College |
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
|
January 1, 2014 | Phase 2 |
NCT04384692 | Fred Hutchinson Cancer Center |
Primary Myelofibrosis|Secondary Myelofibrosis
|
December 18, 2020 | Phase 2 |
NCT00379457 | European Paediatric Soft Tissue Sarcoma Study Group|Italian Association for Pediatric Hematology Oncology|Children´s Cancer and Leukaemia Group|Dutch Childhood Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
June 2006 | Phase 3 |
NCT00262210 | National Health Research Institutes, Taiwan |
Non-Hodgkin´s Lymphoma
|
June 1995 | Phase 2 |
NCT03909412 | Hackensack Meridian Health|Amgen |
Multiple Myeloma
|
October 8, 2019 | Phase 1 |
NCT00012311 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
January 2000 | Phase 2 |
NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical |
Breast Cancer
|
January 11, 2019 | Phase 3 |
NCT02282904 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Chronic Granulomatous Disease
|
October 23, 2014 | Phase 1|Phase 2 |
NCT05088356 | Stanford University|Orca Biosystems, Inc. |
Allogeneic Hematopoietic Cell Transplantation (HCT)|Advanced Hematologic Malignancies|Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorders
|
September 7, 2021 | Phase 1 |
NCT00056095 | UNICANCER |
Kidney Cancer
|
November 4, 2002 | Phase 2 |
NCT00022737 | National Cancer Institute (NCI) |
Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia
|
October 2002 | Phase 3 |
NCT00577122 | Indiana University|Translational Breast Cancer Research Consortium |
Estrogen Receptor-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
July 2007 | Phase 2 |
NCT04626739 | Hebei Senlang Biotechnology Inc., Ltd. |
Refractory Indolent Adult Non-Hodgkin Lymphoma
|
April 1, 2020 | Early Phase 1 |
NCT00558519 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
March 12, 2008 | Phase 2 |
NCT00002638 | University of Nebraska|National Cancer Institute (NCI) |
Leukemia
|
March 1995 | Phase 2 |
NCT00976300 | Institute of Rheumatology, Prague|Ministry of Health, Czech Republic|Charles University, Czech Republic|Palacky University|Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic|National Institute of Rheumatology, Piestany, Slovakia|St. Anna Hospital, Brno, Czech |
Systemic Lupus Erythematosus|Lupus Nephritis
|
January 2002 | Phase 2 |
NCT03036904 | Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma
|
February 6, 2017 | Phase 1 |
NCT01861106 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
GATA2|Immunodeficiency|MDS
|
July 24, 2013 | Phase 2 |
NCT03399773 | Fred Hutchinson Cancer Center|Nohla Therapeutics, Inc.|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid Cell Neoplasm|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts
|
May 10, 2022 | Phase 2 |
NCT01200758 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
February 15, 2011 | Phase 3 |
NCT01288131 | Chulalongkorn University |
Anti-r-HuEpo Associated PRCA Subjects
|
January 2009 | Phase 3 |
NCT03829566 | Northwestern University |
Neuromyelitis Optica|Devic´s Disease|NMO Spectrum Disorder
|
November 2019 | Phase 2|Phase 3 |
NCT03696784 | UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals|The V Foundation |
Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases
|
March 12, 2019 | Phase 1 |
NCT02212574 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Matthew Larson Foundation |
Medulloblastoma
|
April 4, 2017 | Early Phase 1 |
NCT00692939 | Paul Szabolcs|University of Pittsburgh |
Crohn´s Disease
|
June 26, 2012 | Phase 1|Phase 2 |
NCT00003150 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group |
Lymphoma
|
December 1997 | Phase 3 |
NCT04245839 | Celgene |
Lymphoma, Non-Hodgkin
|
July 14, 2020 | Phase 2 |
NCT00609167 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 2006 | Phase 2 |
NCT00478452 | University of Pennsylvania|Fox Chase Cancer Center |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma
|
August 2005 | Phase 1 |
NCT02451982 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Pancreatic Cancer
|
March 28, 2016 | Phase 2 |
NCT00119262 | National Cancer Institute (NCI) |
Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer
|
October 2005 | Phase 2 |
NCT05621759 | NYU Langone Health |
Graft Vs Host Disease
|
August 23, 2022 | Phase 2 |
NCT04195633 | Fred Hutchinson Cancer Center|medac GmbH |
Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult Diffuse Large Cell Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma
|
January 25, 2021 | Phase 2 |
NCT00429026 | M.D. Anderson Cancer Center |
Renal Cell Cancer
|
January 2004 | Phase 2 |
NCT04796675 | Wuhan Union Hospital, China|Shanghai Simnova Biotechnology Co.,Ltd. |
Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin´s Lymphoma
|
April 10, 2021 | Phase 1 |
NCT01614197 | Therapeutic Advances in Childhood Leukemia Consortium|Pfizer |
Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma
|
March 2015 | Phase 1 |
NCT05103631 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
Liver Cell Carcinoma
|
June 17, 2021 | Phase 1 |
NCT00003815 | Scotland and Newcastle Lymphoma Group|National Cancer Institute (NCI) |
Lymphoma
|
June 1994 | Phase 3 |
NCT00003955 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
September 1999 | Phase 2 |
NCT01869192 | University of Colorado, Denver |
Malignant Neoplasm of Female Breast
|
March 5, 2003 | Phase 2 |
NCT00337246 | Cancer Research UK|National Cancer Institute (NCI) |
Leukemia
|
July 2005 | Phase 2 |
NCT05207358 | Institutul Clinic Fundeni |
Lupus Nephritis
|
March 2, 2022 | Phase 4 |
NCT00407888 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
May 2006 | Phase 2 |
NCT03752723 | Genexine, Inc.|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer
|
March 27, 2019 | Phase 1|Phase 2 |
NCT00612716 | Masonic Cancer Center, University of Minnesota |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
October 6, 1999 | Phase 2 |
NCT00146588 | Craig A. Bunnell, MD, MPH|Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Pharmacia |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
April 2002 | Not Applicable |
NCT03655002 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Hepatocellular Carcinoma|Refractory Liver Carcinoma|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8
|
February 21, 2019 | Phase 1 |
NCT00008190 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 1999 | Phase 2 |
NCT01208818 | Assistance Publique - Hôpitaux de Paris |
Chronic Renal Failure With Uremic Nephropathy
|
June 2011 | Phase 3 |
NCT00040469 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
Sickle Cell Anemia|Hemoglobinopathy|Thalassemia
|
August 2000 | Phase 2 |
NCT03983850 | National Cancer Institute (NCI)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
Graft Versus Host Disease|Hematologic Neoplasms
|
July 9, 2019 | Phase 1|Phase 2 |
NCT03401372 | Jian Li|Peking University First Hospital|Beijing Anzhen Hospital|Beijing Chao Yang Hospital|West China Hospital Affiliated with Sichuan University|Tongji Hospital|Union Hospital Affiliated with Tongji Medical College of HUST|Shanghai Changzheng Hospital|Nanfang Hospital of Southern Medical University|Peking Union Medical College Hospital |
Amyloidosis; Systemic
|
April 21, 2018 | Not Applicable |
NCT00478244 | Masonic Cancer Center, University of Minnesota |
Epidermolysis Bullosa
|
April 2007 | Not Applicable |
NCT00198978 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
January 2003 | Phase 4 |
NCT04293393 | Spanish Breast Cancer Research Group|Eli Lilly and Company |
Early Breast Cancer
|
October 2, 2020 | Phase 2 |
NCT00060255 | Roswell Park Cancer Institute |
Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific
|
December 1991 | Phase 2 |
NCT03321890 | Sun Yat-sen University |
Peripheral T-cell Lymphoma
|
March 7, 2017 | Phase 2 |
NCT02181478 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia
|
July 22, 2015 | Early Phase 1 |
NCT00003784 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
May 1999 | Phase 2 |
NCT04896658 | University of Maryland, Baltimore |
Relapsed+Refractory Multiple Myeloma
|
January 1, 2022 | Phase 1|Phase 2 |
NCT05600426 | Boston Children´s Hospital|Center for International Blood and Marrow Transplant Research|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|North American Pediatric Aplastic Anemia Consortium|Pediatric Transplantation and Cellular Therapy Consortium|Blood and Marrow Transplant Clinical Trials Network |
Severe Aplastic Anemia
|
December 2022 | Phase 3 |
NCT02220985 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Allogeneic Hematopoietic Stem Cell Transplant Recipient|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Donor|Lymphoblastic Lymphoma|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission
|
February 3, 2015 | Phase 2 |
NCT05468359 | St. Jude Children´s Research Hospital |
Refractory Solid Tumor|Hepatocellular Carcinoma|Malignant Solid Tumor|Pediatric Cancer|Pediatric Solid Tumor
|
November 2022 | Phase 1|Phase 2 |
NCT00057811 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2004 | Phase 2 |
NCT00509288 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Skin Cancer
|
June 2007 | Phase 2 |
NCT02194374 | M.D. Anderson Cancer Center|CLL Global Research Foundation Alliance |
Leukemia
|
January 2015 | Phase 1 |
NCT01496131 | EMD Serono|National Cancer Institute (NCI) |
Prostate Cancer
|
October 24, 2011 | Phase 2 |
NCT02693210 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
February 2001 | Phase 2 |
NCT03020030 | Dana-Farber Cancer Institute|Servier |
Acute Lymphoblastic Leukemia, Pediatric
|
March 3, 2017 | Phase 3 |
NCT00024193 | Children´s Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI) |
Neuroblastoma
|
April 1999 | Phase 2 |
NCT05411497 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
June 20, 2022 | Phase 1 |
NCT04558736 | St. Jude Children´s Research Hospital |
Aplastic Anemia|Bone Marrow Failure Syndrome
|
January 21, 2021 | Phase 2 |
NCT00498316 | M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Myelodysplastic Syndrome|Leukemia
|
July 3, 2007 | Phase 1 |
NCT00025597 | European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1999 | Phase 2 |
NCT00687648 | National Cancer Centre, Singapore|National Cancer Institute (NCI) |
Breast Cancer
|
May 2008 | Phase 2 |
NCT01446211 | Nordic Pharma SAS |
Wegeners Granulomatosis
|
November 2011 | Phase 3 |
NCT04614636 | Fate Therapeutics |
Acute Myeloid Leukemia|AML, Adult|Multiple Myeloma|Myeloma
|
October 17, 2020 | Phase 1 |
NCT00002514 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council |
Leukemia
|
April 1993 | Phase 3 |
NCT03943901 | University of Wisconsin, Madison|Medical College of Wisconsin |
Diffuse Large B Cell Lymphoma|DLBCL|Cancer
|
February 16, 2021 | Phase 2 |
NCT01236456 | Stony Brook University |
Chronic Inflammatory Demyelinating Polyneuropathy
|
October 2003 | Phase 2 |
NCT00518206 | Ludwig Institute for Cancer Research|Austin Health|Peter MacCallum Cancer Institute |
Melanoma
|
November 28, 2003 | Phase 2 |
NCT01532635 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematologic Malignancy|Leukemia|Acute Lymphoblastic Leukemia|ALL|Acute Myelogenous Leukemia|AML|Chronic Lymphocytic Leukemia|CLL|Lymphoma|Hodgkin´s Lymphoma|Non-hodgkin´s Lymphoma|Myeloma
|
March 2012 | Phase 2 |
NCT02901145 | Hadassah Medical Organization |
Antibodies, Neoplasm
|
November 2016 | Phase 1|Phase 2 |
NCT02256150 | Asahi Kasei Pharma Corporation |
Lupus Nephritis
|
November 2014 | Phase 3 |
NCT00005589 | EBMT Solid Tumors Working Party|Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 3 |
NCT01370772 | French Innovative Leukemia Organisation|Roche Pharma AG |
B-cell Chronic Lymphocytic Leukemia CLL
|
May 2011 | Phase 2 |
NCT00727441 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
July 2, 2008 | Phase 2 |
NCT00002502 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
July 1992 | Phase 2 |
NCT02457221 | Astellas Pharma China, Inc.|Astellas Pharma Inc |
Lupus Nephritis
|
March 10, 2015 | Phase 3 |
NCT01583686 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer
|
May 4, 2012 | Phase 1|Phase 2 |
NCT02533401 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
February 2006 | Phase 2 |
NCT00004174 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer
|
October 1999 | Phase 1 |
NCT00002665 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia|Neutropenia|Thrombocytopenia
|
July 1995 | Phase 2 |
NCT00578903 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
Aplastic Anemia
|
February 2002 | Phase 2 |
NCT02756546 | Cairo University |
Systemic Lupus Erythematosis
|
September 2014 | Phase 1|Phase 2 |
NCT00652691 | Mayo Clinic|National Cancer Institute (NCI) |
Ovarian Cancer|Peritoneal Cavity Cancer
|
August 1998 | Phase 1 |
NCT03873805 | City of Hope Medical Center|National Cancer Institute (NCI) |
Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
August 20, 2019 | Phase 1 |
NCT04517435 | Deepa Jagadeesh|Case Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma
|
April 28, 2021 | Phase 1|Phase 2 |
NCT00000703 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Not Applicable | |
NCT00085735 | Children´s Oncology Group|National Cancer Institute (NCI) |
Untreated Childhood Medulloblastoma
|
April 2004 | Phase 3 |
NCT04030195 | Precision BioSciences, Inc. |
Non-Hodgkin´s Lymphoma, Relapsed|Chronic Lymphoid Leukemia in Relapse|Non-Hodgkin´s Lymphoma Refractory|Chronic Lymphocytic Leukemia|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, Chronic|B-cell Chronic Lymphocytic Leukemia|B-cell Non Hodgkin Lymphoma|Small Lymphocytic Lymphoma
|
March 24, 2020 | Phase 1|Phase 2 |
NCT04029688 | Hoffmann-La Roche |
Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Neuroblastoma|Solid Tumors
|
January 27, 2020 | Phase 1|Phase 2 |
NCT02793856 | Sichuan University|Chengdu MedGenCell, Co., Ltd. |
Metastatic Non-small Cell Lung Cancer
|
August 26, 2016 | Phase 1 |
NCT00002579 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
March 1993 | Phase 3 |
NCT01300247 | Genentech, Inc. |
Lymphocytic Leukemia, Chronic
|
May 2011 | Phase 1 |
NCT03384277 | Zhang Lei|Qilu Hospital of Shandong University|Tianjin First Central Hospital|The Second Affiliated Hospital of Kunming Medical University|Henan Cancer Hospital|Institute of Hematology & Blood Diseases Hospital |
Acquired Hemophilia A
|
October 26, 2017 | Phase 3 |
NCT01925612 | Seagen Inc. |
Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse
|
August 2013 | Phase 2 |
NCT00890955 | Lawrence Einhorn|Celgene Corporation|Hoosier Cancer Research Network |
Lung Cancer
|
March 2009 | Phase 1 |
NCT02523976 | Institute of Hematology & Blood Diseases Hospital |
Acute,Leukemia, Lymphoid
|
August 1, 2015 | Phase 2 |
NCT03016806 | University of Rochester |
Acute Leukemia|Immune Deficiency Disorder|Congenital Hematological Disorder|Metabolism Disorder|Aplastic Anemia|Myelodysplastic Syndromes|Chronic Leukemia|Lymphoma|Multiple Myeloma|Solid Tumor
|
June 2015 | Phase 1 |
NCT03166397 | Sheba Medical Center |
Malignant Melanoma Stage IV
|
June 5, 2017 | Phase 2 |
NCT00190229 | Assistance Publique - Hôpitaux de Paris |
Henoch-Schoenlein Purpura
|
September 2002 | Not Applicable |
NCT04620772 | All India Institute of Medical Sciences, New Delhi |
Tuberculosis|Tubercular Meningitis|Arachnoiditis; Tuberculous (Etiology)
|
January 1, 2021 | Phase 2|Phase 3 |
NCT00567567 | Children´s Oncology Group|National Cancer Institute (NCI) |
Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma
|
November 5, 2007 | Phase 3 |
NCT00847171 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
December 2008 | Phase 2 |
NCT00299182 | M.D. Anderson Cancer Center|Amgen |
Lymphoma
|
March 2006 | Phase 1|Phase 2 |
NCT02101853 | National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia
|
December 8, 2014 | Phase 3 |
NCT03187756 | NYU Langone Health |
Hematopoietic Malignancies
|
June 2, 2017 | Phase 2 |
NCT00003352 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
June 1998 | Phase 2 |
NCT04510051 | City of Hope Medical Center|National Cancer Institute (NCI) |
Malignant Brain Neoplasm|Recurrent Malignant Brain Neoplasm|Refractory Malignant Brain Neoplasm
|
December 4, 2020 | Phase 1 |
NCT01920932 | St. Jude Children´s Research Hospital|Seagen Inc. |
Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
August 12, 2013 | Phase 2 |
NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1996 | Phase 3 |
NCT00544167 | SCRI Development Innovations, LLC|Bayer |
Breast Cancer
|
May 2007 | Not Applicable |
NCT00453388 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Acute Myeloid Leukemia in Remission|de Novo Myelodysplastic Syndrome|Fanconi Anemia|Previously Treated Myelodysplastic Syndrome
|
February 2007 | Phase 2 |
NCT03198195 | Capital Research Institute of Pediatrics |
Wiskott-Aldrich Syndrome
|
March 10, 2015 | |
NCT00562978 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
May 16, 2000 | Phase 1|Phase 2 |
NCT00003606 | UNICANCER |
Lung Cancer
|
March 1996 | Phase 3 |
NCT00019409 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 3 |
NCT02682693 | German Breast Group|Amgen|Celgene Corporation |
Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III
|
February 13, 2017 | Phase 2 |
NCT02828358 | National Cancer Institute (NCI) |
Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia
|
March 27, 2017 | Phase 2 |
NCT00392834 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
September 2006 | Phase 2 |
NCT00005946 | University of Maryland, Baltimore |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
October 2000 | Phase 1 |
NCT00002943 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific
|
February 1993 | Phase 2 |
NCT00002945 | Roswell Park Cancer Institute |
Leukemia
|
December 1996 | Phase 3 |
NCT00004908 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
November 1999 | Phase 2 |
NCT01947062 | Swami Rama Cancer Hospital and Research Institute |
Lung Cancer|Squamous Cell Carcinoma of the Lung|Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung
|
October 2013 | Phase 3 |
NCT02985333 | Sun Yat-sen University |
Relapse+Refractory Multiple Myeloma
|
January 2014 | Phase 2 |
NCT03935893 | Udai Kammula|University of Pittsburgh |
Gastric Cancer|Colorectal Cancer|Pancreatic Cancer|Sarcoma|Mesothelioma|Neuroendocrine Tumors|Squamous Cell Cancer|Merkel Cell Carcinoma|Mismatch Repair Deficiency|Microsatellite Instability
|
December 3, 2019 | Phase 2 |
NCT00499733 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Cancer
|
June 2007 | Early Phase 1 |
NCT01026220 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
December 7, 2009 | Phase 3 |
NCT04668365 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma|CD79A Gene Mutation|CD79B Gene Mutation
|
December 25, 2020 | Phase 2 |
NCT04423926 | The First Affiliated Hospital with Nanjing Medical University |
PTCL, NOS|AITL|ALK- ALCL|Phase III-IV ALK&addition; ALCL|EATL
|
June 10, 2020 | Phase 1|Phase 2 |
NCT03697824 | GlaxoSmithKline|Merck Sharp & Dohme LLC |
Neoplasms
|
February 25, 2019 | Phase 2 |
NCT00887536 | NSABP Foundation Inc|Genentech, Inc.|US Oncology Research |
Breast Cancer
|
May 2009 | Phase 3 |
NCT00025441 | Societe Internationale d´Oncologie Pediatrique|Children´s Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI) |
Ovarian Cancer|Sarcoma|Small Intestine Cancer
|
November 1998 | Phase 2 |
NCT02206503 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
March 2013 | Phase 2 |
NCT04119024 | Jonsson Comprehensive Cancer Center|City of Hope National Medical Center |
Clinical Stage IV Cutaneous Melanoma AJCC v8|IL13RA2 Positive|Metastatic Melanoma|Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV
|
November 27, 2019 | Phase 1 |
NCT04002401 | Kite, A Gilead Company|Gilead Sciences |
Refractory Large B-cell Lymphoma
|
November 5, 2019 | Phase 2 |
NCT00002600 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
October 21, 1994 | Phase 1 |
NCT00003913 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
December 1998 | Phase 2 |
NCT00022178 | The Christie NHS Foundation Trust|National Cancer Institute (NCI) |
Carcinoma of Unknown Primary
|
December 1998 | Phase 3 |
NCT01731587 | Merck KGaA, Darmstadt, Germany |
Non-small Cell Lung Cancer (NSCLC) Stage III
|
January 2001 | Phase 1 |
NCT01569204 | University of Cologne |
Hodgkin Lymphoma
|
October 2012 | Phase 2 |
NCT04473911 | Zachariah Michael DeFilipp|Regimmune Corporation|Massachusetts General Hospital |
GVHD|AML|ALL|MDS|MPN|CMML|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Blood Stem Cell Transplant Failure|Graft Vs Host Disease|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorder|Chronic Myelomonocytic Leukemia|Chemosensitive Hodgkin Lymphoma
|
August 14, 2020 | Phase 1 |
NCT00354419 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Aplastic Anemia
|
February 2006 | Phase 1 |
NCT04945954 | Seoul National University Hospital|National Institute of Food and Drug Safety Evaluation (Republic of Korea) |
Hematopoietic Stem Cell Transplantation
|
June 2021 | Not Applicable |
NCT02871869 | Xinjiang Medical University |
Diffuse, Large B-Cell, Lymphoma
|
September 2016 | Phase 2|Phase 3 |
NCT05400122 | Jennifer Eva Selfridge|Case Comprehensive Cancer Center |
Colorectal Cancer|Hematologic Malignancy|Rectum Cancer|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Syndrome|Plasma Cell Myeloma
|
September 9, 2022 | Phase 1 |
NCT02553460 | St. Jude Children´s Research Hospital|Gateway for Cancer Research|Baylor College of Medicine |
Acute Lymphoblastic Leukemia
|
January 29, 2016 | Phase 1|Phase 2 |
NCT02280694 | HaEmek Medical Center, Israel |
Colorectal Cancer
|
January 2015 | Phase 2 |
NCT01271907 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cutaneous Melanoma
|
April 15, 2011 | Phase 2 |
NCT01205217 | GlaxoSmithKline |
Neoplasms, Breast
|
December 2010 | Phase 2 |
NCT00400946 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia
|
April 2005 | Phase 3 |
NCT03338972 | Fred Hutchinson Cancer Center|Juno Therapeutics, Inc.|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 29, 2017 | Phase 1 |
NCT00005984 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
August 2000 | Phase 2 |
NCT02905188 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|Cancer Prevention Research Institute of Texas |
Hepatocellular Carcinoma
|
March 28, 2019 | Phase 1 |
NCT00005798 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Breast Cancer
|
July 1995 | Phase 2 |
NCT00003050 | University of Southern California|National Cancer Institute (NCI) |
Breast Cancer
|
April 1997 | Phase 2 |
NCT04762901 | Wake Forest University Health Sciences|Tesaro, Inc. |
Breast Cancer
|
April 1, 2021 | Phase 1 |
NCT02206425 | Oncotherapeutics|Takeda |
Multiple Myeloma
|
September 2014 | Phase 1|Phase 2 |
NCT00309478 | Austrian Breast & Colorectal Cancer Study Group|AstraZeneca |
Early-stage Breast Cancer
|
December 1990 | Phase 3 |
NCT00394251 | Celgene |
Breast Cancer
|
August 1, 2006 | Phase 2 |
NCT01860937 | Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber+Children´s Hospital |
Relapsed B-Cell Acute Lymphoblastic Leukemia
|
May 2013 | Phase 1 |
NCT02343536 | Celgene |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular
|
April 29, 2015 | Phase 1 |
NCT00002838 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
December 1995 | Phase 1|Phase 2 |
NCT03169738 | ImmunityBio, Inc. |
Non-small Cell Lung Cancer
|
February 2018 | Phase 1|Phase 2 |
NCT03070327 | Memorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc. |
Multiple Myeloma
|
February 27, 2017 | Phase 1 |
NCT00490529 | Ronald Levy|National Institutes of Health (NIH)|Stanford University |
Lymphoma, Mantle-Cell
|
August 2009 | Phase 2 |
NCT01883297 | University Health Network, Toronto |
Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
January 2015 | Phase 1 |
NCT01322776 | Sun Yat-sen University|Fudan University|Zhejiang University|West China Hospital|Ruijin Hospital|Tianjin Medical University Cancer Institute and Hospital|Peking University Cancer Hospital & Institute|Jiangsu Cancer Institute & Hospital |
Mantle Cell Lymphoma Recurrent
|
March 2011 | Phase 1|Phase 2 |
NCT01779206 | West German Study Group |
Breast Cancer
|
May 2012 | Phase 2|Phase 3 |
NCT00439296 | Therapeutic Advances in Childhood Leukemia Consortium|Abbott |
Recurrent Pediatric ALL|Relapsed Pediatric ALL|Acute Lymphoblastic Leukemia|Refractory Pediatric ALL
|
May 22, 2006 | Phase 1|Phase 2 |
NCT00722137 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda |
Mantle Cell Lymphoma
|
May 1, 2008 | Phase 3 |
NCT02918292 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Severe Aplastic Anemia
|
July 3, 2017 | Phase 2 |
NCT03295383 | University Hospital, Rouen |
Severe Forms of Mucous Membrane Pemphigoid
|
July 11, 2019 | Phase 3 |
NCT00611351 | Lori Maness Harris, MD|National Cancer Institute (NCI)|University of Nebraska |
Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Secondary Myelofibrosis
|
June 2005 | Phase 2 |
NCT02529852 | M.D. Anderson Cancer Center|Celgene|Genentech, Inc. |
Lymphoma
|
November 4, 2015 | Phase 1|Phase 2 |
NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
December 23, 2013 | Phase 3 |
NCT02461888 | University of Leeds|Myeloma UK|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
December 2015 | Phase 2 |
NCT02248428 | Jinling Hospital, China |
Multiple Myeloma
|
April 2012 | Phase 3 |
NCT00005908 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasm
|
June 2000 | Phase 2 |
NCT00003667 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Sarcoma
|
September 1998 | Phase 2 |
NCT02115152 | Guangxi Medical University |
Stage II Breast Cancer|Stage III Breast Cancer
|
June 2014 | Phase 2 |
NCT01445522 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Neoplasms|Lymphoma
|
December 3, 2008 | Phase 1 |
NCT04469530 | Emory University|PeachBowl LegACy Fund |
Solid Tumor
|
September 16, 2020 | Phase 2 |
NCT01445821 | Northwestern University |
Scleroderma, Systemic
|
September 15, 2011 | Phase 3 |
NCT04526509 | GlaxoSmithKline |
Neoplasms
|
December 21, 2020 | Phase 1 |
NCT00607581 | IRCCS Policlinico S. Matteo|Celgene Corporation |
Amyloidosis
|
February 2008 | Phase 2 |
NCT01612247 | University of Vermont|Maimonides Medical Center|Dartmouth-Hitchcock Medical Center |
Breast Cancer
|
February 2011 | Not Applicable |
NCT05197842 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
ANCA-associated Vasculitis
|
February 22, 2022 | Phase 1|Phase 2 |
NCT04319757 | Acepodia Biotech, Inc. |
Locally Advanced Solid Tumor|Metastatic Cancer|Solid Tumor|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer
|
May 19, 2020 | Phase 1 |
NCT04790903 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
July 2, 2021 | Phase 1 |
NCT04227275 | Tmunity Therapeutics |
Metastatic Castration-resistant Prostate Cancer
|
November 22, 2019 | Phase 1 |
NCT00003093 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
March 1988 | Phase 3 |
NCT00010387 | Johns Hopkins University|Office of Rare Diseases (ORD) |
Anemia, Hemolytic, Autoimmune|Felty Syndrome|Purpura, Thrombocytopenic|Autoimmune Diseases
|
March 1999 | Phase 2 |
NCT00245115 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
October 2005 | Phase 1 |
NCT04240054 | Medical College of Wisconsin |
Multiple Myeloma
|
November 2, 2021 | Phase 2 |
NCT00303667 | Masonic Cancer Center, University of Minnesota |
Acute Myelogenous Leukemia
|
January 2005 | Phase 1|Phase 2 |
NCT00104299 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Genentech, Inc. |
Vasculitis|Wegener´s Granulomatosis|Microscopic Polyangiitis
|
January 2005 | Phase 2|Phase 3 |
NCT03799913 | Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Hrain Biotechnology Co., Ltd. |
Ovarian Cancer
|
April 10, 2019 | Early Phase 1 |
NCT00003754 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
September 1998 | Phase 2 |
NCT02953184 | Jilin University |
Antineoplastic Combined Chemotherapy Protocols
|
November 2016 | Phase 2 |
NCT05168423 | University of Pennsylvania|Tmunity Therapeutics |
Glioblastoma
|
March 19, 2023 | Phase 1 |
NCT00004010 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
NCT01606878 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Solid Neoplasm|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Neuroblastoma
|
April 29, 2013 | Phase 1 |
NCT00169156 | Lymphoma Study Association|Hoffmann-La Roche |
Untreated T-cell Angioimmunoblastic Lymphoma
|
December 2005 | Phase 2 |
NCT00670748 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Melanoma|Metastatic Renal Cell Cancer|Metastatic Cancer
|
May 29, 2008 | Phase 2 |
NCT01661400 | Washington University School of Medicine |
Glioma|Neuroectodermal Tumors, Primitive|Wilms Tumor|Rhabdomyosarcoma|Sarcoma, Ewing|Osteosarcoma|Retinoblastoma
|
October 26, 2012 | Phase 1 |
NCT04025216 | Tmunity Therapeutics |
Non-Small Cell Lung Cancer|Ovarian Cancer|Fallopian Tube Cancer|Triple Negative Breast Cancer|Multiple Myeloma|Pancreatic Ductal Adenocarcinoma
|
October 10, 2019 | Phase 1 |
NCT00115700 | Trans Tasman Radiation Oncology Group|Australasian Leukaemia and Lymphoma Group |
Follicular Lymphoma
|
February 2000 | Phase 3 |
NCT02117024 | Heat Biologics |
Non Small Cell Lung Cancer
|
July 2014 | Phase 2 |
NCT00084838 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Central Nervous System Tumor, Pediatric
|
February 2003 | Phase 2 |
NCT00376961 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
August 2006 | Phase 2 |
NCT03106662 | Ankara University|The Scientific and Technological Research Council of Turkey |
Hematopoietic Stem Cell Transplantation
|
October 2014 | Phase 3 |
NCT01008150 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Breast Cancer
|
October 2010 | Phase 2 |
NCT03623750 | Instituto Oncológico Dr Rosell|Bioven Europe|MFAR |
Carcinoma, Non-Small-Cell Lung
|
July 6, 2018 | Phase 1|Phase 2 |
NCT00794820 | M.D. Anderson Cancer Center|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
December 2003 | Phase 2 |
NCT00004188 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
February 2001 | Phase 3 |
NCT03514836 | SOTIO a.s.|SOTIO Biotech |
Castration-resistant Prostate Cancer
|
May 23, 2018 | Phase 1|Phase 2 |
NCT00002696 | Grupo Oncologico Cooperativo del Sur|National Cancer Institute (NCI) |
Breast Cancer
|
October 1995 | Phase 3 |
NCT03056339 | M.D. Anderson Cancer Center |
B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma
|
June 21, 2017 | Phase 1|Phase 2 |
NCT03630211 | Paul Szabolcs|University of Pittsburgh |
Systemic Sclerosis|Diffuse Sclerosis Systemic|Interstitial Lung Disease|Pulmonary Hypertension
|
July 31, 2018 | Phase 2 |
NCT01833767 | Western Regional Medical Center |
Metastatic Melanoma
|
October 2012 | Phase 2 |
NCT00008203 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 1996 | Phase 3 |
NCT00885326 | New Approaches to Neuroblastoma Therapy Consortium|National Cancer Institute (NCI) |
Neuroblastoma
|
December 2009 | Phase 1 |
NCT00002658 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Neutropenia
|
January 1994 | Phase 3 |
NCT01639456 | Masonic Cancer Center, University of Minnesota|Miltenyi Biomedicine GmbH |
Acute Myelogenous Leukemia
|
October 2013 | Phase 2 |
NCT03467386 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
March 19, 2018 | Phase 1 |
NCT05566223 | Intima Bioscience, Inc. |
Carcinoma, Non-Small-Cell Lung|Metastatic Non Small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Adenocarcinoma of Lung|Large Cell Lung Cancer
|
November 2022 | Phase 1|Phase 2 |
NCT00007813 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen|Baxter Healthcare Corporation|Nexell Therapeutics Inc |
Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor
|
May 31, 1997 | Phase 1 |
NCT00002679 | Yale University |
Breast Cancer
|
February 1994 | Phase 2 |
NCT04809766 | Fred Hutchinson Cancer Center|Lonza Walkersville, Inc. |
Metastatic Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8
|
December 14, 2021 | Phase 1 |
NCT00002598 | Memorial Sloan Kettering Cancer Center |
Leukemia
|
June 1994 | Phase 2 |
NCT00002704 | National Cancer Institute (NCI) |
Leukemia
|
January 1996 | Phase 2 |
NCT00003388 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 1999 | Phase 2 |
NCT04301739 | Shanghai Henlius Biotech |
Triple Negative Breast Cancer
|
April 17, 2020 | Phase 3 |
NCT00782379 | Northside Hospital, Inc. |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
October 2008 | Phase 2 |
NCT00445744 | Fred Hutchinson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic Syndrome With Isolated Del(5q)|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
December 2006 | Not Applicable |
NCT02981628 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma
|
June 5, 2017 | Phase 2 |
NCT00755313 | University of California, San Francisco|National Cancer Institute (NCI) |
Breast Cancer|Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment
|
May 2007 | |
NCT00005622 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 1996 | Phase 2 |
NCT00002482 | St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
June 1991 | Phase 1|Phase 2 |
NCT04771871 | University College Hospital, Ibadan|Lagos State University|Obafemi Awolowo University Teaching Hospital|University of Chicago|University of Lagos, Nigeria|University of Ibadan |
Triple Negative Breast Cancer
|
November 29, 2021 | Phase 2 |
NCT05061017 | Diwakar Davar|Zucero Pty Ltd|University of Pittsburgh |
NSCLC|Metastatic Colorectal Carcinoma|Refractory Melanoma
|
October 28, 2021 | Phase 2 |
NCT03169790 | ImmunityBio, Inc. |
Non Hodgkin Lymphoma
|
December 2017 | Phase 1|Phase 2 |
NCT00002616 | University of Illinois at Chicago|National Cancer Institute (NCI) |
Breast Cancer
|
February 1995 | Phase 1 |
NCT00274924 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2006 | Phase 2 |
NCT00301925 | Institute of Cancer Research, United Kingdom |
Breast Cancer
|
December 16, 2005 | Phase 3 |
NCT00002844 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 5, 1991 | Phase 2 |
NCT01163201 | Masonic Cancer Center, University of Minnesota |
Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia in Blast Crisis|Anemia, Refractory, With Excess of Blasts|Chronic Myeloproliferative Disease|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Lymphoma|Large Cell Non-Hodgkin´s Lymphoma|Lymphoblastic Lymphoma|Burkitt´s Lymphoma|High Grade Non-Hodgkin´s Lymphoma
|
January 2014 | Phase 1|Phase 2 |
NCT05008575 | Xinqiao Hospital of Chongqing|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Leukemia, Myeloid, Acute
|
December 23, 2021 | Phase 1 |
NCT00808899 | St. Jude Children´s Research Hospital |
Neuroblastoma
|
December 2008 | Phase 2 |
NCT05554939 | Chinese PLA General Hospital |
Non Hodgkin´s Lymphoma
|
December 1, 2022 | Phase 1|Phase 2 |
NCT00003013 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI) |
Breast Cancer
|
October 1996 | Phase 3 |
NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
|
November 13, 2015 | Phase 2 |
NCT00408005 | National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
January 22, 2007 | Phase 3 |
NCT00079105 | Newcastle-upon-Tyne Hospitals NHS Trust |
Lymphoma
|
January 2004 | Phase 2 |
NCT02623439 | University of California, San Diego |
Hematologic Malignancies
|
July 2012 | Phase 2 |
NCT02953340 | Spectrum Pharmaceuticals, Inc |
Neutropenia|Breast Cancer
|
May 10, 2017 | Phase 3 |
NCT04895761 | Providence Health & Services |
Breast Cancer
|
September 10, 2021 | Phase 1 |
NCT03518242 | Fred Hutchinson Cancer Center|GlaxoSmithKline |
Breast Cancer Female|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
June 6, 2018 | Phase 1 |
NCT01181271 | Massachusetts General Hospital|Dana-Farber Cancer Institute |
Diffuse, Large B-Cell, Lymphoma|Lymphoma, Low-Grade|T-Cell Lymphoma|Mantle-Cell Lymphoma|Hodgkin´s Lymphoma|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic
|
August 2010 | Phase 2 |
NCT00241254 | University Hospital, Bordeaux|Ministry of Health, France |
Multiple Sclerosis, Chronic Progressive
|
December 2005 | Phase 3 |
NCT03885947 | Alla Keyzner|Icahn School of Medicine at Mount Sinai |
Hematological Malignancy|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Hodgkin Lymphoma
|
February 21, 2019 | Phase 1 |
NCT04947501 | Memorial Sloan Kettering Cancer Center |
Neuroblastoma|Pediatric Cancer
|
June 22, 2021 | Early Phase 1 |
NCT02650648 | Memorial Sloan Kettering Cancer Center|Y-mAbs Therapeutics |
Neuroblastoma|High-Risk
|
January 2016 | Phase 1 |
NCT00589238 | National Cancer Centre, Singapore |
Breast Cancer
|
January 2008 | Phase 2 |
NCT00049569 | National Cancer Institute (NCI) |
L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
January 2003 | Not Applicable |
NCT00809341 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
January 2009 | Phase 2 |
NCT00006461 | Children´s Oncology Group|National Cancer Institute (NCI) |
Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
|
October 2000 | Phase 3 |
NCT02609386 | Brooklyn ImmunoTherapeutics, LLC |
Squamous Cell Carcinoma of the Oral Cavity
|
December 2015 | Phase 2 |
NCT01203722 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Hematologic Malignancies
|
September 2010 | Phase 1|Phase 2 |
NCT00795899 | German Breast Group|AGO Study Group |
Breast Cancer
|
January 2002 | Phase 2 |
NCT03585465 | Centre Oscar Lambret|Anticancer Fund, Belgium|Bristol-Myers Squibb|CTD-CNO|ECS-Progastrin SA |
Childhood Solid Tumor
|
March 26, 2019 | Phase 1|Phase 2 |
NCT05351346 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
June 1, 2022 | Phase 3 |
NCT04187898 | Spectrum Pharmaceuticals, Inc |
Neutropenia|Breast Cancer
|
March 11, 2020 | Phase 1 |
NCT00727415 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Chronic Lymphocytic Leukemia
|
February 2008 | Phase 1|Phase 2 |
NCT00601796 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|National Institutes of Health (NIH) |
Lung Cancer
|
October 2006 | Phase 2 |
NCT01350245 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Acute Myeloid Leukemia|Myelodysplastic Syndromes|Biphenotypic Leukemia|Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Plasma Cell Neoplasms|Lymphoma|Hodgkin´s Disease|Aplastic Anemia
|
July 2010 | Phase 2 |
NCT03553537 | Southwest Hospital, China |
Peripheral T-cell Lymphoma
|
June 2018 | Phase 3 |
NCT00176839 | Masonic Cancer Center, University of Minnesota |
Leukemia, Lymphocytic, Acute|AML|MDS
|
June 7, 2000 | Phase 2|Phase 3 |
NCT03448393 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin
|
March 26, 2018 | Phase 1 |
NCT02648282 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme LLC |
Pancreatic Cancer
|
July 18, 2016 | Phase 2 |
NCT00990496 | Milton S. Hershey Medical Center |
Glioblastoma Multiforme
|
September 2009 | Phase 1 |
NCT00004128 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto|National Cancer Institute (NCI) |
Leukemia
|
September 1999 | Phase 3 |
NCT00002521 | Temple University |
Lymphoma
|
February 1993 | Phase 2 |
NCT01140373 | Memorial Sloan Kettering Cancer Center|United States Department of Defense |
Prostate Cancer
|
June 2010 | Phase 1 |
NCT01881789 | Amgen |
Multiple Myeloma
|
October 28, 2013 | Phase 1|Phase 2 |
NCT00004563 | The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI) |
Lung Diseases|Pulmonary Fibrosis|Systemic Scleroderma|Scleroderma, Systemic
|
August 1999 | Phase 3 |
NCT05382338 | Children´s Oncology Group|National Cancer Institute (NCI) |
Medulloblastoma
|
December 9, 2022 | Phase 3 |
NCT01145209 | National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlaxoSmithKline|National Institutes of Health Clinical Center (CC) |
Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia)
|
July 1, 2010 | Phase 2 |
NCT02889523 | The Lymphoma Academic Research Organisation|Epizyme, Inc. |
Lymphoma|DLBCL|Follicular Lymphoma
|
October 2016 | Phase 1|Phase 2 |
NCT02303821 | Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium |
Acute Lymphoblastic Leukemia (ALL)
|
February 16, 2015 | Phase 1 |
NCT01949129 | St. Anna Kinderkrebsforschung|ALL SCTped Forum|European Society for Blood and Marrow Transplantation|ALL-BFM Study Group|Assistance Publique - Hôpitaux de Paris|Dutch Childhood Oncology Group|Swiss Pediatric Oncology Group|Australian & New Zealand Children´s Haematology+Oncology Group |
Acute Lymphoblastic Leukaemia
|
April 2013 | Phase 2|Phase 3 |
NCT00003671 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1998 | Phase 2 |
NCT00420563 | Centre Oscar Lambret |
Cancer
|
September 2006 | Phase 2 |
NCT03329378 | Icahn School of Medicine at Mount Sinai |
Locally Advanced Breast Cancer
|
January 30, 2019 | Phase 2 |
NCT02605421 | Masonic Cancer Center, University of Minnesota |
Neuroblastoma
|
June 2016 | Phase 2 |
NCT00043979 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sarcoma
|
September 19, 2002 | Phase 2 |
NCT04880434 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Mantle Cell Lymphoma
|
April 27, 2021 | Phase 2 |
NCT00004228 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 3 |
NCT03967223 | GlaxoSmithKline |
Neoplasms
|
December 31, 2019 | Phase 2 |
NCT00118274 | Craig L Slingluff, Jr|National Cancer Institute (NCI)|University of Virginia |
Melanoma (Skin)
|
March 2005 | Phase 1|Phase 2 |
NCT00003152 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland |
Lymphoma
|
March 1997 | Phase 3 |
NCT01873833 | University of Southern California|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
July 29, 2013 | Phase 2 |
NCT00525642 | Fudan University |
Breast Neoplasms|Adjuvant|Chemotherapy
|
June 2003 | Phase 2|Phase 3 |
NCT04138979 | First Affiliated Hospital of Harbin Medical University |
Microbiota
|
September 12, 2019 | |
NCT01451489 | Nanjing University School of Medicine |
FSGS
|
October 13, 2011 | Not Applicable |
NCT03100877 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia in Remission|Plasma Cell Myeloma
|
January 2018 | Phase 1|Phase 2 |
NCT05442515 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin
|
November 28, 2022 | Phase 1|Phase 2 |
NCT02883049 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Central Nervous System Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Testicular Leukemia
|
February 27, 2012 | Phase 3 |
NCT00276731 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Neuroblastoma
|
March 1995 | Phase 3 |
NCT00720109 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
July 14, 2008 | Phase 2|Phase 3 |
NCT00070200 | Children´s Oncology Group|National Cancer Institute (NCI) |
Neuroblastoma
|
March 2004 | Phase 1 |
NCT03575234 | Emory University|Bristol-Myers Squibb|Brooklyn ImmunoTherapeutics, LLC |
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
|
July 1, 2020 | Phase 1 |
NCT00003217 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1998 | Phase 1 |
NCT03169764 | ImmunityBio, Inc. |
Head and Neck Squamous Cell Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT01632150 | Bristol-Myers Squibb|AbbVie |
Relapsed and+or Refractory Multiple Myeloma
|
May 2012 | Phase 2 |
NCT00003397 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Lymphoma
|
September 1998 | Phase 2 |
NCT00629499 | SCRI Development Innovations, LLC|Celgene Corporation |
Breast Cancer
|
April 2008 | Phase 2 |
NCT03296137 | Inge Marie Svane|Herlev Hospital |
Cancer
|
October 13, 2017 | Phase 1|Phase 2 |
NCT00381004 | M.D. Anderson Cancer Center|Bayer |
Chronic Lymphocytic Leukemia
|
September 2006 | Phase 2 |
NCT00796562 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Otsuka Pharmaceutical Co., Ltd.|National Center for Research Resources (NCRR) |
MDS|Leukemias|Lymphomas
|
December 2008 | Phase 2 |
NCT01864109 | Memorial Sloan Kettering Cancer Center |
Newly Diagnosed Ewing Sarcoma
|
May 2013 | Phase 2 |
NCT03749850 | UMC Utrecht|Dutch Cancer Society|Center for Translational Molecular Medicine|Vrienden UMC Utrecht |
Metastatic Breast Cancer|Breast Cancer|Breast Neoplasms|Stage IV Breast Cancer|Metastatic Cancer|Invasive Ductal Carcinoma of Female Breast|Invasive Ductal Breast Cancer|Adenocarcinoma Breast
|
March 2021 | Phase 1 |
NCT00526409 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2005 | Phase 4 |
NCT00070083 | British Columbia Cancer Agency|National Cancer Institute (NCI) |
Lymphoma
|
July 2003 | Phase 1 |
NCT01019876 | Columbia University |
Bone Marrow Failure|Osteopetrosis|Fanconi Anemia|Severe Combined Immunodeficiency
|
June 2002 | Phase 2|Phase 3 |
NCT00001832 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Melanoma|Neoplasm Metastasis
|
August 1999 | Phase 2 |
NCT04877613 | University of Pennsylvania |
Metastatic Medullary Thyroid Cancer
|
August 19, 2021 | Phase 1 |
NCT02248597 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Graft Versus Host Disease|Hematopoietic+Lymphoid Cancer
|
February 25, 2015 | Phase 2 |
NCT03952572 | Peking University |
Peripheral T-cell Lymphoma
|
May 10, 2019 | Phase 3 |
NCT00357500 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Boston Children´s Hospital |
Central Nervous System Tumor, Pediatric|Leukemia|Lymphoma|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific
|
January 2005 | Phase 2 |
NCT01313884 | Stanford University|Amgen |
Bone Cancer|Ewing´s Sarcoma
|
May 2011 | Phase 2 |
NCT01191957 | Gruppo Italiano Trapianto di Midollo Osseo |
Acute Myeloid Leukemia (AML)
|
January 2008 | Phase 3 |
NCT02566993 | PharmaMar |
Small-cell Lung Cancer
|
August 30, 2016 | Phase 3 |
NCT02062359 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer|Metastatic Melanoma
|
February 2014 | Phase 2 |
NCT02082405 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
April 2015 | Phase 2 |
NCT03110640 | First Affiliated Hospital of Wenzhou Medical University|Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Hematopoietic+Lymphoid Cancer|Refractory Chronic Lymphocytic Leukemia
|
October 1, 2016 | Phase 1 |
NCT01349101 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematological Malignancies
|
February 10, 2011 | Phase 2 |
NCT00313235 | Baylor Research Institute |
Malignant Melanoma Stage IV
|
March 2006 | Phase 1|Phase 2 |
NCT04090775 | Rampart Health, L.L.C. |
Metastatic Prostatic Adenocarcinoma
|
June 28, 2019 | Phase 2 |
NCT03647423 | ImmunityBio, Inc. |
Chordoma|Unresectable Malignant Neoplasm
|
August 31, 2018 | Phase 1|Phase 2 |
NCT03719105 | New York Medical College|University of Alabama at Birmingham |
NK-Cell Lymphoma|NK-Cell Leukemia|Peripheral T Cell Lymphoma
|
March 1, 2019 | Early Phase 1 |
NCT02486952 | Hoffmann-La Roche|Serbian Lymphoma Group |
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin´s Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
August 2005 | |
NCT04037566 | Xijing Hospital|Xi´An Yufan Biotechnology Co.,Ltd |
Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive
|
August 2019 | Phase 1 |
NCT00005603 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2000 | Phase 3 |
NCT02251548 | Dana-Farber Cancer Institute|Pharmacyclics LLC.|The Leukemia and Lymphoma Society|Blood Cancer Research Partnership |
Chronic Lymphocytic Leukemia|Leukemia
|
October 2014 | Phase 2 |
NCT01341496 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancy
|
April 18, 2011 | Phase 1 |
NCT05158608 | National Research Center for Hematology, Russia |
Graft Versus Host Disease|Hematologic Malignancy|Cyclophosphamide Adverse Reaction
|
January 1, 2022 | Phase 3 |
NCT01746992 | Ruijin Hospital |
ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma
|
September 2012 | Phase 4 |
NCT05303727 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Neuroblastoma
|
August 2022 | Phase 2 |
NCT00040937 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma
|
June 2002 | Phase 2 |
NCT00003877 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer
|
September 1998 | Phase 1|Phase 2 |
NCT01144403 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
June 2010 | Phase 2 |
NCT02423928 | Alden Cancer Therapy II|Haukeland University Hospital|Norwegian Radium Hospital |
Prostate Cancer
|
May 2015 | Phase 1 |
NCT00039481 | National Cancer Institute (NCI) |
Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol Specific
|
November 2002 | Phase 1 |
NCT00052351 | National Cancer Institute (NCI) |
Breast Cancer
|
September 2002 | Phase 2 |
NCT01319981 | M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc |
Leukemia
|
March 5, 2013 | Phase 2 |
NCT00326417 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Anemia, Aplastic
|
January 2006 | Phase 1|Phase 2 |
NCT03003520 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
February 28, 2017 | Phase 2 |
NCT00569985 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
June 2007 | Phase 1 |
NCT00396682 | Hannover Medical School |
Advanced HCC
|
February 2007 | Phase 3 |
NCT00999986 | Huazhong University of Science and Technology |
Genital Wart
|
January 2007 | Phase 3 |
NCT03991884 | University of Washington|Pfizer |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma
|
September 24, 2019 | Phase 1 |
NCT03029273 | Guangzhou Institute of Respiratory Disease|Xiangxue Life Science Research Center|Guangdong Xiangxue Precision Medical Technology Co., Ltd.|Xiangxue Pharmaceutical |
Lung Cancer, Nonsmall Cell, Recurrent
|
March 21, 2017 | Phase 1 |
NCT04540692 | Latin American Cooperative Oncology Group|Brazilian Breast Cancer Study Group (GBECAM) |
Breast Cancer
|
January 12, 2021 | Phase 3 |
NCT02750254 | Washington University School of Medicine |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia
|
June 27, 2016 | Phase 1 |
NCT00336024 | Children´s Oncology Group|National Cancer Institute (NCI) |
Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
|
October 22, 2007 | Phase 3 |
NCT00002756 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 1996 | Phase 2 |
NCT04049513 | Malaghan Institute of Medical Research|Wellington Zhaotai Therapies Limited (WZTL) |
Lymphomas Non-Hodgkin´s B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)
|
October 11, 2019 | Phase 1 |
NCT01861561 | Mahidol University |
Renal Insufficiency|Infection
|
May 2013 | Phase 4 |
NCT04182568 | Xijing Hospital |
Breast Cancer
|
August 21, 2019 | Phase 4 |
NCT01031030 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|National Cancer Institute (NCI) |
Breast Cancer
|
November 1997 | Phase 3 |
NCT04389073 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Huanxing Cancer Hospital |
Metastatic Breast Cancer
|
April 1, 2020 | Phase 2 |
NCT02567435 | National Cancer Institute (NCI) |
Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma
|
May 23, 2016 | Phase 3 |
NCT00004169 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
November 1993 | Phase 2 |
NCT00020943 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
June 2001 | Phase 2 |
NCT04081389 | Roswell Park Cancer Institute |
Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
|
December 6, 2019 | Phase 1 |
NCT03837873 | Institute of Hematology & Blood Diseases Hospital |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma
|
January 21, 2019 | Phase 2 |
NCT02065154 | University of Alabama at Birmingham |
Leukemia|Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Severe Aplastic Anemia|Allogeneic Transplant
|
August 27, 2013 | Phase 2 |
NCT03241940 | Crystal Mackall, MD|Stanford University |
B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
October 20, 2017 | Phase 1 |
NCT00002630 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
June 1993 | Phase 2 |
NCT00091104 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Melanoma (Skin)
|
July 2004 | Phase 1 |
NCT00165451 | Dana-Farber Cancer Institute |
Neoplasms
|
June 2001 | Phase 2 |
NCT04223765 | UNC Lineberger Comprehensive Cancer Center |
Mantle Cell Lymphoma|Follicular Lymphoma|Splenic Marginal Zone Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma
|
November 12, 2020 | Phase 1 |
NCT04714372 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia|Myeloid Leukemia|Monocytic Leukemia
|
November 3, 2021 | Phase 1 |
NCT04390399 | ImmunityBio, Inc. |
Pancreatic Cancer
|
July 21, 2020 | Phase 2 |
NCT01696877 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|David H. Koch Charitable Foundation|BioSante Pharmaceuticals |
Prostate Cancer Adenocarcinoma in Situ
|
January 18, 2013 | Phase 1|Phase 2 |
NCT03267680 | University of Southern California|National Cancer Institute (NCI)|Brooklyn ImmunoTherapeutics, LLC |
Cervical Squamous Cell Carcinoma In Situ|Vulvar High Grade Squamous Intraepithelial Lesion
|
November 8, 2017 | Phase 2 |
NCT00004114 | Jonsson Comprehensive Cancer Center |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
Phase 1 | |
NCT05528887 | The Affiliated People´s Hospital of Ningbo University|UTC Therapeutics Inc. |
Relapsed+Refractory Hematological Malignancies|Lymphoma|Myeloma|Leukemia
|
September 16, 2021 | Phase 1 |
NCT00562640 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
October 16, 2007 | Phase 1 |
NCT02806375 | St. Petersburg State Pavlov Medical University |
Primary Myelofibrosis|Myeloproliferative Disorders
|
January 2016 | Phase 1|Phase 2 |
NCT00589901 | Fudan University |
Breast Cancer
|
August 2006 | Phase 2 |
NCT00281879 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms|Unusual Cancers of Childhood
|
February 2006 | Phase 2 |
NCT00601003 | Wake Forest University Health Sciences|Bayer |
Neuroblastoma|Medulloblastoma
|
February 2008 | Phase 2 |
NCT00003893 | University Hospital Birmingham|National Cancer Institute (NCI) |
Breast Cancer
|
July 1998 | Phase 3 |
NCT00801411 | National Cancer Centre, Singapore|National Cancer Institute (NCI) |
Breast Cancer
|
October 2008 | Phase 2 |
NCT03879382 | Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital |
POMES Syndrome|Relapsed and Refractory POMES Syndrome
|
February 27, 2019 | Phase 1 |
NCT01539083 | Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
January 13, 2012 | Phase 3 |
NCT05616468 | The Affiliated Hospital of Xuzhou Medical University|Guangzhou Bioresette Biomedical Technology Co., Ltd. |
Nasopharyngeal Carcinoma
|
November 30, 2022 | Early Phase 1 |
NCT02115204 | West German Study Group|AGO Germany |
Breast Cancer
|
June 2000 | Phase 3 |
NCT01329640 | Instituto do Cancer do Estado de São Paulo|Fundação Faculdade de Medicina |
Locally Advanced HER2-positive Breast Cancer
|
September 2010 | Phase 2 |
NCT00006379 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Precancerous+Nonmalignant Condition|Small Intestine Cancer
|
June 2000 | Phase 2 |
NCT03615105 | Memorial Sloan Kettering Cancer Center |
Acute Lymphoid Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML)|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
July 25, 2018 | Phase 2 |
NCT03318016 | University of Colorado, Denver |
Acute Myeloid Leukemia|Relapsed+Refractory Acute Myeloid Leukemia
|
December 15, 2017 | Phase 1 |
NCT01905943 | Hoffmann-La Roche |
Chronic Lymphocytic Leukemia
|
November 4, 2013 | Phase 3 |
NCT00669812 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma|Small Intestine Cancer
|
February 2008 | Phase 2 |
NCT00208923 | Emory University |
Hematologic Malignancies
|
July 1998 | Phase 2 |
NCT02412228 | John L. Reagan|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Brown University |
Multiple Myeloma
|
August 2015 | Phase 2 |
NCT02436707 | Canadian Cancer Trials Group|Janssen, LP|Roche Pharma AG|Karyopharm Therapeutics Inc |
Lymphoma
|
May 5, 2015 | Phase 2 |
NCT02161783 | Masonic Cancer Center, University of Minnesota |
Primary Graft Failure|Secondary Graft Failure
|
October 2014 | |
NCT02280811 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Vaginal Cancer|Cervical Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer
|
October 14, 2014 | Phase 1|Phase 2 |
NCT03517137 | European Organisation for Research and Treatment of Cancer - EORTC |
Advanced Hodgkin Lymphoma
|
August 1, 2019 | Phase 2 |
NCT04025593 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 17, 2019 | Phase 2 |
NCT00751517 | University of Parma |
Wegener´s Granulomatosis|Churg-Strauss Syndrome|Microscopic Polyangiitis|Polyarteritis Nodosa
|
Phase 2 | |
NCT00049413 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Leukemia|Lymphoma
|
June 2002 | Phase 2 |
NCT00107380 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2005 | Phase 2 |
NCT03252600 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)|Bristol-Myers Squibb|Multiple Myeloma Research Consortium |
Recurrent Primary Amyloidosis
|
August 25, 2017 | Phase 2 |
NCT00544115 | City of Hope Medical Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases|Precancerous+Nonmalignant Condition
|
October 16, 2001 | Phase 2 |
NCT03220022 | National Cancer Institute (NCI) |
AIDS-Related Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
November 3, 2017 | Phase 1 |
NCT01275677 | National Cancer Institute (NCI)|NRG Oncology |
HER2+Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
January 6, 2011 | Phase 3 |
NCT00067002 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cellgenix |
Leukemia, Lymphocytic, Acute|Leukemia, Myelocytic, Acute|Leukemia, Myeloid, Chronic|Lymphoma, Non-Hodgkin
|
April 2003 | Phase 2 |
NCT03860844 | Sanofi |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
August 6, 2019 | Phase 2 |
NCT00317876 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Fanconi Anemia
|
June 1998 | Phase 1 |
NCT00825149 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
February 2009 | Phase 1 |
NCT00083915 | University of Arkansas |
Multiple Myeloma
|
June 2001 | Phase 3 |
NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genzyme, a Sanofi Company |
Myelodysplastic Syndrome|Acute Myeloid Leukemia|Myeloproliferative Disorders|Acute Lymphocytic Leukemia|Acute Promyelocytic Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia
|
September 1, 2007 | Phase 1 |
NCT02724579 | Children´s Oncology Group|National Cancer Institute (NCI) |
Medulloblastoma
|
October 2, 2017 | Phase 2 |
NCT01959477 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK+T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia+Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides+Sezary Syndrome|Stage IB Mycosis Fungoides+Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia+Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides+Sezary Syndrome|Stage IIB Mycosis Fungoides+Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides+Sezary Syndrome|Stage IIIB Mycosis Fungoides+Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides+Sezary Syndrome|Stage IVB Mycosis Fungoides+Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
March 2014 | Early Phase 1 |
NCT04626765 | Hebei Senlang Biotechnology Inc., Ltd.|The Second Hospital of Hebei Medical University |
Childhood Acute Lymphoblastic Leukemia
|
April 1, 2020 | Early Phase 1 |
NCT03029403 | University Health Network, Toronto|Merck Sharp & Dohme LLC|ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Advanced Cancer|Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer
|
February 12, 2018 | Phase 2 |
NCT00425802 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
November 28, 2006 | Phase 2 |
NCT00041288 | University of Texas Southwestern Medical Center |
Leukemia|Lymphoma
|
October 2001 | Phase 2 |
NCT02574728 | Emory University|Cannonball Kids´ Cancer Foundation|Hyundai Hope On Wheels |
Cancer
|
June 2015 | Phase 2 |
NCT03563144 | ImmunityBio, Inc. |
Metastatic Pancreatic Cancer
|
August 2018 | Phase 2 |
NCT02419495 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma
|
June 26, 2015 | Phase 1 |
NCT01548573 | University of Iowa|National Cancer Institute (NCI) |
Multiple Myeloma
|
May 2012 | Phase 2 |
NCT02858804 | Institute of Hematology & Blood Diseases Hospital |
Mantle Cell Lymphoma
|
January 2016 | Phase 4 |
NCT00002516 | University Hospital Muenster|Medical Research Council|National Cancer Institute (NCI) |
Sarcoma
|
July 1992 | Phase 3 |
NCT00349778 | Stanford University |
Multiple Myeloma
|
August 2006 | Phase 2 |
NCT05420467 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
NCT00203502 | University of Arkansas|Genentech, Inc. |
Breast Cancer
|
September 2005 | Phase 2 |
NCT01048892 | Children´s Oncology Group|National Cancer Institute (NCI) |
Adrenocortical Carcinoma|Gastrointestinal Carcinoid Tumor|Kidney Cancer|Neuroblastoma|Retinoblastoma|Sarcoma
|
September 2009 | Phase 1 |
NCT03982771 | Peking Union Medical College Hospital |
Idiopathic Multicentric Castleman´s Disease
|
January 1, 2019 | Phase 2 |
NCT04713956 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|First Affiliated Hospital of Guangxi Medical University |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
January 15, 2021 | Phase 2|Phase 3 |
NCT00305682 | Masonic Cancer Center, University of Minnesota |
Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes
|
June 2005 | Phase 2 |
NCT00025545 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 1996 | Phase 2 |
NCT00004231 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
NCT00641381 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
May 10, 2000 | Phase 1 |
NCT03096782 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chemotherapy-Related Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Minimal Residual Disease|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Myelodysplastic Syndrome|Small Lymphocytic Lymphoma|Therapy-Related Myelodysplastic Syndrome
|
October 13, 2017 | Phase 2 |
NCT01174121 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer|Metastatic Ovarian Cancer|Metastatic Breast Carcinoma|Metastatic Endocrine Tumors+ Neuroendocrine Tumors
|
August 26, 2010 | Phase 2 |
NCT00526305 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2000 | Phase 4 |
NCT02951819 | Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 9, 2016 | Phase 2 |
NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
August 26, 2011 | Phase 1|Phase 2 |
NCT01363128 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|Burkitt Leukemia|Burkitt Lymphoma|CD20 Positive|Childhood Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma
|
July 12, 2011 | Phase 2 |
NCT00003203 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumors|Central Nervous System Tumors|Neuroblastoma
|
March 1998 | Phase 2 |
NCT03015974 | Peking University First Hospital|Nanjing PLA General Hospital|Beijing Children´s Hospital|Central South University|The Children´s Hospital of Zhejiang University School of Medicine|First Affiliated Hospital, Sun Yat-Sen University|Tongji Hospital|Hunan Children´s Hospital|Shanghai Children´s Hospital|Nanjing Children´s Hospital|Children´s Hospital of Chongqing Medical University|Shandong Provincial Hospital|Fuzhou General Hospital|Second Affiliated Hospital of Wenzhou Medical University|Children´s Hospital of Hebei Province|Guangzhou Women and Children´s Medical Center|Jiangxi Province Children´s Hospital|Guangzhou First People´s Hospital|Xian Children´s Hospital|Capital Institute of Pediatrics, China|The First Hospital of Jilin University|Wuhan Women and Children´s Medical Center|Tianjin Children´s Hospital|Chengdu Women´s and Children´s Central Hospital|The First People´s Hospital of Yunnan |
IgA Nephropathy|Proteinuria in Nephrotic Range|Immunosuppressive Treatment
|
January 2016 | |
NCT02444728 | Chinese SLE Treatment And Research Group|Peking Union Medical College Hospital |
Thrombocytopenia
|
July 2015 | Phase 3 |
NCT04067102 | Hebei Medical University Fourth Hospital |
Triple Negative Breast Cancer
|
May 10, 2019 | Not Applicable |
NCT02456350 | Shenzhen Second People´s Hospital|Shenzhen Institute for Innovation and Translational Medicine |
Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|Lymphoma
|
April 2015 | Phase 1 |
NCT00003680 | Scottish Cancer Therapy Network|National Cancer Institute (NCI) |
Breast Cancer
|
November 1998 | Phase 3 |
NCT01415765 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, Diffuse Large-Cell B-cell|Diffuse, Large B-cell Lymphoma|Lymphoma, Diffuse Large-Cell|Large-Cell Lymphoma, Diffuse
|
July 15, 2011 | Phase 1|Phase 2 |
NCT02199041 | St. Jude Children´s Research Hospital |
Hematological Malignancies
|
July 11, 2014 | Phase 2 |
NCT02529813 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ziopharm Oncology |
Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|CD19 Positive|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
December 16, 2015 | Phase 1 |
NCT01414855 | Genentech, Inc. |
Lymphoma, B-Cell
|
August 31, 2011 | Phase 2 |
NCT00006054 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Immunologic Deficiency Syndromes|Chediak-Higashi Syndrome|Common Variable Immunodeficiency|Graft Versus Host Disease|X-Linked Lymphoproliferative Syndrome|Familial Erythrophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|X-linked Agammaglobulinemia|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Hyper IgM Syndrome|Severe Combined Immunodeficiency|Leukocyte Adhesion Deficiency Syndrome|Virus-Associated Hemophagocytic Syndrome
|
March 2000 | Not Applicable |
NCT00061893 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
April 2004 | Phase 2 |
NCT03853044 | Ruijin Hospital |
Angioimmunoblastic T-cell Lymphoma
|
December 29, 2018 | Phase 2 |
NCT03555851 | Wake Forest University Health Sciences |
Leukemia, Not Otherwise Specified|Leukemia, Other
|
July 13, 2018 | |
NCT05000450 | Allogene Therapeutics |
Relapsed+Refractory Multiple Myeloma
|
June 6, 2021 | Phase 1|Phase 2 |
NCT02360111 | Memorial Sloan Kettering Cancer Center |
Leukemia|Myelodysplastic Syndrome|Non-Hodgkin´s Lymphoma
|
February 2015 | Not Applicable |
NCT01312376 | Abramson Cancer Center of the University of Pennsylvania |
Ovarian Carcinoma|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
March 2011 | Phase 1 |
NCT02566395 | Northwell Health|New York Blood Center |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia|Non-Hodgkin Lymphoma|Hodgkin Lymphoma
|
December 2014 | Phase 3 |
NCT05498896 | Queen Mary University of London|Westdeutsche Studiengruppe GmbH (WSG)|MedSIR|Hoffmann-La Roche |
Triple Negative Breast Cancer
|
December 19, 2018 | Phase 2 |
NCT00003899 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
January 1999 | Phase 1 |
NCT04146298 | Changhai Hospital |
Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Ductal Adenocarcinoma|Advanced Cancer
|
October 21, 2021 | Phase 1|Phase 2 |
NCT03105336 | Kite, A Gilead Company|Gilead Sciences |
Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-Hodgkin Lymphoma
|
June 20, 2017 | Phase 2 |
NCT03643276 | Martin Schrappe|Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Schleswig-Holstein |
Acute Lymphoblastic Leukemia, Pediatric
|
July 15, 2018 | Phase 3 |
NCT00567554 | German Breast Group|AGO Study Group |
Breast Cancer
|
October 2007 | Phase 3 |
NCT01540110 | National Cancer Centre, Singapore |
Breast Cancer
|
August 11, 2010 | Phase 2 |
NCT04923893 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 19, 2021 | Phase 3 |
NCT00509496 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Skin Cancer|Melanoma
|
June 2007 | Phase 2 |
NCT00201721 | Ohio State University Comprehensive Cancer Center|Astex Pharmaceuticals, Inc. |
B-Chronic Lymphocytic Leukemia
|
July 2002 | Phase 2 |
NCT01750073 | University of Nebraska|National Cancer Institute (NCI) |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
December 2012 | Phase 2 |
NCT03329248 | ImmunityBio, Inc. |
Pancreatic Cancer
|
November 6, 2017 | Phase 1|Phase 2 |
NCT04824092 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
May 11, 2021 | Phase 3 |
NCT02637375 | University of Chicago |
Breast Cancer
|
May 2016 | Not Applicable |
NCT03849651 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)|NK-Cell Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma (NHL)|Juvenile Myelomonocytic Leukemia (JMML)|Chronic Myeloid Leukemia (CML)
|
January 31, 2019 | Phase 2 |
NCT00051311 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hematologic Neoplasms
|
January 3, 2003 | Phase 2 |
NCT03373708 | Zhiyong Yu|Shandong Cancer Hospital and Institute |
Breast Cancer|Chemotherapy|Endocrine Breast Diseases
|
December 20, 2017 | Phase 2|Phase 3 |
NCT03958656 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myeloma-Multiple|Myeloma, Plasma-Cell
|
June 13, 2019 | Phase 1 |
NCT00787761 | Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia |
Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
April 2007 | Phase 2 |
NCT00547196 | City of Hope Medical Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
August 16, 2005 | Not Applicable |
NCT00540644 | Attaya Suvannasankha|Celgene|Indiana University |
Multiple Myeloma
|
October 2007 | Phase 2 |
NCT02383212 | Regeneron Pharmaceuticals|Sanofi |
Advanced Cancer|Advanced Malignancies
|
February 2, 2015 | Phase 1 |
NCT01176006 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
DOCK8 Deficiency
|
October 5, 2010 | Phase 2 |
NCT05122221 | Corregene Biotechnology Co., Ltd |
Cervical Cancer|Anal Cancer|Head and Neck Cancers
|
July 17, 2022 | Phase 1 |
NCT00544219 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
September 2007 | Not Applicable |
NCT02641847 | Fudan University |
Triple Negative Breast Cancer|Breast Cancer
|
July 2015 | Phase 2|Phase 3 |
NCT00615602 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
October 2004 | Phase 3 |
NCT02950051 | German CLL Study Group|Janssen-Cilag Ltd.|Hoffmann-La Roche|AbbVie|Stichting Hemato-Oncologie voor Volwassenen Nederland|Nordic CLL Study Group (NCLLSG)|Swiss Group for Clinical Cancer Research|Cancer Trials Ireland|Israeli CLL Study Group |
Chronic Lymphocytic Leukemia
|
December 13, 2016 | Phase 3 |
NCT05625594 | City of Hope Medical Center|National Cancer Institute (NCI) |
Central Nervous System Lymphoma
|
December 30, 2022 | Phase 1 |
NCT00613457 | Associazione Italiana Ematologia Oncologia Pediatrica |
Leukemia
|
September 2000 | Phase 3 |
NCT00003595 | National Cancer Institute (NCI) |
Lymphoma
|
January 1999 | Phase 3 |
NCT00427336 | M.D. Anderson Cancer Center |
Aplastic Anemia
|
December 2000 | Not Applicable |
NCT04803201 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Follicular T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Peripheral T-Cell Lymphoma, Not Otherwise Specified
|
July 30, 2021 | Phase 2 |
NCT02328950 | Fujian Medical University |
Myelodysplastic Syndromes|Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
December 2014 | |
NCT02768701 | UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer
|
October 18, 2016 | Phase 2 |
NCT00052936 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
January 2001 | Phase 3 |
NCT00004906 | Hackensack Meridian Health|National Cancer Institute (NCI) |
Breast Cancer
|
October 1999 | Phase 2 |
NCT00003060 | Louisiana State University Health Sciences Center Shreveport |
Melanoma (Skin)
|
March 1995 | Phase 1 |
NCT02120157 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Myeloablative Conditioning|HLA-mismatched Bone Marrow Transplantation|Graft Survival|Transplantation, Bone Marrow
|
July 2, 2015 | Phase 2 |
NCT01462253 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Acute Lymphoblastic Leukemia
|
October 2012 | Phase 2 |
NCT00513188 | University of Miami |
Lymphoma
|
February 2007 | Not Applicable |
NCT00021255 | Sanofi|Cancer International Research Group (CIRG) |
Breast Neoplasms
|
April 2001 | Phase 3 |
NCT00722098 | Baylor Research Institute |
Malignant Melanoma Stage IV
|
June 2008 | Phase 2 |
NCT00546377 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 1|Phase 2 |
NCT01760226 | Baylor College of Medicine|National Cancer Institute (NCI) |
Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma
|
January 2013 | Early Phase 1 |
NCT00689156 | Danish Breast Cancer Cooperative Group|Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning|Sanofi|Dako |
Breast Neoplasms
|
June 2008 | Phase 3 |
NCT04264078 | Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People´s Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|Central South University|The First Affiliated Hospital of Kunming Medical College|The General Hospital of Western Theater Command|Second Affiliated Hospital of Xi´an Jiaotong University|Nanfang Hospital of Southern Medical University|Fujian Medical University Union Hospital|The First Affiliated Hospital of Anhui Medical University|Tang-Du Hospital |
T-cell Leukemia|T-cell Lymphoma
|
March 1, 2021 | Early Phase 1 |
NCT00924287 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Cancer
|
November 2008 | Phase 1|Phase 2 |
NCT03959241 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Acute Leukemia|Chronic Myelogenous Leukemia (CML)|Myelodysplasia|Lymphoma
|
June 25, 2019 | Phase 3 |
NCT00039546 | Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) |
Breast Cancer
|
August 2001 | Phase 3 |
NCT00210470 | Brooklyn ImmunoTherapeutics, LLC |
Squamous Cell Carcinoma of the Head and Neck
|
July 2005 | Phase 2 |
NCT00451178 | Eli Lilly and Company |
Lymphoma
|
May 2007 | Phase 2 |
NCT02897050 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
September 2016 | Phase 2 |
NCT00070564 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
November 2003 | Phase 3 |
NCT00083031 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Genentech, Inc. |
Breast Cancer
|
July 2003 | Phase 2 |
NCT02605460 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
February 2014 | Phase 2 |
NCT01093235 | Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI) |
Breast Cancer|Cardiac Toxicity|Perioperative+Postoperative Complications
|
April 2009 | Phase 3 |
NCT00715208 | Millennium Pharmaceuticals, Inc. |
Relapsed Follicular Lymphoma
|
September 2008 | Phase 2 |
NCT00014508 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
April 2001 | Phase 2 |
NCT00923845 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Renal Cell Carcinoma|Graft-Versus-Host Disease|Engraftment Syndrome
|
March 1, 2008 | Phase 2 |
NCT00072566 | National Cancer Institute (NCI) |
Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma|Stage IV Ovarian Cancer
|
December 2003 | Phase 2 |
NCT05016063 | Xinqiao Hospital of Chongqing|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Leukemia, Myeloid, Acute
|
September 1, 2021 | Early Phase 1 |
NCT01481194 | Vejle Hospital|The University of Hong Kong |
Multiple Myeloma
|
November 2011 | Phase 2 |
NCT00005892 | Fairview University Medical Center|Office of Rare Diseases (ORD) |
Fanconi´s Anemia|Myelodysplastic Syndromes|Leukemia, Nonlymphocytic, Acute|Leukemia, Lymphocytic, Acute
|
March 2000 | Not Applicable |
NCT03233854 | Crystal Mackall, MD|California Institute for Regenerative Medicine (CIRM)|Stanford University |
B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive
|
September 1, 2017 | Phase 1 |
NCT01955434 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 2013 | Phase 2 |
NCT01008462 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
B-Cell Prolymphocytic Leukemia|Hypodiploidy|Loss of Chromosome 17p|Plasma Cell Leukemia|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|t(14;16)|t(4;14)|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia
|
March 18, 2010 | Phase 2 |
NCT02070406 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 17, 2014 | Phase 1 |
NCT01775475 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma
|
September 15, 2016 | Phase 2 |
NCT00578344 | Tami D. John|Baylor College of Medicine|The Methodist Hospital Research Institute |
Sickle Cell Disease|Hemoglobin SC
|
July 2005 | Not Applicable |
NCT00002798 | National Cancer Institute (NCI) |
Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Anemia With Ringed Sideroblasts|Secondary Myelodysplastic Syndromes|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
August 1996 | Phase 3 |
NCT01670084 | Mayo Clinic |
B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia
|
December 2012 | Phase 2 |
NCT02742051 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
June 2016 | Phase 2 |
NCT00144807 | Lymphoma Study Association |
Diffuse Large Cell Lymphoma
|
December 2003 | Phase 2 |
NCT05176470 | Richard Wu|Iovance Biotherapeutics, Inc.|Ohio State University Comprehensive Cancer Center |
Locally Advanced Melanoma|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Stage IV Melanoma
|
July 1, 2022 | Phase 1 |
NCT02926053 | Inge Marie Svane|Herlev Hospital |
Metastatic Renal Cell Carcinoma
|
December 2016 | Phase 1 |
NCT04418219 | Thomas Jefferson University |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Refractory Breast Carcinoma
|
December 21, 2020 | Phase 1|Phase 2 |
NCT00004907 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 1|Phase 2 |
NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
March 28, 2018 | Phase 2 |
NCT04974996 | ADC Therapeutics S.A. |
Diffuse Large B-Cell Lymphoma
|
February 1, 2022 | Phase 1 |
NCT01146834 | Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
March 2011 | Phase 3 |
NCT00276809 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
June 2001 | Phase 2 |
NCT03528421 | Beijing Immunochina Medical Science & Technology Co., Ltd.|Peking University Cancer Hospital & Institute |
Non Hodgkin Lymphoma
|
May 22, 2018 | Phase 1 |
NCT00005985 | Masonic Cancer Center, University of Minnesota |
Lymphoma
|
August 2000 | Phase 2 |
NCT02366546 | Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd. |
Solid Tumors
|
March 2015 | Phase 1 |
NCT00003270 | Roswell Park Cancer Institute |
Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
September 4, 1997 | Phase 2 |
NCT00958854 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
NCT02419742 | Hoffmann-La Roche |
Breast Cancer
|
August 18, 2015 | Phase 4 |
NCT01099436 | Borstkanker Onderzoek Groep|Dutch Cancer Society|Amgen|Sanofi|Novartis |
Breast Cancer
|
April 2010 | Phase 3 |
NCT00365365 | Sanofi |
Breast Cancer
|
August 2006 | Phase 2 |
NCT00265889 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 2002 | Phase 2 |
NCT01119066 | Memorial Sloan Kettering Cancer Center |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Multiple Myeloma
|
May 3, 2010 | Phase 2 |
NCT02782754 | Samsung Medical Center |
Intracranial Germinoma
|
January 2013 | Phase 2 |
NCT02581007 | Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia |
Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Hodgkin´s Lymphoma|Non-Hodgkin´s Lymphoma|Myelofibrosis|CMML|Multiple Myeloma
|
October 26, 2015 | Phase 2 |
NCT00003032 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Breast Cancer
|
April 25, 1997 | Phase 3 |
NCT02627573 | St. Petersburg State Pavlov Medical University |
Leukemia, Chronic Myeloid|Myelodysplastic Syndromes|Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
|
July 2015 | Phase 2 |
NCT00003631 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
August 1998 | Phase 2 |
NCT03287674 | Inge Marie Svane|Herlev Hospital |
Metastatic Ovarian Cancer
|
October 9, 2017 | Phase 1|Phase 2 |
NCT03161054 | Fondazione Italiana Linfomi ONLUS |
Aggressive Non-Hodgkin Lymphoma
|
September 12, 2017 | Phase 2 |
NCT04135092 | National Institutes of Health Clinical Center (CC) |
|
||
NCT03550781 | Chinese Academy of Medical Sciences, Fuwai Hospital |
Takayasu Arteritis|Anti-Inflammatory Agents
|
June 1, 2018 | Phase 2|Phase 3 |
NCT00981708 | University of Athens|Hellenic Cooperative Oncology Group |
Amyloidosis
|
February 2008 | Phase 1|Phase 2 |
NCT03126864 | M.D. Anderson Cancer Center|Intrexon Corporation |
Hematopoietic+Lymphoid Cancer|Acute Myeloid Leukemia
|
August 4, 2017 | Phase 1 |
NCT04893915 | Washington University School of Medicine|Wugen, Inc. |
Relapsed Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
June 30, 2022 | Phase 2 |
NCT04377932 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor
|
December 8, 2021 | Phase 1 |
NCT00003927 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 18, 1999 | Phase 1 |
NCT00134004 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
October 2004 | Phase 2 |
NCT00002488 | Ottawa Regional Cancer Centre|National Cancer Institute (NCI) |
Lymphoma
|
December 1991 | Phase 2 |
NCT00281983 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
June 2000 | Phase 1|Phase 2 |
NCT00756470 | M.D. Anderson Cancer Center|GlaxoSmithKline |
Breast Cancer
|
October 2008 | Phase 2 |
NCT05578976 | AbbVie|Genmab |
Diffuse Large B-Cell Lymphoma
|
February 5, 2023 | Phase 3 |
NCT00002501 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
October 1992 | Phase 2 |
NCT01992653 | Genentech, Inc. |
Lymphoma, Non Hodgkin
|
November 29, 2013 | Phase 1|Phase 2 |
NCT00531453 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Multiple Myeloma
|
October 2007 | Phase 2 |
NCT00083681 | University of Arkansas |
Multiple Myeloma
|
June 1998 | Phase 2 |
NCT00861705 | National Cancer Institute (NCI) |
Male Breast Carcinoma|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
May 15, 2009 | Phase 2 |
NCT00206388 | Baylor College of Medicine|New Approaches to Neuroblastoma Therapy Consortium |
NEUROBLASTOMA
|
April 2005 | Phase 1 |
NCT00002599 | Medical Research Council|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1994 | Phase 3 |
NCT05624554 | Merck Sharp & Dohme LLC |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia
|
December 22, 2022 | Phase 3 |
NCT01303887 | University of Liverpool|Liverpool University Hospitals NHS Foundation Trust|Cancer Research UK|Roche Pharma AG |
Follicular Lymphoma
|
October 2009 | Phase 3 |
NCT00750815 | H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. |
Multiple Myeloma
|
September 2008 | Phase 1|Phase 2 |
NCT00002989 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
March 1997 | Phase 3 |
NCT01814046 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Ocular Melanoma|Metastatic Uveal Melanoma
|
March 1, 2013 | Phase 2 |
NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute |
Non-Hodgkin´s Lymphoma|Acute Leukemia in Remission|Chronic Myeloid Leukemia|Primary Myelofibrosis|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Hodgkin Lymphoma|Multiple Myeloma
|
January 31, 2017 | Phase 1 |
NCT00002837 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Breast Cancer
|
September 1995 | Phase 1|Phase 2 |
NCT01220297 | Stanford University |
Hematologic Diseases|Acute-graft-versus-host Disease|Leukemia|Non-Hodgkin Lymphoma (NHL)|Hodgkin Lymphoma
|
August 2006 | Phase 2 |
NCT00450385 | University of Miami |
Lymphoma
|
April 24, 2007 | Phase 2 |
NCT04759586 | National Cancer Institute (NCI) |
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
June 7, 2021 | Phase 3 |
NCT00134017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
June 2004 | Phase 2 |
NCT01903330 | Epitopoietic Research Corporation|University of California, Irvine |
Glioblastoma|Gliosarcoma
|
March 2014 | Phase 2 |
NCT00005596 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
NCT04899570 | Peking Union Medical College Hospital |
Intravascular Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
NCT05289167 | NYU Langone Health |
Graft-versus-host Disease
|
March 13, 2022 | Phase 1|Phase 2 |
NCT00335556 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of the Kidney|Papillary Renal Cell Carcinoma|Rhabdoid Tumor of the Kidney|Stage I Renal Cell Cancer|Stage I Renal Wilms Tumor|Stage II Renal Cell Cancer|Stage II Renal Wilms Tumor|Stage III Renal Cell Cancer|Stage III Renal Wilms Tumor|Stage IV Renal Cell Cancer|Stage IV Renal Wilms Tumor
|
June 2006 | Phase 2 |
NCT00002566 | UNICANCER |
Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor
|
February 1994 | Phase 3 |
NCT02308527 | University of Birmingham|Cancer Research UK|Roche Pharma AG|Imagine for Margo|EUSA Pharma, Inc. |
Neuroblastoma
|
July 2013 | Phase 2 |
NCT01898039 | Hadassah Medical Organization |
Malignant Melanoma
|
May 2013 | Phase 1|Phase 2 |
NCT02406092 | Hoffmann-La Roche |
Non-Hodgkin Lymphoma
|
October 13, 2015 | Phase 3 |
NCT04754945 | Emory University|Sanofi|National Cancer Institute (NCI) |
AL Amyloidosis
|
April 28, 2021 | Phase 1 |
NCT00795678 | Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2008 | |
NCT00230282 | Steven E. Coutre|Bayer|Stanford University |
Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL)
|
July 2004 | Phase 2 |
NCT04375631 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myelodysplastic Syndrome|Refractory Acute Leukemia of Ambiguous Lineage|Refractory Acute Undifferentiated Leukemia
|
December 3, 2020 | Phase 1 |
NCT04612582 | Guangdong Provincial People´s Hospital |
Immunoglobulin Light-Chain Amyloidosis
|
January 1, 2020 | Phase 4 |
NCT00003402 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Leukemia|Lymphoma
|
January 1999 | Phase 2 |
NCT02379585 | Western Regional Medical Center |
HER2-positive Breast Cancer
|
January 2013 | Phase 1|Phase 2 |
NCT00551889 | City of Hope Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 2001 | Phase 1 |
NCT00818961 | Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
May 2005 | Phase 2 |
NCT04859946 | M.D. Anderson Cancer Center|Incyte Corporation |
Hematologic and Lymphocytic Disorder
|
January 11, 2022 | Phase 1 |
NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. |
HIV-associated Hodgkin Lymphoma
|
March 2004 | Phase 2 |
NCT01074060 | City of Hope Medical Center |
Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
April 2010 | Phase 1 |
NCT02273583 | Grupo de Apoio ao Adolescente e a Crianca com Cancer |
High Grade Osteosarcoma
|
May 2006 | Phase 2 |
NCT02413320 | Priyanka Sharma|University of Kansas Medical Center |
Triple-negative Breast Cancer
|
July 2015 | Phase 2 |
NCT00002592 | Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI) |
Leukemia
|
June 1993 | Phase 2 |
NCT02685670 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Xinqiao Hospital of Chongqing|Xuzhou Medical University |
Hematopoietic+Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma
|
February 2016 | Phase 1|Phase 2 |
NCT00193011 | SCRI Development Innovations, LLC|Aventis Pharmaceuticals |
Breast Cancer
|
March 2002 | Phase 3 |
NCT02853318 | Roswell Park Cancer Institute |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma
|
September 1, 2016 | Phase 2 |
NCT00381680 | Children´s Oncology Group|National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
|
March 2007 | Phase 3 |
NCT01175785 | Nohla Therapeutics, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes
|
August 2010 | Phase 2 |
NCT03596892 | Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People´s Hospital|Peking University People´s Hospital|Zhujiang Hospital|Third Affiliated Hospital, Sun Yat-Sen University |
Allogeneic Hematopoietic Stem Cell Transplantation|Conditions|Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia
|
July 2018 | Phase 2|Phase 3 |
NCT04888741 | University of Birmingham |
Graft Versus Host Disease (GvHD)
|
February 22, 2021 | Phase 2 |
NCT00006042 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
December 1999 | Phase 1 |
NCT03674411 | Masonic Cancer Center, University of Minnesota |
Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Biphenotypic+Undifferentiated Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Relapsed Large Cell Lymphoma|Mantle Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Lymphoplasmacytic Lymphoma
|
January 2, 2019 | Phase 2 |
NCT05257083 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 2022 | Phase 3 |
NCT02996773 | University of Arizona |
Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Lymphoma,Non-Hodgkin|Lymphoma, Hodgkin|Lymphoma, Follicular|Marginal Zone Lymphoma|Large Cell Lymphoma|Mantle-Cell Lymphoma|Gray Zone Lymphoma|Burkitt Lymphoma|High Risk Undifferentiated Acute Leukemia
|
November 29, 2016 | Phase 1|Phase 2 |
NCT02278887 | The Netherlands Cancer Institute|Copenhagen University Hospital at Herlev |
Metastatic Melanoma
|
September 23, 2014 | Phase 3 |
NCT00085423 | Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) |
Melanoma (Skin)
|
February 2004 | Phase 2 |
NCT00596154 | Memorial Sloan Kettering Cancer Center |
CNS Lymphoma|CNS Brain Cancer|Non-Hodgkin´s Lymphoma
|
December 2004 | Phase 2 |
NCT04314219 | King Faisal Specialist Hospital & Research Center |
Acute Lymphoblastic Leukemia (ALL) in Partial Remission|Acute Lymphoblastic Leukemia (ALL) in Complete Remission|Acute Myeloid Leukemia (AML) in Remission
|
August 15, 2021 | Phase 3 |
NCT00578292 | Baylor College of Medicine |
Thalassemia
|
February 2004 | Not Applicable |
NCT00550784 | City of Hope Medical Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
January 2001 | Phase 1 |
NCT05357027 | TCRCure Biopharma Ltd.|Fudan University |
Cervical Carcinoma
|
August 10, 2022 | Phase 1|Phase 2 |
NCT03554109 | ImmunityBio, Inc. |
Triple Negative Breast Cancer (TNBC)
|
September 2018 | Phase 2 |
NCT03294954 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine |
Neuroblastoma
|
January 18, 2018 | Phase 1 |
NCT01039025 | M.D. Anderson Cancer Center|SmithKline Beecham |
Myeloma
|
February 18, 2002 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
DMSO : ≥ 38 mg/mL ( 145.54 mM )
H 2 O : 33.33 mg/mL ( 127.66 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.8301 mL | 19.1505 mL | 38.3010 mL |
5 mM | 0.7660 mL | 3.8301 mL | 7.6602 mL |
10 mM | 0.3830 mL | 1.9150 mL | 3.8301 mL |
Add each solvent one by one: PBS
Solubility: 25 mg/mL (95.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution